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Lisa Monique Darby 
 
THE ROLE OF PROTEIN KINASE C IN THE MODULATION OF NEURONAL 
SENSITIVITY AND NEURITE MORPHOLOGY FOLLOWING TREATMENT WITH 
PACLITAXEL IN CULTURED SENSORY NEURONS 
 
Paclitaxel is a chemotherapeutic drug that is used in the treatment of solid 
tumors including breast and ovarian cancer. However, a debilitating and severe side 
effect associated with paclitaxel treatment is peripheral neuropathy. Clinically, peripheral 
neuropathy is characterized by a gain and loss of sensory neuronal function with 
symptoms including burning pain, tingling and numbness, respectively. In addition, 
paclitaxel also elicits a reduction in the length of intraepidermal nerve fibers. Currently, 
there are no effective therapies to prevent or alleviate the symptoms of peripheral 
neuropathy. Further studies are needed to elucidate the mechanisms underlying the 
changes in neuronal function and neurite morphology induced by paclitaxel in order to 
develop therapeutics to address the symptoms of peripheral neuropathy. 
Our laboratory previously demonstrated that paclitaxel altered capsaicin-
stimulated release of calcitonin gene-related peptide (CGRP) from cultured sensory 
neurons, indicating that paclitaxel altered the function of the transient receptor potential 
vanilloid I (TRPV1) channels. Because protein kinase C (PKC) modulates the function of 
TRPV1, we questioned whether PKC mediated changes in neuronal sensitivity induced 
by chronic treatment with paclitaxel. We used the release of CGRP as an index of 
neuronal sensitivity. Our data show that paclitaxel decreased the activity and membrane 
localization of the conventional PKC isozymes, PKCα and PKCβI/II, to elicit a reduction 
in the release of CGRP from cultured sensory neurons. For our neurite morphology 
studies, we focused on the importance of the novel PKC isozyme, PKCε, in mediating 
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the changes in neurite morphology induced by treatment with paclitaxel because studies 
have demonstrated that PKCε is important for enhancing neurite outgrowth. Since our 
preliminary data showed a correlative reduction in PKCε protein expression and neurite 
length and branching following treatment with paclitaxel, we questioned whether loss of 
PKCε mediated altered neurite morphology induced by paclitaxel. Unexpectedly, we 
found that downregulation of PKCε did not exacerbate the reduction in neurite length 
and branching induced by paclitaxel. Our work highlights the significance of PKCα and 
PKCβI/II as critical mediators of changes in neuronal sensitivity induced by paclitaxel 
and illuminates our understanding of the mechanisms underlying the neurotoxic effects 
of paclitaxel on sensory neuronal function.  
 
       Jill Fehrenbacher, Ph.D., Chairperson 
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     INTRODUCTION 
 
1. Pain and Neuronal Sensitization 
 
Pain is important for our survival. It acts as a warning system, informing us of 
harmful stimuli in our environment to elicit behavioral responses meant to safeguard 
against tissue damage and injury (Woolf and Mannion, 1999, Woolf and Salter, 2000). 
While pain is crucial for our existence, it can evolve into a chronic and debilitating 
condition that serves no physiological importance. The International Association for the 
Study of Pain describes pain as “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such 
damage” (International Association for the Study of Pain, 2012). There are reports that 
approximately 105 million people in the United States suffer from chronic pain 
(Melnikova, 2010). Pain adversely affects a person’s quality of life and not surprisingly, 
increases a person’s medical expenditure and reduces their work productivity 
(Melnikova, 2010). Currently, analgesics including non-narcotics (acetaminophen), 
narcotics (opioids) and non-steroidal anti-inflammatory drugs (ibuprofen) are the 
mainstays for pain management; however, it is estimated that only 1 in 4 people achieve 
effective relief from pain (Melnikova, 2010). Furthermore, these drugs are associated 
with a number of different adverse side effects and complications including substance 
abuse and addiction (Dworkin et al., 2007). Therefore, there is a need to better 
understand pain-signaling mechanisms in order for the development of more effective 
and targeted therapeutic options with minimal side effects and complications.  
Pain can manifest as both spontaneous pain (stimulus-independent) and as pain 
hypersensitivity elicited by a given stimuli (stimulus-dependent pain) (Woolf and 
Mannion, 1999). Spontaneous pain is due to an increase in the spontaneous activity of 
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neurons, in other words, an increase in the firing of action potentials (i.e. enhanced 
excitability) of a neuron (Woolf and Mannion, 1999). On the other hand, pain 
hypersensitivity describes a state of heightened neuronal sensitivity to innocuous or 
noxious stimuli as defined by allodynia and hyperalgesia, respectively. Allodynia is an 
enhancement in the neuronal responsiveness to innocuous stimuli to elicit pain (Dubin 
and Patapoutian, 2010). A classic example is pain elicited from light stroking of sunburnt 
skin. Conversely, hyperalgesia is an enhanced responsiveness to a noxious stimulus 
(i.e. stimulus normally perceived as painful) (Dubin and Patapoutian, 2010). Our ability to 
feel and experience pain is important for our survival and serves to protect against injury 
from damaging stimuli within our environment.   
Neuronal sensitization, a state of enhanced responsiveness of a sensory neuron, 
underpins the development of persistent pain. Neurons in both the peripheral and central 
nervous system can undergo sensitization. Peripheral sensitization occurs in response 
to the release of inflammatory mediators (such as, bradykinin, histamine and nerve 
growth factor) at sites of tissue injury/damage, where inflammatory mediators activate 
(i.e. enhance excitability leading to the generation of spontaneous pain) or sensitize (i.e. 
lower the threshold for activation) membrane-bound ion channels (such as G-protein 
coupled receptors and Transient Receptor Potential channels) on the peripheral terminal 
endings of sensory neurons (Julius and Basbaum, 2001, Bhave and Gereau, 2004, 
Basbaum et al., 2009, Gold and Gebhart, 2010). In contrast, central sensitization occurs 
in the dorsal horn of the spinal cord as a result of neurotransmitter (such as glutamate) 
and neuropeptide (such as calcitonin-gene related peptide) release from central terminal 
endings of sensory neurons onto central neurons (Basbaum et al., 2009). Neurons that 
project from the spinal cord are at the center of multiple ascending pathways, including 
the spinothalamic and spinoreticulothalamic tracts, which transmit nociceptive signals to 
the thalamus and brainstem, respectively (Basbaum et al., 2009). The transmission of 
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nociceptive signals from projection neurons to cortical structures within the brain 
activates specific regions (for example, somatosensory cortex activation provides 
information about the location and intensity of painful stimulus) that are important for us 
to sense and experience pain (Basbaum et al., 2009).  
For our studies, we examine the cellular mechanisms that underlie changes in 
sensory neuronal function induced by paclitaxel. Physiologically, paclitaxel elicits 
peripheral neuropathy which is characterized by chronic and painful neuropathic 
symptoms including burning pain and tingling. Due to the clinical presentation of 
peripheral neuropathy, it is believed that paclitaxel enhances the excitability and 
sensitivity of sensory neurons. Our goal is to gain a better understanding of the 
mechanisms by which paclitaxel alters neuronal sensitivity in order for the development 
of therapeutics to alleviate the symptoms of peripheral neuropathy. Within this 
dissertation, the term ‘neuronal sensitivity’ will be used to refer to how sensitive a neuron 
is to a given stimulus, in other words, the changes in the activity of the neuron following 
application of a stimulus.  
 
2. Primary Sensory Neurons 
 
There are four main types of primary afferent sensory nerve fibers, the Aα, Aβ, 
Aδ and C fibers. Primary afferent sensory nerve fibers detect and transmit sensory 
information via electrochemical signals from the periphery to the central nervous system. 
The cell bodies for the sensory neurons that make up these fibers (i.e. primary sensory 
neurons) are located peripherally in dorsal root ganglia (DRG) that lie within the vertebral 
column. These neurons are pseudounipolar and consist of a single axon that bifurcates 
into a peripheral branch that innervates distal tissues including skin and organs and a 
central branch that innervates the dorsal horn of the spinal cord (Melli and Hoke, 2009, 
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Dubin and Patapoutian, 2010). They have diverse functions and can be distinguished 
from one another based on their ability to detect one or more sensory modalities (i.e. 
sensitivity to mechanical, chemical, hot and/or cold stimuli), conduction velocity and 
neurotransmitter release (Hogan, 2010). 
 Primary sensory nerve fibers can be broadly classified according to their size 
and conduction velocity. The Aα and Aβ fibers, which detect proprioception and light 
touch are heavily myelinated and have a large diameter soma (> 45 μm) (Scroggs and 
Fox, 1992, Julius and Basbaum, 2001). In the peripheral nervous system, myelination is 
a process where specialized glial cells (Schwann cells) wrap around the neuronal axons 
with their plasma membrane allowing for fast saltatory conduction of action potentials 
(Pereira et al., 2012). Due to the high level of myelination, the Aα and Aβ fibers are the 
fastest conductors of electrical signals (14 - 55 m/s) amongst the primary sensory nerve 
fibers (Harper and Lawson, 1985b). The lightly myelinated Aδ fibers have a conduction 
velocity of 2.2 – 8 m/s whereas the unmyelinated C fibers conduct electrical current at 
speeds < 1.4 m/s (Harper and Lawson, 1985a, b, Scroggs and Fox, 1992). The neurons 
derived from Aδ and C fibers also differ in their size. Aδ neurons have a medium 
diameter soma (33 – 38 μm) whereas C neurons have a small diameter soma (20 - 27 
μm) (Harper and Lawson, 1985a, b, Scroggs and Fox, 1992). The Aδ and C fibers are 
traditionally described as nociceptors as they can respond to noxious mechanical, 
chemical and thermal stimuli (Julius and Basbaum, 2001, Basbaum et al., 2009, Dubin 
and Patapoutian, 2010). 
The Aδ and C fibers can be further classified based on their sensitivity to specific 
types of stimuli. The Aδ fibers are physiologically divided into two main groups: the type I 
mechano-sensitive high heat (> 49°C) threshold neurons and the type II mechano-
sensitive low heat (~43 °C) threshold neurons (Raja et al., 1988). C fibers, which have a 
low heat threshold (~43 °C), can be classified based on their sensitivity to mechanical 
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(M) and heat (H) stimuli. Common classifications include, the MH-sensitive, M-sensitive, 
H-sensitive, or MH-insensitive (Raja et al., 1988, Dubin and Patapoutian, 2010). The 
majority of C neuronal fibers (82%) are heat sensitive, unlike Aδ fibers with only 12% 
(Cain et al., 2001). There are also subpopulations of Aδ and C fibers that detect other 
noxious and innocuous stimuli such as cold temperatures and innocuous touch; for 
example, 50% of Aδ fibers and 77% of C fibers are responsive to cold (Darian-Smith et 
al., 1973, Koltzenburg et al., 1997, Cain et al., 2001, Liljencrantz and Olausson, 2014). 
The ability of Aδ and C fibers to respond to a wide spectrum of stimulus modalities with 
varying degrees of sensitivity is what enables us to make distinctions between pleasant 
innocuous stimuli and harmful stimuli. Interestingly, Aβ fibers, low threshold fibers that 
are responsive to innocuous tactile stimuli, can undergo a phenotypic switch to resemble 
the nociceptive Aδ and C nerve fibers following nerve injury and inflammation via the 
expression of neuropeptides (Neumann et al., 1996, von Hehn et al., 2012). Studies 
show that Aβ fibers contribute to enhancing synaptic transmission in the spinal cord to 
elicit a greater central response to a given innocuous stimuli (Neumann et al., 1996).  
Historically, neurons derived from Aδ and C fibers were classified by 
neurochemistry into peptidergic and non-peptidergic subpopulations. The peptidergic 
population contains neuropeptides including calcitonin gene-related peptide (CGRP) and 
substance P. They also express the nerve growth factor receptor, tyrosine kinase 
receptor (TrkA). As the name suggests, the non-peptidergic population do not contain 
peptides. Instead, they are commonly distinguished from peptidergic neurons based on 
their expression of c-Ret (the neurotrophin receptor for glial-derived neurotrophic factor), 
isolectin B4 (IB4; an α-D-galactosyl-binding lectin), G-protein coupled receptors of the 
Mrg family and the purinergic receptors, P2X3 (Molliver et al., 1997, Bennett et al., 1998, 
Dong et al., 2001). It is important to note that in order to distinguish between peptidergic 
and non-peptidergic populations, it is necessary to examine the presence of multiple 
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markers, as studies show that there is an overlap in the localization (45%) between 
peptidergic and IB4 positive neurons (Price and Flores, 2007) and new studies are 
demonstrating less clear delineations between subpopulations (Usoskin et al., 2015, Li 
et al., 2016). 
For our studies, we focused on the CGRP positive subpopulation of small 
diameter sensory neurons. CGRP is a 37 amino acid peptide that is generated from 
alternatively spliced mRNA of the calcitonin gene (Rosenfeld et al., 1983). The receptor 
for CGRP is a seven transmembrane G-protein coupled receptor (GPCR), calcitonin 
receptor-like receptor (CALCRL), that signals via the Gs signaling pathway (Juaneda et 
al., 2000, Brain and Grant, 2004). Association of CALCRL with the single 
transmembrane domain protein, receptor activity-modifying protein (RAMP, particularly 
RAMP1), is required for receptor activity (Juaneda et al., 2000, Brain and Grant, 2004). 
CGRP is expressed in 46% of C neurons (McCarthy and Lawson, 1990) and is 
expressed in 49% of the heat-sensitive transient receptor potential vanilloid 1 (TRPV1) 
receptor positive subpopulation of neurons (Price and Flores, 2007). CGRP is 
synthesized in the cell bodies of DRG and is anterogradely transported to peripheral and 
central terminal endings (Kashihara et al., 1989). At the peripheral terminal endings, 
release of CGRP and other neuropeptides, such as substance P, elicits vasodilation and 
the recruitment of pro-inflammatory immune cells (neurogenic inflammation) at sites of 
tissue injury/damage (Dray and Bevan, 1993, Julius and Basbaum, 2001, Richardson 
and Vasko, 2002). Conversely, the release of neuropeptides at the central terminal 
endings of C fibers serves to transmit nociceptive signaling from the peripheral nervous 
system to the central nervous system, i.e. the dorsal horn of the spinal cord. CGRP also 
modulates synaptic transmission by altering the intracellular levels of calcium and 
sodium in primary afferent neurons. Studies show that treatment with CGRP enhances 
voltage-dependent calcium currents and tetrodotoxin-resistant sodium currents in DRG 
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neurons in a PKA and PKC signaling-dependent mechanism (Ryu et al., 1988b, a, 
Natura et al., 2005). In addition, intrathecal administration of CGRP induces mechanical 
hyperalgesia in a PKA- and PKC-dependent manner in animal behavior models (Sun et 
al., 2004). These studies provide strong evidence for the role of CGRP in nociceptive 
signaling mechanisms. 
The work presented in this dissertation measures the release of CGRP as an 
index of sensory neuronal function. Our studies investigate the mechanisms underlying 
altered sensory neuronal function induced by the chemotherapeutic agent, paclitaxel. 
Paclitaxel is used in the treatment of solid tumors but its use in cancer therapy is limited 
due to the development of peripheral neuropathy, which is characterized by a gain and 
loss of sensory neuronal function. Researchers are currently working to understand how 
paclitaxel elicits neurotoxic effects in specific subpopulations of neurons. Our work 
focuses on the effects of paclitaxel on the peptidergic subpopulation of sensory neurons. 
Using an in vitro system, our laboratory and other researchers have determined that 
paclitaxel modulates the release of CGRP from cultured DRG sensory neurons (Miyano 
et al., 2009, Pittman et al., 2014, He and Wang, 2015, Pittman et al., 2016). We 
demonstrated that treatment with low concentrations of paclitaxel (10 nM) for 5 days 
increased capsaicin-stimulated CGRP release whereas high concentrations (300 nM) 
decreased capsaicin-stimulated CGRP release (Pittman et al., 2014). These findings 
indicate that paclitaxel differentially modulates neuronal sensitivity in capsaicin-positive 
neurons; however, the cellular mechanisms remain unknown. This dissertation 
establishes the intracellular signaling messenger, PKC, as a critical mediator of the 
effects of paclitaxel on neuronal function in small diameter capsaicin-sensitive sensory 
neurons.  
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3. Paclitaxel  
 
Taxanes are structurally related compounds that share a taxane ring, also known 
as baccatin III ring, with a C-4 and C-5 attached oxetan and a C-13 ester moiety 
(Kearns, 1997, Vaishampayan et al., 1999). The microtubule stabilizing agents, 
paclitaxel and docetaxel, are members of this class of compounds. While these two 
compounds share similar mechanisms of action, they differ in their chemical structure 
since they have different chemical substituents at the C-10 position of the taxane ring 
and at the 3’ position of the C-13 side chain (Kearns, 1997). The work presented in this 
dissertation will focus on paclitaxel and its effects on sensory neuronal function.  
Paclitaxel is the active ingredient in the chemotherapeutic drug, Taxol 
(Vaishampayan et al., 1999). It was originally extracted from the Taxus brevifolia (Pacific 
Yew) bark in the 1960s as part of an exploratory plant screening program led by the 
National Cancer Institute (Cragg, 1998). Early studies found that paclitaxel exhibited 
cytotoxic effects in a variety of tumor models, including the B16 murine melanoma model 
and the MX1 human breast cancer xenograft model (Cragg, 1998), generating much 
interest in its applicability to the treatment of cancer in humans. Drs. Wani and Wall 
elucidated the structure of paclitaxel in 1971 (Wani et al., 1971) and years later Dr. 
Horwitz and colleagues discovered its cytostatic mechanism of action. It was found that 
paclitaxel binds and stabilizes microtubules and blocks cells in the G2 and M phase of 
the cell cycle resulting in the formation of microtubule bundles and inhibition of cell 
division in mitotic cells (Schiff et al., 1979, Schiff and Horwitz, 1980).  
 Microtubules are cytoskeletal components that regulate numerous cellular 
processes. They are important for maintenance and integrity of the cellular shape, the 
transport of vesicles and cargo throughout the interior of the cell and for regulating 
cellular mitosis. Microtubules are composed of α and β tubulin heterodimers which form 
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linear protafilaments that associate laterally to form a hollow 25 nM wide cylindrical 
microtubule structure (Desai and Mitchison, 1997, Wade et al., 1998).  The orientation of 
the α and β tubulin subunits yields a (-) end with α tubulin and a (+) end with β tubulin 
(Brunden et al., 2016). Guanosine triphosphate (GTP) bound α/β tubulin heterodimers 
are added to the growing (+) end of microtubules in a process known as polymerization 
(elongation) (Brunden et al., 2016). Upon addition to the microtubule, GTP is hydrolyzed 
to guanosine diphosphate (GDP) to yield an unstable GDP bound α/β heterodimer cap, 
which is prone to depolymerization (shortening) (Brunden et al., 2016). This dynamic 
nature of polymerization and depolymerization occurs under normal conditions and is 
important for the proper function of microtubules.  
 The binding of paclitaxel stabilizes microtubules and prevents cellular mitosis in 
dividing cells.  Paclitaxel binds to the β-subunit of tubulin to exert its neurotoxic effects. 
In fact, paclitaxel shares the same binding site with the taxane, docetaxel, however, it 
binds with a lower affinity and produces smaller microtubules (12 protafilaments) 
compared to docetaxel (13 protafilaments) (Andreu et al., 1994). The binding of 
paclitaxel to the β-tubulin subunit of polymerized tubulin dimers occurs in an 
approximate 1:1 stoichiometry in the N-terminal 31 amino acid region and it is believed 
that this association induces conformation changes in the protein structure to impact 
microtubule stability (Parness and Horwitz, 1981, Rao et al., 1994). The binding of 
paclitaxel to microtubules shifts the chemical equilibrium in favor of microtubule 
assembly, rather than disassembly (depolymerization) and decreases the critical 
concentration of tubulin necessary for assembly (Schiff et al., 1979).  
Paclitaxel has been used as a first line agent in the treatment of solid tumors 
including breast, ovarian, and non-small cell lung cancer (McGuire et al., 1989, Holmes 
et al., 1991, Murphy et al., 1993). It is administered intravenously and is formulated in 
50% dehydrated ethanol and 50% polyoxyethylated castor oil derivative (Cremophor EL) 
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due to its insolubility in aqueous solution (Vaishampayan et al., 1999, Surapaneni et al., 
2012). Similar to other chemotherapeutic agents, there are a number of adverse side 
effects associated with paclitaxel treatment. Side effects include peripheral neuropathy, 
alopecia, myalgia, myelosuppression, neutropenia, mucositis, gastrointestinal toxicity, 
cardiac arrhythmias and hypersensitivity reactions (such as, erythematous rashes, 
labored breathing and bronchospasms) (Weiss et al., 1990, Vaishampayan et al., 1999). 
The majority of these side effects are tolerated or can be addressed through medication. 
For instance, it was discovered during early clinical trials that hypersensitivity reactions 
occurred as a result of the Cremophor EL formulation. This unwanted side effect was 
circumvented by premedication with corticosteroids (e.g. dexamethasone) and H1 and H2 
histamine receptor antagonists (e.g. cimetidine and diphenhydramine) (Wiernik et al., 
1987a, Gelmon, 1994) whereas side effects like myalgia and myelosuppression were 
treated with analgesics and granulocyte colony-stimulating factor (Sarosy et al., 1992, 
Reichman et al., 1993). In fact, myelosuppression, which predominantly manifests as 
leukopenia and/or neutropenia, used to be a dose-limiting and severe adverse effect of 
paclitaxel treatment (McGuire et al., 1989, Thigpen et al., 2003) but clinicians were able 
to control the development of myelosuppression through medication with neutrophil-
enhancing agents such as granulocyte colony stimulating factor (Sarosy et al., 1992, 
Eisenhauer et al., 1994).  However, the major problematic side effect associated with 
paclitaxel treatment is peripheral neuropathy (Wiernik et al., 1987a, Wiernik et al., 
1987b, Sarosy et al., 1992). Interestingly, the clinical presentation and incidence of 
peripheral neuropathy differs amongst the taxanes (paclitaxel, docetaxel and 
cabazitaxel). While peripheral neuropathy is associated with docetaxel treatment, there 
are differences in the localization of neuropathic symptoms when compared to patients 
treated with paclitaxel (Tofthagen et al., 2013, Rivera and Cianfrocca, 2015). In addition, 
peripheral neuropathy is not frequently associated with cabazitaxel, a semi-synthetic 
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derivative of docetaxel (de Bono et al., 2010, Villanueva et al., 2011). Studies have 
found that only 1% of patients experience peripheral neuropathic symptoms following 
treatment with cabazitaxel (de Bono et al., 2010). An interesting question that arises is 
why peripheral neuropathy is associated with some taxanes (paclitaxel) and not others 
(cabazitaxel). Currently the exact answer to this question remains unknown. However, it 
is plausible that paclitaxel, unlike cabazitaxel, has a greater number of “off-target” effects 
which adversely affect sensory nerve fiber function. The work presented in this 
dissertation and research from other laboratories seeks to determine the mechanism of 
how paclitaxel elicits changes in the function of sensory neurons because this is crucial 
to our understanding of why peripheral neuropathy is associated with paclitaxel 
treatment. 
 Paclitaxel-induced peripheral neuropathy (PIPN) is a debilitating condition that 
has adverse effects on the quality of life for cancer patients and is one of the main 
reasons for discontinuing treatment with this life-saving therapy. The goal in this work is 
to identify the cellular mechanisms that underlie changes in neuronal function induced by 
paclitaxel in order to develop a therapeutic agent to prevent and/or ameliorate the 
debilitating symptoms of peripheral neuropathy.  
 
4. Paclitaxel-Induced Peripheral Neuropathy: Clinical Manifestation and Assessment 
 
Peripheral neuropathy is the dose-limiting side effect of paclitaxel therapy and is 
a result of the damage to and/or dysfunction of peripheral nerve fibers. In patients 
treated with paclitaxel, peripheral neuropathy predominantly manifests as a sensory 
neuropathy (Lipton et al., 1989) and is characterized by a gain and loss of sensory 
neuronal function. Common symptoms include burning pain, tingling, hypersensitivity to 
mechanical stimuli, hypersensitivity to cold and hot temperatures, numbness, impaired 
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vibration sense, loss of proprioception (awareness of the relative position of one’s body 
parts) and loss of deep tendon reflexes (Wiernik et al., 1987a, Sarosy et al., 1992, 
Dougherty et al., 2004). Symptoms manifest in a “glove and stocking” distribution in the 
distal extremities of the hands and feet of cancer patients (Wiernik et al., 1987a, Wiernik 
et al., 1987b, Sarosy et al., 1992). In fact, peripheral neuropathy induced by paclitaxel is 
generally considered a length-dependent distal sensory axonopathy (Carlson and 
Ocean, 2011). Because peripheral nerve axons are very long and lie outside the 
protection of the blood-brain barrier they are more susceptible to the toxic effects of 
paclitaxel than central neurons (Hogan, 2010). In addition to altering the function of 
sensory peripheral nerve fibers, paclitaxel also adversely affects nerve fiber morphology. 
Studies show that paclitaxel decreases intraepidermal nerve fiber innervation (i.e. nerve 
fibers that innervate the epidermal layer of the skin) (Boyette-Davis et al., 2013). The 
effects of paclitaxel on nerve fiber morphology are described in greater detail in 
upcoming paragraphs. In addition to sensory deficits, studies have found to a lesser 
extent that paclitaxel causes motor deficits and autonomic neuropathy characterized by 
orthostatic hypotension (Sarosy et al., 1992, Jerian et al., 1993, Iniguez et al., 1998). 
Symptoms have been reported to occur as early as 24–72 hours following treatment with 
paclitaxel and although partially reversible, symptoms sometimes persist for months to 
years following the cessation of therapy (Wiernik et al., 1987a, Wiernik et al., 1987b, 
Postma et al., 1995, Osmani et al., 2012). In a small study (n = 10 cancer patients) that 
evaluated neuropathic symptoms 1-6 years following treatment with paclitaxel and other 
adjuvant therapies (which included 5-FU and platinum-based agents), it was found that 
57% of persons still experienced persistent neuropathic symptoms (Osmani et al., 2012). 
There are currently no therapies available to adequately address peripheral neuropathy. 
Clinicians depend on reduction in treatment dose, reduction in the frequency of drug 
administration and/or discontinuation of treatment to mitigate the severity of peripheral 
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neuropathic symptoms in cancer patients (Pachman et al., 2011), highlighting that 
patients may be given sub-optimal treatment schedules due to the development of 
debilitating peripheral neuropathy.  
In addition to peripheral neuropathy, paclitaxel also induces acute pain known as 
paclitaxel-associated pain syndrome (P-APS). P-APS and paclitaxel-induced peripheral 
neuropathy (PIPN) can be distinguished based on their temporal profile and clinical 
manifestation. Paclitaxel-associated acute pain syndrome (P-APS) occurs within 1-4 
days following paclitaxel treatment and resolves within a week (Loprinzi et al., 2011, 
Reeves et al., 2012). The majority of patients receiving paclitaxel experience pain in the 
lower extremities and hips, and describe the pain as aching, sharp, cramping, and 
throbbing (Loprinzi et al., 2011, Reeves et al., 2012). This is in sharp contrast to the 
clinical presentation of peripheral neuropathic symptoms which occurs 3-6 weeks 
following paclitaxel administration and often lasts for months to years following the 
cessation of paclitaxel treatment (Wiernik et al., 1987a, Wiernik et al., 1987b, Postma et 
al., 1995, Forsyth et al., 1997, Osmani et al., 2012). Furthermore, neuropathic 
symptoms, which include burning pain, tingling and numbness, present in the hands and 
feet of cancer patients (Wiernik et al., 1987a, Wiernik et al., 1987b, Dougherty et al., 
2004). It is important to be cognizant of P-APS as studies have shown that there is a 
direct correlation between the severity of peripheral neuropathic symptoms and P-APS. 
It was found that persons who experienced severe acute pain were more likely to 
develop severe chronic peripheral neuropathy (Reeves et al., 2012). Such findings 
suggest that prevention of acute pain could prevent the development of peripheral 
neuropathy or reduce the severity of peripheral neuropathy symptoms. Therefore, it is 
important for researchers to have a good mechanistic understanding of the temporal 
nature of the effects of paclitaxel on sensory neuronal function. 
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Paclitaxel-induced peripheral neuropathy is clinically assessed using grading 
systems. These grading systems provide a method for the assessment and report of 
drug toxicity and patient response to cancer treatment. The World Health Organization 
(WHO), the Eastern Cooperative Oncology Group (ECOG) and the National Cancer 
Institute – Common Terminology Criteria (NCI-CTC) scales are the most commonly used 
systems used to grade the severity of peripheral neuropathy (Miller et al., 1981, Oken et 
al., 1982, Postma and Heimans, 2000). According to the NCI-CTC for Adverse Effects, 
grade 1 indicates asymptomatic neuropathy with loss of deep tendon reflexes and 
paresthesia, grade 2 indicates moderate neuropathy with sensory loss or paresthesia 
but no effects on daily living activities, grade 3 indicates severe neuropathy with sensory 
loss or paresthesia that interferes with daily living activities, and grade 4 indicates life-
threatening neuropathy with permanent sensory loss (National Cancer Institute, Postma 
and Heimans, 2000, Fehrenbacher, 2015). These scales employ both objective and 
subjective methodology as exemplified by the quantifiable assessment of deep tendon 
reflexes in combination with subjective patient description of neuropathic symptoms (e.g. 
numbness felt in fingers) (Postma and Heimans, 2000). In addition to these grading 
scales, there has been the development of the Total Neuropathy Score. This scoring 
system was designed to provide a composite measure of changes in nerve function 
based on objective quantification of nerve function, including nerve conduction velocity 
analysis, vibration sensory threshold and sensitivity to pinprick (Cavaletti et al., 2006, 
Cavaletti et al., 2007, Carlson and Ocean, 2011, Fehrenbacher, 2015). 
There are multiple risk factors associated with the development of peripheral 
neuropathy. These include the individual dose per treatment cycle, the cumulative dose, 
the frequency of treatment (treatment schedule), the duration of treatment infusion and 
concurrent treatment with other chemotherapy agents (Lee and Swain, 2006) (see Table 
1).  
 15
 
 
 
Factors Associated 
with the 
Development of 
Peripheral 
Neuropathy 
 
Paclitaxel Treatment 
Schedule 
% of Patients With 
Neuropathic 
Symptoms and 
Grade of 
Neuropathy (NCI-
CTC/WHO scale) 
Single and 
Cumulative Dose 
250 vs. 210 vs. 175 mg/m2  
(3 hr infusion every 3 wks) 
 
 
175 vs. 135 mg/m2     
(3 hr infusion every 3 wks) 
 
 
 
175 vs. 135 mg/m2         
(every 3 wks) 
33 vs.19 vs. 7%       
(Grade III) (Winer 
et al., 2004) 
 
9 vs. 3%   
(Grade III/IV) 
(Nabholtz et al., 
1996) 
 
52 vs. 36%      
(Grade III/IV) 
(Eisenhauer et al., 
1994) 
Frequency of Dose 80 mg/m2 weekly dosing for 
3 wks vs. 
175 mg/m2 every 3 wks 
24 vs.12%         
(Grade III) 
(Seidman et al., 
2008) 
Duration of Drug 
Infusion 
250 mg/m2 24 hr infusion vs. 
250 mg/m2 3 hr infusion 
every 3 wks 
7 vs.13%         
(Grade III) (Smith 
et al., 1999) 
Concurrent 
Treatment with 
Other 
Chemotherapeutic 
Drugs 
250 mg/m2 paclitaxel 
followed by 100 mg/m2 
cisplatin vs. 
250 mg/m2 paclitaxel 
followed by 75 mg/m2 
cisplatin (over 24 hrs every 3 
wks) 
 
Grade II vs. 
No neuropathy 
(Rowinsky et al., 
1993) 
 
Table 1: Risk factors associated with the development of peripheral 
neuropathy.   
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 Painful neuropathy is commonly associated with changes in the intraepidermal 
nerve fiber density and axonal swellings (Lauria et al., 2003). Clinicians, therefore, 
assess peripheral neuropathy by measuring changes in the length of intraepidermal 
nerve fibers (IENF) (Griffin et al., 2001, England et al., 2009, Lauria et al., 2010). 
Paclitaxel, similar to other chemotherapeutic drugs that cause peripheral neuropathy, 
causes loss of intraepidermal nerve fiber innervation (Boyette-Davis et al., 2013). 
Clinicians can quantify changes in the length and density of the nerve fibers once a 
sample of skin in the affected region is obtained via a skin punch biopsy or by removal of 
the epidermal skin layer using a suction cap (Griffin et al., 2001). The skin biopsy 
puncture is a more invasive technique but allows for the analysis of the nerve fibers in 
the dermal-epidermal skin layer, whereas the epidermal sampling method, although less 
invasive, only removes the epidermal skin layer, therefore it does not allow for the 
analysis of nerve fiber length in the dermal skin layer (Griffin et al., 2001). While analysis 
of IENF loss following treatment with paclitaxel is a valid tool for assessing the severity 
of peripheral neuropathy, there is evidence to show that a correlation between IENF loss 
and the development of peripheral neuropathy does not always exist (Kalliomaki et al., 
2011). Furthermore, IENF loss also occurs in response to other factors outside of 
chemotherapy, such as diabetes mellitus (Lauria et al., 1998) and HIV (Polydefkis et al., 
2002).  Given that IENF is not always a predictor of peripheral neuropathy, it is best to 
use this technique in addition to multiple assessment tools as described earlier to assess 
changes in sensory neuronal function induced by treatment with paclitaxel.  
 
5. Animal Models of Paclitaxel-Induced Peripheral Neuropathy 
 
Animal models of paclitaxel-induced peripheral neuropathy (PIPN) have been 
established and are widely used to examine the effects of paclitaxel on neuronal 
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sensitivity. While the various models differ with regards to paclitaxel dosing, length of 
treatment and route of administration, these models evaluate changes in nerve 
morphology and nerve conduction and quantitatively assess nociceptive behavioral 
responses as a functional read-out of the effects of paclitaxel on neuronal sensitivity. 
The most extensively used model was developed by Dr. Gary Bennett’s laboratory. In 
this low dose chronic model of PIPN, rats are injected intraperitoneally with paclitaxel 
(0.5, 1 and 2 mg/kg; cumulative doses = 2, 4 and 8 mg/kg, respectively) on four alternate 
days and behavioral responses to a variety of different stimuli (mechanical, cold and 
heat) are measured days to weeks following the first administration of paclitaxel 
(Polomano et al., 2001). To assess sensitivity to the different stimulants, researchers 
apply the given stimulant to the hind paw of rodents and measure the evoked withdrawal 
response to the stimulant. Application of calibrated von Frey filaments, acetone and heat 
from a light source is used to assess mechanical-, cold- and heat- hypersensitivity, 
respectively. Using this low dose chronic model of PIPN, it was determined that 
paclitaxel induced mechanical, cold and thermal hypersensitivity (Polomano et al., 
2001), paralleling some of the findings observed in cancer patients treated with 
paclitaxel (Dougherty et al., 2004). There was also no impaired motor coordination or 
degeneration of somatosensory or motor axons observed using this model (Polomano et 
al., 2001). Researchers have replicated similar behavioral nocifensive findings using the 
low dose PIPN chronic model (Chen et al., 2011, Hara et al., 2013, Janes et al., 2014, 
Griffiths and Flatters, 2015, He and Wang, 2015). The aforementioned studies suggest 
enhanced function of heat-responsive neurons, however, additional studies showed that 
assessment of a different nociceptive functional endpoint indicate a loss of function of 
heat-responsive neurons. It was found that treatment with low doses of paclitaxel 
decreased capsaicin-evoked vasodilation, suggesting a loss, rather than gain, of TRPV1 
function in the small diameter sensory neurons (Gracias et al., 2011). These findings 
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highlight the importance of evaluating multiple functional endpoints in order to have a full 
understanding of the effects of paclitaxel on sensory neuronal function 
In addition to the low dose chronic model of PIPN, investigators demonstrated 
that paclitaxel differentially altered behavioral nocifensive responses in a high dose 
chronic model of PIPN. In the high dose model, animals were injected intraperitoneally 
with 1.2 mg/kg paclitaxel five times per week for 3 weeks (cumulative dose = 18 mg/kg) 
or given 25 mg/kg, 12.5 mg/kg and 12.5 mg/kg every third day for 10 days (cumulative 
dose = 50 mg/kg) (Campana et al., 1998). Using this model, it was determined that 
paclitaxel induced thermal hypoalgesia (Campana et al., 1998), suggesting a loss of 
TRPV1 function which is in contrast to findings for the low dose chronic model of PIPN. 
These findings highlight that paclitaxel differentially alters sensory neuronal function in a 
concentration-dependent manner. Another study examined the effects of high doses of 
paclitaxel on neuronal function. In this model, rats were administered 16 mg/kg paclitaxel 
every week for 5 weeks (cumulative dose = 80 mg/kg) or a single dose of 16 or 32 mg/kg 
of paclitaxel (Authier et al., 2000). Using these models, it was shown that paclitaxel 
induced thermal hypoalgesia and mechanical hypersensitivity with no changes in motor 
coordination (Authier et al., 2000). However, there was a decrease in the nerve 
conduction velocity and degenerative changes were present in the sciatic nerve and 
subcutaneous paw tissue (Authier et al., 2000), indicating that very high doses of 
paclitaxel causes overt damage which not surprisingly would result in altered nerve 
function. In agreement with the latter studies, researchers demonstrated a decrease in 
nerve conduction velocity accompanied by morphological changes such as altered 
Schwann cells (dilatation of cisternae and enlarged mitochondria), Wallerian-like 
degeneration and neurotubule aggregation in large myelinated nerve fibers (Cavaletti et 
al., 1995). In combination with findings from the low dose chronic model, these findings 
indicate that paclitaxel differentially alters the sensitivity of neurons in a concentration-
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dependent manner to elicit either a gain or loss of neuronal function as found in the 
clinical setting.  
Researchers have also examined the short-term effect of different doses of 
paclitaxel on mechanical hypersensitivity. Intraperitoneal injection with a single dose of 
paclitaxel (1 mg/kg) in rats elicited a reduction in the paw withdrawal threshold to a 
mechanical stimulus as early as 1 hour following injection (Dina et al., 2001). These 
behavioral changes lasted 6 hours and completely resolved within 24 hours following 
drug administration (Dina et al., 2001). Likewise, a single intravenous injection of 2 
mg/kg paclitaxel into the tail vein resulted in a similar nocifensive response (Yan et al., 
2015). It was found that paclitaxel also decreased the burrowing activities of rats (Yan et 
al., 2015). Burrowing is a spontaneous innate rodent behavior that can be evaluated by 
researchers to assess the general well-being of an animal in its natural state, as 
opposed to stimulus-evoked nocifensive behavioral assays, which describe paw 
withdrawal responses to a given stimulus (Deacon, 2006, Andrews et al., 2012). Studies 
examining the short-term effects of paclitaxel on nerve fiber function are vital to our 
understanding of the temporal development of peripheral neuropathy given the high 
degree of correlation between the development of acute pain (associated with P-APS) 
and chronic pain (associated with peripheral neuropathy).  
 
6. In Vitro Models of Paclitaxel-Induced Peripheral Neuropathy 
 
Researchers have established the use of dorsal root ganglia (DRG) sensory 
neuronal cultures as an effective model system to study chemotherapy-induced 
peripheral neuropathy (Melli and Hoke, 2009). The use of dissociated DRG sensory 
neurons allows researchers to study the effects of chemotherapeutic agents on mature 
and fully developed neurons that share similar characteristics to neurons in vivo (Melli 
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and Hoke, 2009). For our studies, we used DRG sensory neurons derived from adult 
rats to examine the effects of paclitaxel on neuronal sensitivity and neurite morphology. 
The effects on neurite morphology are highlighted in Section 7: Paclitaxel-Induced 
Modulation of Neurite Length. Studies suggest that the axons of peripheral sensory 
neurons are the sites of action for the neurotoxic effects of paclitaxel (Yang et al., 2009).  
As such, the majority of studies are focused on examining the effects of paclitaxel on the 
function and structure of sensory neurons. As mentioned previously, the release of the 
neuropeptides, calcitonin gene related peptide (CGRP) and substance P, is commonly 
used as an indicator of sensory neuronal function in paclitaxel studies. Currently, in vitro 
studies have focused on both the short-term and chronic effects of paclitaxel on sensory 
neuronal function. Because of the temporal profile of paclitaxel as it relates to the 
distinction between acute pain and chronic neuropathy induced by paclitaxel, it is 
important to assess mechanisms underlying acute and chronic changes in neuronal 
sensitivity induced by paclitaxel.  
Our laboratory demonstrated that paclitaxel altered neuronal sensitivity in a 
concentration- and time-dependent manner. Treatment with low concentrations of 
paclitaxel (10 nM) for 5 days enhanced capsaicin-evoked stimulated peptide release, 
whereas treatment with high concentrations of paclitaxel (300 nM) attenuated capsaicin-
evoked stimulated release (Pittman et al., 2014). This model focused on the function of a 
specific subpopulation of sensory neurons, i.e. the TRPV1 positive peptidergic neurons. 
Our results recapitulated the gain and loss of TRPV1 neuronal function that has been 
shown in animal models of paclitaxel-induced peripheral neuropathy (Campana et al., 
1998, Authier et al., 2000, Chen et al., 2011, Gracias et al., 2011, Hara et al., 2013, Li et 
al., 2015). Our ability to recapitulate in vivo findings gives us confidence that our in vitro 
cell culture treatment paradigm models the chronic effects of paclitaxel on sensory 
neuronal function (i.e. chronic peripheral neuropathy pain). In addition to altered TRPV1 
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function, we showed that paclitaxel treatment differentially altered allyl isothiocyanate-
(AITC) evoked peptide release in a concentration- and time-dependent manner 
indicating that paclitaxel not only affected the function of TRPV1, but also altered TRPA1 
function (Pittman et al., 2014). The work in this dissertation expands upon these findings 
to determine signaling proteins involved in the modulation of neuronal sensitivity induced 
by chronic treatment with paclitaxel in the peptidergic subpopulation of cultured sensory 
neurons.  
Studies examining the effects of short-term exposure to paclitaxel show that 
paclitaxel enhances neuronal sensitivity. Treatment with 1 and 10 μM paclitaxel for 30 
minutes elicited an increase in the release of substance P from cultured DRG sensory 
neurons whereas treatment with a lower concentration of paclitaxel (100 nM) did not, 
indicating that the effects of paclitaxel are concentration-dependent (Miyano et al., 
2009). Interestingly, another study showed that treatment with 10 nM paclitaxel for 10 
minutes enhanced the release of CGRP from cultured DRG neurons (He and Wang, 
2015). Differences in cell density, the time of exposure to paclitaxel and levels of nerve 
growth factor (NGF) are potential factors to account for the lack of effects observed 
following treatment with 100 nM paclitaxel for 30 minutes versus the increase in peptide 
release following treatment with 10 nM paclitaxel for 10 minutes. In general, the in vitro 
cell studies demonstrate that paclitaxel modulates neuronal sensitivity as measured by 
changes in neuropeptide release. 
Apart from altered PKC signaling, multiple alternate mechanisms have been 
proposed to underlie the neurotoxic effects of paclitaxel. Some of these mechanisms 
include mitochondrial dysfunction, altered microtubules and oxidative damage. 
Mitochondria are the site of ATP synthesis and impairment of mitochondrial energetics 
could lead to impaired energy generation and subsequent reduction in ATP-dependent 
cellular processes. Studies showed an increase in the prevalence of “atypical 
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mitochondria” (mitochondria that are swollen and vacuolated) within saphenous nerve 
sections of C fibers and myelinated axons isolated from animals treated with paclitaxel. 
(Flatters and Bennett, 2006, Jin et al., 2008). Studies also found that administration of 
the mitochondrial protective agent, acetyl -carnitine (ALCAR), blocked the development 
of both hypernociceptive behavioral responses and the increase in the number of 
atypical mitochondria within C fibers following treatment with paclitaxel (Jin et al., 2008). 
In addition, it was found that pharmacological inhibition of the mitochondrial electron 
transport chain complex I and III reversed paclitaxel-induced hypersensitivity (Griffiths 
and Flatters, 2015). These findings demonstrate that paclitaxel alters both the 
morphology and function of mitochondria.  
Microtubules are essential for cellular integrity, regulating mitosis and the 
intracellular transport of proteins and organelles. Studies found that paclitaxel blocked 
the transport of proteins and organelles within different types of cells. Using 
immunohistochemistry and cryo-electron microscopy, it was found that treatment with 
paclitaxel (10 μM, 1-3 days) blocked the anterograde transport of microinjected 
horseradish peroxidase in DRG cells (Theiss and Meller, 2000). Another study 
demonstrated that paclitaxel (100 nM, 1-3 days) caused microtubule polar 
reconfiguration and impaired the movement of organelles (mitochondria) in Aplysia 
neurons (Shemesh and Spira, 2010). Because the anti-cancer effect of paclitaxel is 
based on its ability to disrupt microtubule dynamics, it is unsurprising that paclitaxel 
affects the trafficking of proteins and organelles since a core function of microtubules is 
to facilitate the transport of cargo throughout the interior of the cell.  
The production of reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) has also been suggested to underlie the changes in neuronal sensitivity induced 
by paclitaxel. Studies in animal models of paclitaxel-induced peripheral neuropathy 
(PIPN), demonstrate that paclitaxel increased nicotinamide adenine dinucleotide 
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phosphate (NADPH)-oxidase activation, and nitric oxide synthase and peroxynitrite 
levels in the dorsal horn of the spinal cord. Furthermore, administration of peroxynitrite 
decomposition catalysts including FeTMPyP5+ and MnTE-2-PyP5+, attenuated the 
development of mechanical hypersensitivity induced by paclitaxel (Doyle et al., 2012). 
Studies also found that inhibition of ROS with the superoxide selective scavenger 4-
hydroxy-2,2,6,6-tetramethylpiperidine (TEMPOL) and a non-specific ROS scavenger N-
tert-Butyl-α-phenylnitrone (PBN) reversed hypernociceptive behavioral responses 
induced by paclitaxel (Fidanboylu et al., 2011), suggesting that antioxidants are 
important for the reversal of neurotoxic effects elicited by paclitaxel in animal models. 
While there are a number of proposed mechanisms to explain the effects of paclitaxel on 
neuronal sensitivity, subsequent drug targets evaluated in clinical trials have been 
unsuccessful in preventing the development of PIPN (Rivera and Cianfrocca, 2015). 
Therefore, there is still much detailed work needed to investigate how paclitaxel affects 
sensory neuronal function.  
 
7. Paclitaxel-Induced Modulation of Neurite Length 
 
There is much research focused on how paclitaxel alters the morphology of 
nerve fibers. It is well established that paclitaxel causes a reduction in the length of 
intraepidermal nerve fibers in patients treated with paclitaxel (Boyette-Davis et al., 2013). 
Studies in animal models of paclitaxel-induced peripheral neuropathy (PIPN) and in vitro 
culture models have found parallel effects of paclitaxel on nerve fiber and neurite 
morphology, respectively (described in detail below). Within the field, it is widely 
speculated that the changes in sensitivity and morphology of sensory nerve fibers are 
interdependent because a number of researchers have found an association between 
the development of hypernociceptive behavioral responses and altered nerve fiber 
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length (Siau et al., 2006, Jin et al., 2008, Boyette-Davis et al., 2011, Zhang et al., 2016). 
A plausible explanation is that the loss of nerve fiber innervation (i.e. IENF damage) 
enhances the sensitivity of the nerve fibers, or that damage to IENF occurs secondary to 
changes in the nerve fiber sensitivity. This section will discuss some of the main findings 
pertaining to the effects of paclitaxel on the morphology of neurites/nerve fibers. 
 In vitro assays have examined the effects of paclitaxel on neurite length using 
neuronal explants and dissociated neuronal cultures. Paclitaxel decreased neurite length 
in a concentration- and time-dependent manner in neuronal explants derived from dorsal 
root ganglia (DRG) and superior cervical ganglia (SCG) (Hayakawa et al., 1994, Konings 
et al., 1994, Scuteri et al., 2006). Treatment with concentrations as low as 100 nM for 24 
hours resulted in ~50% reduction in neurite length (Scuteri et al., 2006). Similarly, 
paclitaxel decreased the length of neurites in embryonic and adult DRG neuronal 
cultures (Malgrange et al., 1994, Melli et al., 2006, Yang et al., 2009, Pittman et al., 
2016). We have demonstrated that chronic treatment with 300 nM paclitaxel for 5 day 
decreases the length of neurites in cultured sensory neurons. In this work, I have 
expanded this finding to show that loss of neurite length occurs at an early earlier time 
point (i.e. 3 days) following exposure to 300 nM paclitaxel in cultured sensory neurons. 
Paclitaxel exerts its effect on neurite length at specific cellular sites. Investigators 
have used a compartmentalized microfluidic culture platform to isolate cellular 
compartments in a physical and fluidic manner so that the direct effects of paclitaxel on 
the soma versus the axonal processes can be assessed. Application of 29.3 nM 
paclitaxel for 24 hours to the axonal compartment caused a reduction in axonal length, 
with no changes in axonal length when paclitaxel was applied to the soma in embryonic 
DRG neuronal cultures (Yang et al., 2009). These studies suggest that the primary site 
of paclitaxel uptake or site of action is along the axons at the peripheral terminals of 
sensory neurons. 
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In addition to in vitro findings, the effects of paclitaxel on the length of nerve 
fibers have been substantiated using in vivo models of paclitaxel-induced peripheral 
neuropathy. Skin biopsies from animals injected intraperitoneally with a cumulative dose 
of 8 mg/kg indicate that paclitaxel decreased intraepidermal nerve fiber innervation 
(IENF) (Siau et al., 2006, Jin et al., 2008, Boyette-Davis et al., 2011, Ko et al., 2014). In 
this model, animals are injected with four doses of 2 mg/kg paclitaxel on alternate days 
and skin biopsy samples are typically taken 14–30 days following the first administration 
of paclitaxel in accordance with the development of nociceptive behavioral responses. 
The majority of studies found that IENF loss occurred 14 days or later following the first 
injection of paclitaxel (Siau et al., 2006, Jin et al., 2008, Boyette-Davis et al., 2011), 
however, a single study found pronounced loss of IENF 7 days following the first 
injection of paclitaxel (Ko et al., 2014). Higher cumulative doses of 24 mg/kg and 75 
mg/kg, injected both intravenously and intraperitoneally, also results in pronounced loss 
of IENF innervation (Melli et al., 2006, Liu et al., 2010). Because there is evidence to 
demonstrate that nociceptive behavioral changes (i.e. enhanced thermal sensitivity) can 
occur as early as 5 days following the first administration of paclitaxel (Polomano et al., 
2001), it appears that changes in IENF correlate with the development of some 
peripheral neuropathic symptoms, but not all. Of particular importance, studies have 
shown that paclitaxel decreased IENF innervation of peptidergic, substance P- and 
CGRP-positive nerve fibers (Ko et al., 2014). Loss of skin innervation of these neuronal 
populations would undoubtedly impact the detection and response to harmful, 
nociceptive environmental stimuli and could provide insight into the loss of function 
phenotype (i.e. reduced capsaicin-evoked blood flow and thermal hypoalgesia) observed 
following paclitaxel treatment.  
A number of factors have been reported to be involved in paclitaxel-induced loss 
of nerve fiber/neurite length. It has been reported that inflammation mediates the loss of 
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IENF innervation following treatment with paclitaxel. In animal models of PIPN, injection 
with minocycline, a microglial and macrophage inhibitor prior to, during, and after 
administration of paclitaxel reversed the loss of IENF induced by paclitaxel (Liu 2010 
and Davis 2011). However, there are inconsistencies in the literature regarding the role 
of inflammation. Numerous reports show that the inflammatory agent, nerve growth 
factor, has a stimulatory effect on neurite length and is capable of preventing the loss of 
neurite length induced by paclitaxel. In sensory and sympathetic neuronal explants, NGF 
increased neurite length and prevented the loss of neurite length induced by paclitaxel 
(Hayakawa et al., 1994, Konings et al., 1994, Malgrange et al., 1994). However, these 
neuroprotective effects of NGF were not replicable in dissociated DRG sensory neuronal 
cultures (Pittman et al., 2016). It is possible that NGF has different effects on neurite 
outgrowth in explants versus dissociated neurons. Studies have also shown that 
administration of recombinant human erythropoietin, a glycoprotein involved in red blood 
cell proliferation and maturation, reversed the effects of paclitaxel on IENF in embryonic 
DRG neuronal cultures (Melli et al., 2006, Yang et al., 2009).  
Paclitaxel alters the motility and growth of growth cones. Growth cones are 
enlarged regions at the tips of growing neurites that are important for guiding the neurite 
to specific targets based on environmental guidance cues (Tessier-Lavigne and 
Goodman, 1996). Studies have found that destabilization of microtubule dynamics 
caused the formation of “retraction bulbs” in growth cones which inhibited neurite 
extension and growth of neurites (Erturk et al., 2007), suggesting that changes in neurite 
length can occur as a result of retraction and/or inhibition of neurite extension. Because 
paclitaxel disrupts microtubule dynamics, which is important for growth cone motility, 
studies have focused on the effects of paclitaxel on growth cone morphology so as to 
better understand how paclitaxel reduces neurite length. Furthermore, studies are still 
needed to fully elucidate whether the reduction in neurite length induced by paclitaxel is 
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due to neurite retraction or inhibition of neurite extension. For growth cone morphology 
studies, it was found that treatment with 700 nM paclitaxel led to growth cone retraction 
in embryonic chick DRG neuronal cultures (Letourneau and Ressler, 1984), therefore 
implicating growth cone retraction in the reduction of neurite length induced by 
paclitaxel.  
In addition to growth cone motility, paclitaxel altered the structural components of 
growth cones. Within growth cones, microtubules undergo post-translational 
modifications including, tyrosination/detyrosination. α-tubulin microtubule subunits 
consist of a carboxy-terminal tyrosine that can be removed by a tubulin tyrosine 
carboxypeptidase (TTCP) to yield a detyrosinated tubulin with a glutamic acid residue 
exposed on the terminal ending (Argarana et al., 1978, Westermann and Weber, 2003). 
Re-addition of tyrosine is an ATP-dependent process that is catalyzed by tubulin tyrosine 
ligase (TTL) (Westermann and Weber, 2003). Due to the greater affinity of TTCP for 
tubulin polymers and TTL for tubulin dimers, detyrosination occurs after polymerization 
of microtubules and therefore examining the presence of detyrosinated microtubules can 
be used as a marker of microtubule stabilization (i.e. length of time that a microtubule 
exists in a polymerized form) (Webster et al., 1987, Wehland and Weber, 1987, 
Westermann and Weber, 2003). Studies have shown that paclitaxel affects the 
localization of tyrosinated and detyrosinated microtubules in growth cones. Upon 
paclitaxel treatment, it was found that tyrosinated microtubules (i.e. dynamic 
microtubules) did not extend as far into the peripheral region of growth cones (P domain; 
contains filopodia and lamellopodia protrusions and actin filaments) and that 
detyrosinated microtubules (i.e. stable microtubules) remained confined to the central 
region of growth cones (C domain; contains microtubules) compared to control neuronal 
explants (Challacombe et al., 1997). It was found that the effects of paclitaxel on growth 
cone motility and retraction were reversible following washout of drug treatment 
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(Challacombe et al., 1997), indicating that there was not permanent damage to the 
morphology of the neurite. These data indicate that paclitaxel has reversible but 
deleterious effects on the motility and structure of neurites in vitro. The reversible effects 
of paclitaxel on the morphology of neurons have also been confirmed in animal models 
of PIPN. It was found that nerve fiber loss induced by paclitaxel is reversible following 
administration of anti-inflammatory drugs and mitochondrial protective agents (Xiao et 
al., 2009, Boyette-Davis et al., 2011, Zhang et al., 2013).  
 
8. Protein Kinase C as a Molecular Target for PIPN: Evidence for PKC-Induced 
Modulation of Neuronal Sensitivity in In Vitro and In Vivo Models of Paclitaxel-
Induced Peripheral Neuropathy  
 
Conventional and novel protein kinase C isozymes (c/nPKC) are intracellular 
signaling proteins that can be activated by a number of co-factors in sensory neurons, 
including phospholipids, calcium and diacylglycerol, and are well-established modulators 
of neuronal sensitivity in cultured dorsal root ganglion sensory (DRG) neurons. Exposure 
to phorbol esters, which activate c/nPKC enhanced the release of the neuropeptide, 
calcitonin gene-related peptide (CGRP) (Supowit et al., 1995, Barber and Vasko, 1996), 
whereas downregulation of c/nPKC by chronic phorbol ester treatment attenuated 
capsaicin-evoked neuropeptide release in isolated sensory neurons (Barber and Vasko, 
1996). Studies also show that activation of c/nPKC enhanced heat- and capsaicin-
evoked currents in isolated DRG sensory neurons (Cesare et al., 1999, Vellani et al., 
2001, Zhou et al., 2001, Li et al., 2014) and increased calcium uptake via the heat 
responsive transient receptor potential vanilloid 1 (TRPV1) channel (Olah et al., 2002), 
therefore suggesting that c/nPKC play a large role in modulating the function of TRPV1 
channels. Given the precedence in the literature supporting a role for PKC in the 
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regulation of neuronal function and its effect on TRPV1 channel function, it is 
unsurprising that researchers have implicated several PKC isozymes in the gain of 
neuronal function following treatment with paclitaxel.  
 Recent studies have suggested that c/nPKC mediate enhanced neuronal 
sensitivity induced by paclitaxel. In rodent models, administration of PKCβII, PKCδ and 
PKCε inhibitory peptides reversed heat, cold and mechanical hypersensitivity induced by 
chronic administration of paclitaxel (Dina et al., 2001, Chen et al., 2011, He and Wang, 
2015). In an acute in vitro model, c/nPKC mediate an enhanced neuropeptide release 
following 10-30 minute exposures to paclitaxel in isolated DRG sensory neurons (Miyano 
et al., 2009, He and Wang, 2015). However, the onset of symptoms of peripheral 
neuropathy is typically 3-6 weeks following the first infusion of paclitaxel (Forsyth et al., 
1997), and it is not known whether c/nPKC contribute to the maintenance of changes in 
neuronal sensitivity following chronic treatment with paclitaxel in sensory neurons. For 
our work we were interested in evaluating whether c/nPKC were responsible for changes 
in neuronal sensitivity induced by chronic treatment with paclitaxel (1-5 days) in isolated 
DRG sensory neurons. We used the release of calcitonin gene-related peptide (CGRP) 
as a functional read-out of neuronal sensitivity. The use of DRG neuronal cultures are 
advantageous and physiologically relevant since paclitaxel has been found to 
accumulate in sensory axons and soma with little penetration to the central nervous 
system due to its inability to cross the blood-brain barrier (Glantz et al., 1995, Cavaletti 
et al., 2000). In addition, we are able to study the effects of paclitaxel on specific 
subpopulations of sensory neurons, specifically, the CGRP- and TRPV1-positive 
neurons in DRG. Furthermore, the use of DRG neuronal cultures allows us to easily 
manipulate signaling pathways using pharmacological tools.  
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9. Classification, Structure and Regulation of Protein Kinase C 
 
Protein kinase C (PKC) is a family of serine/threonine kinases comprised of ten 
isozymes divided into three classes: conventional (α, βI, βII and γ), novel (ε, δ, θ, η) and 
atypical (ζ and λ/ι) (Steinberg, 2008). The work presented in this dissertation will focus 
on the conventional and novel PKC isozymes. The major functional domains of these 
isozymes are the regulatory N-terminal and the catalytic C-terminal domains (Figure 1).   
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Figure 1: Structure of Protein Kinase C. Diagram showing the linear structure of 
conventional and novel PKC isozymes, adapted from published work from 
Alexandra Newton.  
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The regulatory domain is important for controlling the activation of the protein. It 
consists of a pseudosubstrate autoinhibitory domain, two tandem C1 domains, C1A and 
C1B, and a C2 domain (House and Kemp, 1987, Hurley et al., 1997). It is important to 
note that variable domains are interspersed between the different domains. The 
pseudosubstrate autoinhibitory domain is important for maintaining the protein in an 
inactive conformation by binding to and masking the catalytic site in the C-terminal 
domain (Ron and Mochly-Rosen, 1995). The amino acid sequence of the 
pseudosubstrate autoinhibitory domain resembles a substrate phosphorylation site in the 
distribution of basic residues around a phosphorylation site, with the exception that an 
alanine is in place of a phosphorylatable serine/threonine (House and Kemp, 1987). 
Adjacent to the autoinhibitory domain are the C1 domains, C1A and C1B. 
Crystallography and NMR structural studies show that the C1 domain is a cysteine-rich 
globular domain that is important for anchoring PKC to cellular membranes (Hommel et 
al., 1994, Zhang et al., 1995). It is believed that positively charged residues interact with 
anionic phospholipids in the cellular membrane resulting in penetration of the cellular 
membrane and the subsequent binding of activating lipid co-factors, such as 
diacylglycerol (DAG) and phorbol esters, to the ligand-binding pocket (a polar groove 
within a hydrophobic portion of the domain) (Zhang et al., 1995). This binding creates a 
contiguous hydrophobic surface for membrane interaction (Zhang et al., 1995). The 
association activates PKC by inducing conformational changes resulting in the release of 
the autoinhibitory domain from the catalytic site (Newton, 1996). Novel PKC isozymes, 
which have a tryptophan at position 22 in the C1B domain, bind DAG with higher affinity 
compared to conventional PKC isozymes, which have a tyrosine at position 22 (Dries et 
al., 2007). Therefore, the lipid composition of cellular membranes affects the subcellular 
localization of PKC isozymes, and provides an explanation for why novel PKC isozymes 
are primarily recruited to DAG-rich Golgi membranes (Gallegos et al., 2006, Dries et al., 
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2007). Similar to the C1 domain, the C2 domain in conventional PKC isozymes functions 
as a membrane-anchoring module, however, its relevance in novel PKC isozymes 
remains unknown (Newton, 2001, Giorgione et al., 2006). Structural studies of the C2 
domain from PKCβ indicate that this domain, which consists of two sheets of anti-parallel 
β strands, binds 3 calcium ions (Sutton and Sprang, 1998). In fact, the low affinity 
binding of calcium increases the affinity of the C2 domain for anionic membranes 
(Nalefski and Newton, 2001). In addition, studies also show that acidic phospholipids 
present within cellular membranes increase the affinity of conventional PKC isozymes 
for calcium binding (Bazzi and Nelsestuen, 1990). Conversely, novel PKC isozymes do 
not bind calcium ions as they lack the acidic residues necessary for coordinating calcium 
(Pappa et al., 1998) and are therefore insensitive to changes in intracellular calcium.  
Prior to the activation of PKC by co-factors, PKC must be processed to ensure 
the generation of a stable and catalytically competent enzyme. Phosphorylation at three 
conserved sites in the activation loop, turn motif and hydrophobic motif of the catalytic 
domain enables PKC to respond to second messenger signals (Keranen et al., 1995). 
The first phosphorylation occurs in the activation loop by phosphoinositide-dependent 
kinase 1 (PDK-1) (Dutil et al., 1998). Subsequent autophosphorylation occurs at sites in 
the turn motif and the hydrophobic motif (Keranen et al., 1995, Behn-Krappa and 
Newton, 1999). While phosphorylation at the activation loop is required for the initial 
processing of PKC, it is not needed to maintain enzyme activity once the other two sites 
have been phosphorylated (Keranen et al., 1995). In fact, dephosphorylation by cellular 
phosphatases plays a crucial role in inactivating the enzyme. It was found that, while 
protein phosphatase 1 (PP1) dephosphorylated PKCβII at all three phosphorylation sites 
resulting in an inactive enzyme, protein phosphatase 2A (PP2A) only dephosphorylated 
at T500 (activation loop) and S660 (hydrophobic motif) resulting in an active protein, 
suggesting that phosphorylation at the turn motif, T641 is critical for catalytic activity of 
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the protein (Keranen et al., 1995). In addition to the phosphorylation sites, the catalytic 
domain consists of a glycine-rich ATP binding pocket and a substrate-binding cavity. 
This region of PKC facilitates the binding of ATP and the subsequent transfer of a 
phosphate group from ATP to serine or threonine residues of PKC substrates.  
Prolonged agonist-induced activation of PKC causes protein downregulation. 
Early studies showed that prolonged activation of PKC upon chronic treatment with 
phorbol esters (≥ 5 hrs) increased the rate of protein degradation with no changes in 
mRNA levels or the rate of protein synthesis (Young et al., 1987). Furthermore, there is 
a correlation between membrane translocation and PKC downregulation following 
chronic exposure (≥ 24 hrs) to substances that activate PKC such as bombesin (a 
neuropeptide), 1-oleolyl-2-acetyl-sn-glycerol (OAG, synthetic analog of diacylglycerol) 
and platelet derived growth factor (PDGF) (Olivier and Parker, 1994). When active, PKC 
resides at cellular membranes in an open conformation in which the pseudosubstrate is 
displaced and the phosphate groups are exposed to cellular phosphatases. In this 
conformation, the proteolytically labile hinge between the regulatory and catalytic domain 
is also susceptible to cleavage by proteases. It was found that pre-treatment with calpain 
inhibitors and mutation of calpain cleavage sites in the PKC hinge region did not prevent 
phorbol ester-induced PKC downregulation (Junco et al., 1994, Junoy et al., 2002). 
Instead, dephosphorylation of PKC by phosphatases predisposes PKC to agonist-
induced downregulation (Borner et al., 1989, Lee et al., 1996a, Hansra et al., 1999).  It 
was found that membrane associated heterotrimeric type 2A phosphatase (PP2A) 
dephosphorylates PKCα with subsequent downregulation (Hansra et al., 1996). In 
addition, knockdown of protein phosphatase, PHLPP (PH domain Leucine–rich repeat 
Protein Phosphatase) prevents phorbol ester induced dephosphorylation/downregulation 
of PKCα (Gao et al., 2008).  Downregulation of PKC also occurs via the ubiquitin 
proteasome pathway. One of the main functions of the ubiquitin proteasome pathway is 
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to remove damaged proteins from the cell. Alternatively, it also serves to control 
signaling pathways by removing signaling proteins no longer required or needed by the 
cell. The addition of a ubiquitin “tag” marks the protein for proteasome degradation. In 
this pathway, ubiquitin is activated by the E1 (ubiquitin-activating enzyme) in an ATP-
dependent manner. It is then transferred to E2 (ubiquitin-conjugating enzyme), which 
then transfers the ubiquitin molecule to the target substrate via E3 (ubiquitin-protein 
ligase) (Reinstein and Ciechanover, 2006). Following the additions of several ubiquitin 
moieties to the substrate, ubiquitin-tagged substrate is directed to the 26S proteasome 
complex, where the protein substrate is degraded into peptides and free re-usable 
ubiquitin moieties (Reinstein and Ciechanover, 2006). Studies have shown that 
prolonged treatment with the PKC activators, phorbol esters and bryostatin, increases 
PKC ubiquitination and that pre-treatment with proteasome inhibitors blocks the agonist-
induced downregulation of PKC (Lee et al., 1996a, Lee et al., 1996b, Lu et al., 1998). 
Lastly, studies also demonstrate that downregulation of PKC occurs through 
internalization and trafficking pathways. Studies show that pre-treatment with nystatin, 
an inhibitor of caveolae mediated trafficking, prevented phorbol ester-induced PKC 
downregulation, and that PKC co-localized with the endosome markers, annexin I, 
caveolin I and Rab5 upon chronic treatment with phorbol esters (Prevostel et al., 2000). 
The downregulation of PKC can occur via multiple distinct pathways, however, the cell 
has also designed a mechanism to override the unwanted downregulation of PKC. 
Although mature dephosphorylated PKC is commonly targeted for degradation, the 
binding of heat shock protein 70 (Hsp 70) to the turn motif stabilizes the protein and this 
association is believed to promote the re-phosphorylation of PKC, therefore prolonging 
the signaling capacity of PKC (Gao and Newton, 2002).  
The spatio-temporal function of PKC is regulated by its interaction with anchoring 
proteins. These proteins serve multiple functions: 1. They position individual PKC 
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isozymes in specific locations in order to respond to and facilitate receptor mediated 
signaling; 2. They position PKC isozymes within close proximity to their respective 
substrates; 3. They facilitate the movement of PKC between different intracellular 
compartments and 4. They allow for the integration of multiple signaling pathways by 
bringing PKC into close proximity with other signaling proteins (Jaken and Parker, 2000). 
Receptors for activated C kinase (RACKs) is a term used to collectively describe 
anchoring proteins that bind activated PKC. Work by Mochly-Rosen’s group showed that 
RACKs bind activated PKC at a site distinguishable from the substrate-binding site in a 
concentration-dependent, saturable and specific manner (Mochly-Rosen et al., 1991). 
One such example is RACK1, which was discovered upon screening a rat brain 
expression library for proteins that bind activated PKC. RACK1 is a member of the 
tryptophan, aspartic acid repeat (WD) family of proteins and functions as a scaffolding 
protein and provides binding sites for multiple proteins via its WD repeats (Adams et al., 
2011). In the case of PKC, studies show RACK1 binds to the C2 domain and V5 region 
of PKC; inhibition of this binding interaction prevented agonist-induced translocation of 
PKC (Ron et al., 1995, Stebbins and Mochly-Rosen, 2001). It is believed that RACK1 is 
specific for binding PKCβII as studies showed that RACK1 co-localized with activated 
PKCβII but not PKCε or PKCδ in cardiac myocytes (Ron et al., 1995). Another example 
of a RACK is the coatomer protein, β’COP (also referred to as RACK2). β’COP binds to 
the V1 region of PKCε and both proteins co-localize in cardiac myocytes; inhibition of 
this interaction blocks agonist-induced translocation and function of PKCε in 
cardiomyocytes (Johnson et al., 1996, Csukai et al., 1997). Given the agonist-induced 
translocation of PKC and evidence for RACKs, it has been suggested that receptors for 
inactive C kinase (RICKs) exist and bind and anchor inactivated PKC (Mochly-Rosen 
and Gordon, 1998), however, more studies are needed to evaluate the nature of RICKs. 
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Anchoring proteins play an important role in the localization of PKC within the cell and 
likely provide one mechanism for isozyme-selective function of PKC.  
 
10. Methods to Manipulate Protein Kinase C Activity 
 
 The activity of protein kinase C (PKC) can be manipulated by numerous genetic 
and pharmacological approaches. Common genetic manipulation of PKC activity 
includes siRNA-mediated knockdown, overexpression of wild-type and mutant PKC and 
knockout of PKC-encoding genes. Such manipulation has been used in a wide number 
of studies to study the function of PKC both in vitro and in vivo. Another common 
approach is to use small molecule activators and inhibitors of PKC. Using broad-
spectrum PKC activators/inhibitors can be very useful in preliminary studies to target the 
activation of multiple PKC isozymes at one time. However, these molecules do not 
differentiate between the different PKC isozymes and they may also have non-specific 
effects on other kinases. In our studies, we used this approach in order to first confirm 
the role of PKC in mediating the effects of paclitaxel on sensory neuronal function, and 
then proceeded to use selective PKC inhibitors in order to discriminate between the 
actions of the different PKC isozymes. 
For the most part, the majority of pharmacological activators and inhibitors target 
the regulatory C1 domain and the ATP-binding kinase domain. Interestingly, these are 
the regions of greatest sequence homology amongst the conventional and novel PKC 
isozymes. There is 51%, 41% and 85% sequence homology for PKCβ, PKCε and PKCθ 
respectively within the C1 domain when compared to PKCδ and analysis of the kinase 
domain reveals that there is 65%, 62% and 67% sequence homology for PKCβ, PKCε 
and PKCθ when compared to PKCδ (Mochly-Rosen et al., 2012). This in part provides 
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some explanation for why many of the pharmacological activators and inhibitors are non-
selective for given PKC isozymes (Mochly-Rosen et al., 2012).  
The two main groups of compounds commonly used to inhibit and activate PKC 
are the ATP-competitive small molecule inhibitors and the diacylglycerol mimetics, 
respectively (Figure 2; diagram indicates sites of action for pharmacological agents used 
in the studies within this dissertation to manipulate conventional and novel PKC 
isozymes).  
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inhibitors.  
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The ATP-competitive small molecule inhibitors compete with ATP for binding at 
the ATP-binding site in the catalytic domain of PKC. Examples include staurosporine, 
the bisindolylmaleimides and the indolocarbazoles. Staurosporine is a pan-PKC inhibitor 
that is known to inhibit additional serine/threonine and tyrosine kinases such as 
phosphorylase kinase, PKA and myosin light chain kinase (Way et al., 2000); however, 
the structure of staurosporine has been used to develop the more selective 
bisindolylmaleimides and the indolocarbazoles. I will highlight the features of the most 
commonly used compounds from these two groups of inhibitors as these have been 
used in our experiments. Bisindolylmaleimide I (Bis I; also known as GF 109203X) is a 
selective inhibitor of PKC with IC50 values from 8-230 nM for the different conventional 
and novel PKC isozymes; it also does not interfere with the binding of PDBu to PKC 
(Toullec et al., 1991). Despite the strong homology within the ATP binding domain 
between PKC and other kinases, it is believed that the protein tertiary structure, rather 
than the amino acid sequence, is responsible for selectivity of bisindolylmaleimide I (and 
other structurally-related compounds) for the ATP binding domain of PKC (Toullec et al., 
1991). A widely used indolocarbazole is Gö6976. Unlike bisindolylmaleimide I, which 
inhibits the activity of both conventional and novel PKC isozymes, Gö6976 discriminates 
between these two classes of PKC isozymes and has been shown to be a selective 
inhibitor of conventional PKC isozymes with concentrations up to 3 μM (Martiny-Baron et 
al., 1993). It is important to note that there are numerous bisindolylmaleimides and 
indolocarbazoles and many of them have been found to preferentially inhibit the activity 
of specific PKC isozymes. One such example is the bisindolylmaleimide, LY333531 
(also known as ruboxistaurin). This compound is a PKCβ selective inhibitor that inhibits 
PKCβI and PKCβII in the nanomolar range, resulting in a 76- and 61- fold selectivity for 
inhibition of PKCβI and PKCβII over PKCα (Jirousek et al., 1996). In fact, clinical trial 
studies have demonstrated that administration of ruboxistaurin alleviates sensory 
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neuropathic symptoms associated with diabetic peripheral neuropathy (Vinik et al., 2005, 
Casellini et al., 2007); no clinical studies have investigated the effects of ruboxistaurin on 
chemotherapy-induced peripheral neuropathy. However, like many other drugs, there 
are adverse effects associated with ruboxistaurin, including, myocardial ischemia 
(Bansal et al., 2013). This demonstrates that perturbation of PKC activity disrupts 
signaling events in different cell types.  
Unlike the ATP inhibitors, which target the kinase domain, the diacylglycerol 
mimetics target the C1 domain of PKC. Similar to diacylglycerol, a physiological activator 
of PKC, these compounds bind to the diacylglycerol-binding pocket to elicit the activation 
of PKC. Phorbol esters and bryostatin 1 are commonly used diacylglycerol mimetics for 
PKC activation. For our studies we used the phorbol ester, phorbol 12, 13-dibutyrate 
(PDBu) to activate the conventional and novel PKC isozymes (c/nPKC). Another widely 
used phorbol ester is phorbol 12-myristate 13-acetate (PMA), also referred to as 12-O-
tetradecanoylphorbol-13-acetate (TPA). Phorbol esters are potent activators of c/nPKC 
isozymes and possess a higher affinity for binding the C1 regulatory domain when 
compared to the physiological activator, diacylglycerol (DAG) (Gould and Newton, 2008). 
In fact, phorbol esters are able to elicit the activation of conventional PKC isozymes in 
the absence of calcium because the binding of the C1 domain to phorbol-ester 
containing membranes is two orders of magnitude higher than that of membranes 
containing diacylglycerol (Newton, 2001, Gould and Newton, 2008). Furthermore, unlike 
DAG, phorbol esters are not metabolized in the cell and therefore elicit a more prolonged 
activation of PKC. DAG, on the other hand, elicits short-term activation of PKC because 
it is metabolized in the cell.  There are 3 main pathways for DAG metabolism. The first 
pathway, which is considered to be the main route of DAG metabolism, occurs via 
diacylglycerol kinase phosphorylation of the free hydroxyl group to generate 
phosphatidic acid (Luo et al., 2004). Secondly, the fatty acyl chain is hydrolyzed by 
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diacylglycerol lipase to form monoacylglycerol and a free fatty acid, and thirdly there is 
the addition of CDP-choline or ethanolamine to form phosphatidylcholine or 
phosphatidylethanolamine, respectively (Luo et al., 2004). Therefore, endogenous 
activation of PKC by diacylglycerol is a short-lived and less potent response compared 
to pharmacological activation of PKC. 
Disrupting protein-protein interactions between PKC and its corresponding 
anchoring proteins (receptor for activated C kinase; RACK) is another technique used to 
alter PKC activity. As mentioned in the previous section, RACKs play a role in orienting 
activated PKC at specific subcellular regions within the cell. Peptide inhibitors and 
activators are commonly used to alter the protein-protein interactions to result in either 
inhibition or activation of PKC. For our studies, we used both peptide inhibitors and 
activators of PKCε to modulate PKCε activity. The PKCε inhibitor peptide, εV1-2, is 
derived from a sequence within the V1 domain of PKCε that binds to the RACK2 β’COP 
(Dorn et al., 1999, Brandman et al., 2007). The PKCε inhibitor peptide binds to RACK2 
and therefore disrupts the protein-protein interaction between PKCε and RACK2 which 
subsequently inhibits agonist-induced activation of PKCε and its membrane translocation 
(Csukai and Mochly-Rosen, 1999). Conversely, the PKCε activator peptide, ψεRACK, 
acts as an allosteric activator and is derived from a sequence in the C2 domain of PKCε 
that is involved in autoinhibitory interactions. Short sequences in the C2 domain were 
found to be homologous to a sequence in the corresponding RACK for given PKC 
isozymes (Kheifets and Mochly-Rosen, 2007). These short sequences have a low 
intramolecular affinity for the RACK binding site in comparison to the high intermolecular 
affinity of the RACK binding site with the corresponding RACK (Kheifets and Mochly-
Rosen, 2007). As such, the allosteric activator peptide activates PKC by inhibiting the 
low intramolecular autoinhibitory interaction between the pseudo-RACK site and RACK 
binding site within PKC (Kheifets and Mochly-Rosen, 2007, Mochly-Rosen et al., 2012); 
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the activator peptide binds with high affinity to the RACK binding site. In cardiac 
myocytes, it was shown that treatment with the PKCε activator peptide increases 
translocation of PKCε (Dorn et al., 1999).  
Pseudosubstrate inhibitors can also be used to block the activity of PKC. For our 
studies we used a myristolyated PKCα/β peptide inhibitor to specifically block the activity 
of PKCα and PKCβI/II isozymes. This peptide, which is derived from a homologous 
sequence within the pseudosubstrate region of PKC α, βI and βII consists of Ala25 
instead of a phosphorylatable serine/threonine residue and binds to the substrate 
binding cavity to maintain the protein in an inactive conformation (House and Kemp, 
1987). 
 
11. Protein Kinase C as a Modulator of Neuronal Sensitivity  
 
Protein Kinase C (PKC)-induced phosphorylation of membrane channels alters 
channel function with subsequent changes in neuronal activity. There are numerous 
studies demonstrating that paclitaxel modulates neuronal sensitivity by altering the 
function of membrane bound ligand-gated and voltage-gated ion channels. Given the 
precedence in the literature supporting a role for PKC modulation of neuronal activity, we 
questioned whether PKC mediated changes in neuronal sensitivity induced by chronic 
treatment with paclitaxel. In this section, I will discuss the role of PKC in the modulation 
of membrane channels that have been implicated in paclitaxel-induced neurotoxic 
effects.  
The function of transient receptor potential vanilloid 1 (TRPV1) channels is 
modulated by PKC. TRPV1 channels are expressed in the nociceptive population of 
sensory neurons and can be activated by multiple stimuli including noxious heat (> 
43°C), capsaicin, low pH and reactive oxygen species (Caterina et al., 1997, Tominaga 
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et al., 1998, Caterina and Julius, 2001, Tominaga and Tominaga, 2005, Ibi et al., 2008). 
Pre-treatment with PDBu sensitizes capsaicin-induced currents in trigeminal ganglia 
sensory neurons and TRPV1-expressing oocytes (Premkumar et al., 2005, Jeske et al., 
2009) and sensitizes capsaicin-induced calcium influx in embryonic DRG neurons and 
TRPV1-expressing CHO cells (Premkumar et al., 2005, Jeske et al., 2009). Studies 
found that the scaffolding protein, A-kinase anchoring protein 150 (AKAP 150) is 
necessary for mediating the effects of PKC on TRPV1 function. It was found that 
knockdown of AKAP150 or deletion of the PKC binding site within AKAP150 prevented 
PKC-induced sensitization of TRPV1 channels at both the cellular and behavioral level 
(Jeske et al., 2009). This suggests that AKAP150 positions PKC in close proximity to 
TRPV1 for phosphorylation, therefore indicating that there is no direct interaction 
between the PKC isozyme responsible for this observed effect and TRPV1. Investigators 
have also identified the specific amino acid residues that are phosphorylated by PKC. It 
was found that treatment with phorbol esters increased the phosphorylation of TRPV1 at 
residues S502 and S800 and that these specific residues mediated phorbol ester-
induced potentiation of capsaicin- and heat-evoked currents in COS7 cells and HEK 
cells (Numazaki et al., 2002, Bhave et al., 2003, Mandadi et al., 2006). Using in vitro 
kinase assays it was determined that calcium-independent novel PKC isozyme, PKCε, is 
responsible for TRPV1 phosphorylation at those sites (Numazaki et al., 2002). 
Electrophysiology studies support this finding since treatment with a constitutively active 
PKCε construct enhanced heat-activated membrane currents and treatment with the 
PKCε translocation inhibitor attenuated bradykinin sensitization of heat-activated 
currents (Cesare et al., 1999), implicating PKCε in the sensitization of heat-activated 
TRPV1 channels via a bradykinin/Gq/PLC/DAG/PKC signaling pathway. Phosphorylation 
of TRPV1 by PKC also serves to re-sensitize the TRPV1 channel following 
desensitization. Studies demonstrate that capsaicin-induced desensitization of TRPV1 
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due to successive applications of capsaicin can be reversed upon treatment with phorbol 
esters; an effect that is prevented following pre-treatment with the PKCε inhibitory 
peptide and mutation of S502 and S800 (Mandadi et al., 2004, Mandadi et al., 2006). In 
contrast to PKCε, which has been suggested to potentiate TRPV1-evoked responses, 
the conventional PKC isozyme PKCβII has been implicated in directly altering the basal 
thermal sensitivity of the TRPV1 channel. It was found that PKCβII-induced 
phosphorylation of TRPV1 at T705 was necessary for TRPV1 responsiveness to 
capsaicin and heat; overexpression and knockdown of PKCε did not alter basal TRPV1 
heat responsiveness (Li et al., 2014).  However, similar to other researchers, these 
studies showed that the potentiating effects of PKC on bradykinin sensitization of 
capsaicin-activated currents were mediated by PKCε (Li et al., 2014).  
 The function of voltage-gated calcium channels is modulated by PKC. Treatment 
with the phorbol ester, 4β-phorbol 12-myristate 13-acetate (PMA), increased calcium 
currents in adult rat sensory and sympathetic neurons (Zhu and Ikeda, 1994, King et al., 
1999). The N-type calcium channels, which account for 60-70% of calcium currents in 
sympathetic and sensory neurons (Zhu and Ikeda, 1994, Evans et al., 1996), were 
responsible for the observed effects of PMA enhancement of calcium currents. 
Furthermore, studies have identified that the PKC scaffolding protein, enigma homolog 
(ENH), binds to both PKCε and N-type calcium channels to facilitate the modulation of 
channel activity by PKCε (Maeno-Hikichi et al., 2003). Opposing effects of phorbol esters 
on calcium channel currents has also been documented. In DRG neurons derived from 
fetal mice and chick embryos, exposure to phorbol esters, phorbol 12,13-dibutyrate 
(PDBu) and 12-deoxyphorbol 13-isobutyrate (DPB), decreased calcium currents (Rane 
and Dunlap, 1986, Gross and MacDonald, 1989). These effects were also confirmed 
using 1,2-oleoylacetylglycerol (OAG), a synthetic non-phorbol ester membrane 
permeable diacylglycerol analogue. Studies have also implicated PKC in the modulation 
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of N-type channel function using neuropeptide release as a functional endpoint. In 
cultured sensory neurons, pre-treatment with the N-type calcium channel blocker, ω-
conotoxin GVIA, attenuated PKC-dependent bradykinin-stimulated peptide release 
(Barber and Vasko, 1996, Evans et al., 1996).  
 
12. Protein Kinase C as a Modulator of Neurite Length 
 
Protein Kinase C (PKC) regulates neurite outgrowth in different cell types. Early 
studies examining the role of PKC in neurite length used phorbol esters to manipulate 
the activity of PKC. Chronic exposure to phorbol esters increased the length of neurites 
from sensory, sympathetic and parasympathetic ganglia explants, neuroblastoma cells, 
hypothalamic neuronal cell lines, dissociated ciliary neurons and PC12 cells (Spinelli et 
al., 1982, Hsu, 1985, Hsu et al., 1989, Mehta et al., 1993, Roivainen et al., 1993, Burry, 
1998, Choe et al., 2002). Although a chronic phorbol ester treatment paradigm was 
applied for most of these studies, it was demonstrated that a brief exposure to 20 nM 
phorbol 12-myristate 13-acetate (PMA) for 30 minutes increased neurite length in 
sensory ganglia explants grown in the presence of nerve growth factor (NGF); an effect 
that was reversed by application of the PKC inhibitor staurosporine (Mehta et al., 1993).  
These studies also highlighted the importance of growth factors in PKC regulation of 
neurite length. In PC12 cells, treatment with PMA did not induce neurites in cells grown 
in the absence of NGF, but did enhance NGF-induced neurite outgrowth (Roivainen et 
al., 1993). In addition to the use of PKC activators, it was shown that inhibition of PKC 
activity using the broad spectrum PKC inhibitors, chelerythrine and staurosporine, 
decreased the number of neurites in isolated mouse DRG cells and decreased NGF-
induced neurite outgrowth in chick DRG explants and a subline of PC12 cells, 
respectively (Sano et al., 1994, Hiruma et al., 1999). Studies have also shown that 
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treatment with rottlerin, a PKCδ specific inhibitor, prevented NGF-induced neurite length 
(Corbit et al., 1999). For our studies, we were interested in determining whether 
activation of PKC altered the length of neurites in cultured sensory neurons. We used an 
acute phorbol ester treatment paradigm (≤ 30 minutes) to assess whether phorbol-ester 
induced activation of conventional and novel PKC isozymes altered the length of 
neurites in cultured sensory neurons. Because chronic treatment with paclitaxel 
decreases the length of neurites, our goal was to determine whether activation of PKC 
would attenuate or reverse the effects of paclitaxel on neurite length.  
PKCε has been identified as the major contributor to changes in neurite 
outgrowth using genetic manipulation and treatment with PKC inhibitory peptides. In 
PC12 cells, overexpression of PKCε increased NGF-induced neurite length in PC12 
cells (Hundle et al., 1995, Brodie et al., 1999); an effect that was blocked by the PKC 
inhibitor, bisindolylmaleimide I (Bis I) (Hundle et al., 1995). It was also demonstrated that 
overexpression of dominant negative PKCε mutant blocked NGF-induced neurite 
outgrowth (Brodie et al., 1999). Similar findings were observed in neuroblastoma cells 
and neuronal cell lines, where overexpression of full-length PKCε and overexpression of 
the regulatory domain of PKCε increased neurite length (Zeidman et al., 2002, Ling et 
al., 2004). Furthermore, an inhibitory fragment derived from amino acids 2-144 of PKCε 
blocked phorbol ester enhancement of neurite outgrowth induced by NGF (Hundle et al., 
1997). Studies also have shown that PKCε is localized within growth cones in PC12 cells 
(Hundle et al., 1995) and that treatment with the PKCε inhibitory fragment prevented 
growth cone localization of PKCε (Hundle et al., 1997). Since the growth cone is present 
at the tip of neurites and is important for the navigation of neurites to specific targets, the 
localization of PKCε within these structures suggests that PKCε is involved in the motility 
of neurites. These studies proposed that the modulation of NGF-induced neurite 
outgrowth by PKC involves the mitogen-activated protein kinases (MAPK) signaling 
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pathway. In comparative studies, it was found that PKCδ does not play a role in the 
observed changes in neurite outgrowth because treatment with an inhibitory fragment 
derived from PKCδ did not alter phorbol ester enhancement of neurite length in cells 
treated with NGF nor did it alter ERK1/2 phosphorylation (Hundle et al., 1997). 
Studies have determined the specific regions of PKCε that are important for 
neurite induction. Mutational studies showed that maximal neurite outgrowth was 
dependent on the pseudosubstrate, C1 domains, and the variable 3 region (Ling et al., 
2005) with subsequent lipid overlay studies showing that both the pseudosubstrate and 
C1 domain of PKCε bound strongly to PIP2 and that this interaction with the V3 domain 
was necessary and sufficient for neurite induction (Shirai et al., 2007). Using sequence 
alignment and point mutational studies with PKCα, an established non-neuritogenic, and 
PKCε, a neuritogenic, it was found that residues such as asparagine 49 in the base of 
the C1b domain of PKCε were important for the neurite inducing capacity of PKCε (Ling 
et al., 2007). Because the C1 domains of PKC act as a membrane-targeting module 
following activation of PKC by lipids (such as diacylglycerol and phospholipids), it would 
appear that activation of PKC and its subsequent association with lipid-containing 
cellular membranes is necessary for inducing neurite outgrowth.  
While the majority of studies implicate PKCε in regulating neurite outgrowth, 
there are studies that suggest the involvement of additional PKC isozymes in the 
modulation of neurite induction. Overexpression of the regulatory domains of PKC δ and 
η increased neurite length in neural cell lines and neuroblastoma cells (Zeidman et al., 
2002, Ling et al., 2004). Another study found that treatment with kinase dead mutant 
constructs of PKCα, PKCβI and PKCβII and LY333531 (PKCβ selective inhibitor) 
abolished neural cell adhesion molecule (NCAM)-stimulated neurite outgrowth, but had 
no effect on NGF-stimulated neurite outgrowth. NCAM is a cell recognition protein that 
has been implicated in neurite extension via activation of PKC and Ras-MAPK signaling 
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pathways (Kolkova et al., 2000). This study highlighted that the role of PKC in neurite 
outgrowth is dependent on very specific signaling pathways. Another study found that 
the PKCα inhibitor, safingol, inhibited PMA induced neurite length, whereas, inhibition of 
PKCδ using rottlerin had no effect in a hypothalamic neuronal cell line (Choe et al., 
2002).  
In addition to examining changes in neurite length, studies have also investigated 
the role of PKC in changes in the morphology of growth cones. The growth cone is an 
enlarged region at the tip of neurites that is responsible for responding to local guidance 
cues in the surrounding environment and the regulation of the directionality and growth 
of neurites (Tanaka and Sabry, 1995, Tessier-Lavigne and Goodman, 1996). Therefore 
having an understanding for the role of PKC in growth cone motility sheds light on the 
potential effects of PKC on neurite length. In cultured hippocampal neurons, a 20-minute 
exposure to PMA induces growth cone collapse; the PKC inhibitor, bisindolylmaleimide I, 
reverses the effect (Ren et al., 2015). In this study, knockdown of PKCε and its 
scaffolding protein, the PDZ and LIM domain 5 protein (PDLIM5), prevented growth cone 
collapse induced by PMA (Ren et al., 2015) therefore suggesting that PKCε was 
responsible for reducing the advancement of neuronal growth cones, implying a possible 
role in inhibition of neurite outgrowth. Additionally, it was found that treatment with PMA 
reduced the length of the growth cone structures, filopodia and lamellopodia in cultured 
chick DRG neurons; an effect that was reversed by Bis I (Bonsall and Rehder, 1999).  
Previous studies highlight the importance of PKC in the regulation of the neurite 
outgrowth and motility of growth cones. It is evident that PKC has largely been 
implicated in enhancing the total neurite length with the suggestion that it might have an 
opposite effect on growth cone morphology. There is currently a lack of data focused on 
how PKC modulates neurite length in cultured DRG sensory neurons, specifically, PKCε. 
Our laboratory has previously established an assay to measure total changes in neurite 
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length and branching (Pittman et al., 2014), and we decided to incorporate this assay 
into our neurite morphology studies. For the work presented in this dissertation, we 
chose to use a combination of siRNA knockdown and overexpression of PKCε to assess 
whether PKCε alters neurite outgrowth in cultured sensory neurons. In addition, we 
performed acute phorbol ester treatment studies, to evaluate the possible involvement of 
additional PKC isozymes in the modulation of neurite morphology.  
Interestingly, there have been no studies examining whether PKC plays a role in 
the loss of neurite length induced by paclitaxel. Given the strong data supporting a role 
for PKC in the enhancement of neurite length, we were interested in assessing whether 
paclitaxel-induced loss of neurite length could be attenuated or reversed following 
activation of PKC. If successful, this would provide a new novel target for neurite length 
studies in paclitaxel-treated cells. Further experiments would be necessary to determine 
the PKC signaling proteins that are necessary for mediating these effects. 
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SPECIFIC AIMS OF THE DISSERTATION 
 
Previous studies from our laboratory demonstrated that chronic treatment with 
paclitaxel altered neuronal function and neurite morphology in cultured sensory neurons. 
We showed that chronic treatment with paclitaxel (300 nM, 5 days) attenuated capsaicin-
stimulated release of calcitonin gene-related peptide (CGRP) and neurite length and 
branching (Pittman et al., 2014). The main goal for our current studies was to further 
elucidate the mechanisms underlying the neurotoxic effects of paclitaxel.  
The work presented in this dissertation investigated whether protein kinase C 
(PKC) mediated the chronic effects of paclitaxel on neuronal sensitivity and neurite 
morphology in cultured sensory neurons. We hypothesized that PKC mediated the 
reduction in neuronal sensitivity and neurite length and branching induced by paclitaxel.  
As such, the specific aims for this dissertation are: 
1. To determine whether PKC mediates changes in the release of CGRP 
induced by treatment with paclitaxel.   
2. To determine whether PKC mediates changes in neurite length and 
branching induced by treatment with paclitaxel.   
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MATERIALS AND METHODS 
 
1. Materials 
 
F-12 media, heat-inactivated horse serum, glutamine, penicillin, streptomycin, 5-
fluoro-2-deoxyuridine, uridine, NuPAGE 4-12% Bis-Tris Gels, polyvinylidene difluoride 
(PVDF) membranes, allyl isothiocyanate (AITC), TAT conjugated PKCε peptide inhibitor 
(H2N-YGRKKRRQRRREAVSLKPT-COOH), TAT conjugated scramble control peptide 
for PKCε peptide inhibitor (H2N-YGRKKRRQRRRLSETKPAV-COOH), TAT conjugated 
ΨεRACK peptide activator (H2N-YGRKKKRRQRRRHDAPIGYD-COOH) and TAT 
conjugated scramble control peptide for PKCε activator (H2N-
YGRKKKRRQRRRPDYHDAGI-COOH) were obtained from Thermo Fisher Scientific 
(Waltham, MA). Phorbol, 12-13-dibutyrate (PDBu), bisindolylmaleimide I (Bis I), Gö6976, 
HC 030031, SB 366791, H 89 dihydrochloride, 4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-
dimethylethyl)phenyl]-1-piperazinecarboxamide (BCTC), HOE 140 and (Des-Arg9)-
Bradykinin were obtained from Tocris-BioTechne (Minneapolis, MN). Lys-(Des-
Arg9Leu8)-Bradykinin trifluoroacetate salt was obtained from Bachem (Torrance, CA). 
The myristolyated PKCα/β peptide inhibitor (Myr-RFARKGALRQKNV) and nerve growth 
factor were obtained from Promega (Madison, WI) and Envigo (Indianapolis, IN), 
respectively. 4α-PDBu and the RIPA lysis buffer were obtained from Santa Cruz (Dallas, 
Texas) and EMD Millipore (Billerica, MA), respectively. Bis VIII, nifedipine and U73122 
were obtained from Cayman Chemical (Ann Arbor, Michigan). Rat (Tyr27)αCGRP27-37 
was purchased from Bachem (Torrence CA) and radiolabeled sodium iodine (125NaI) for 
iodination of CGRP27-37 was purchased from Perkin-Elmer (Shelton, CT). The CGRP 
antibody was a kind gift provided by Dr. M. Iadarola (National Institute of Health). All 
other reagents were purchased from Sigma Aldrich (St. Louis, MO).  
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2. Animals 
 
All experiments were done in compliance with the Animal Care and Use 
Committee at Indiana University School of Medicine (Indianapolis, IN) and the National 
Institute of Health Guide for the Care and Use of Lab Animals. Male Sprague Dawley 
rats (150 - 250 g, Envigo, Indianapolis, IN) were housed in group cages in a light 
controlled room with access to food and water ad libitum.  
        
3. Isolation of primary sensory neurons 
 
Dorsal root ganglia (DRG) were isolated and cultured as previously described 
(Pittman et al., 2014). Male Sprague Dawley rats were sacrificed by CO2 asphyxiation 
followed by decapitation. The DRG from all levels of the vertebral column were collected, 
trimmed and enzymatically digested in collagenase (0.125%; ≥ 470 collagen digestion 
units) for 1 hour at 37°C. Using a small diameter fire-polished glass Pasteur pipette, 
DRG were mechanically dissociated in F-12 media supplemented with 10% heat-
inactivated horse serum, 2 mM glutamine, 50 µg/mL penicillin and streptomycin, 50 μM 
5-fluoro-2-deoxyuridine, 150 μM uridine and 30 ng/mL nerve growth factor. The neuronal 
cell suspension was plated on 12-well plates previously coated with poly-D-lysine (0.1 
mg/mL) and laminin (1 mg/mL) to an approximate density of 30,000 cells per well. 
Neuronal cultures were maintained at 37°C with 3% CO2 atmosphere. The media was 
changed every other day prior to experiments. All experiments were performed after 7-
12 days in culture.  
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4. Treatment Paradigms 
 
For chronic paclitaxel experiments, cultured sensory neurons were treated with 
300 nM paclitaxel for 1-5 days or 1 μM paclitaxel for 1-3 days prior to the release and 
neurite outgrowth assay, as previously described (Pittman et al., 2014). For acute 
paclitaxel experiments, cultured sensory neurons were treated with 300 nM paclitaxel for 
10, 30 or 60 minutes prior to the release assay. For the chronic phorbol ester treatment 
paradigm, cultured sensory neurons were treated with 0.3 nM phorbol 12,13-dibutyrate 
(PDBu) for 2 days to downregulate the protein expression of PKCε in the absence or 
presence of 300 nM paclitaxel for 3 days prior to neurite outgrowth assays. For the acute 
phorbol ester treatment paradigm, neuronal cultures were treated with 10 nM PDBu for 
30 minutes, 1 hour or 3 hours, or with increasing concentrations of PDBu (10 nM, 100 
nM or 1 μM) for 10 minute to activate the conventional and novel PKC isozymes prior to 
neurite outgrowth assays.  
 
5. Drug Stocks 
 
100 mM stock of nifedipine, 10 mM stocks of paclitaxel, HC 030031, SB366791, 
4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide 
(BCTC), U73122, and 1 mM stocks of phorbol 12,13-dibutyrate (PDBu), 4α-PDBu, 
bisindolylmaleimide I (Bis I), Gö6976, LY333531, Bis VIII, 12-deoxyphorbol 13-
phenylacetate (dPPA), TAT conjugated PKCε peptide inhibitor, TAT conjugated 
scramble control peptide for PKCε peptide inhibitor, TAT conjugated ΨεRACK peptide 
activator and TAT conjugated scramble control peptide for activator were prepared in 
methyl-2-pyrrolidone (MPL) and stored at -20°C. 1 mM stock of Myr-PKCα/β peptide 
inhibitor and 100 μM stock of ω-Conotoxin GVIA were prepared in sterile ddH2O and 
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stored at -20°C. 100 mM stock of capsaicin and 9.4 M stock of allyl isothiocyanate 
(AITC) were prepared in MPL and stored at 4°C. Drug stocks were further diluted in 
media or HEPES buffer to the desired concentrations for the experiments. 
 
6. siRNA Transfection 
 
For siRNA transfection in cultured DRG sensory neurons, the F-12 media was 
replaced with Opti-MEM media (Thermo Fisher Scientific, Waltham MA) approximately 
three hours prior to siRNA transfection on day 4. PKCε siRNA (100 nM, Santa Cruz, sc-
270096) and control siRNA (100 nM, Santa Cruz, sc-37007) were incubated for 15 
minutes with Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific, 
Waltham MA) diluted in Opti-MEM media and 500 μL of the mixture was added 
accordingly to each well of the 12-well plate. The following day, 500 μL of F-12 media 
supplemented with 30 ng/mL nerve growth factor was added to all wells of the 12-well 
plates previously transfected with siRNA. The F-12 media was changed on alternate 
days prior to experiments as per our common protocol.  
 
7. Calcitonin gene-related peptide release assay 
 
Calcitonin gene-related peptide (CGRP) release assays were performed on days 
7-12 as previously described (Hingtgen and Vasko, 1994, Pittman et al., 2014) with 
slight modifications as follows. Briefly, neuronal cultures were washed with HEPES 
buffer (25 mM HEPES, 135 mM NaCl, 3.5 mM KCl, 2.5 mM CaCl2, 1 mM MgCl2, 3.3 mM 
D-glucose and 0.1 % bovine serum albumin, pH 7.4) followed by four sequential 10-
minute incubations to assess the basal and stimulated release of immunoreactive 
calcitonin gene-related peptide (CGRP) under specific conditions. Neuronal cultures 
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were maintained at 37°C with 3% CO2 atmosphere during the 10-minute intervals. For 
the first and second interval, neuronal cultures were incubated with HEPES buffer +/- 
drug to establish basal release of CGRP. For the third interval, neuronal cultures were 
incubated with HEPES buffer containing stimulatory agent (PDBu, capsaicin, AITC or 
dPPA) +/- drug to stimulate the release of CGRP. For the fourth interval, neuronal 
cultures were incubated with HEPES buffer to re-establish the basal release of CGRP. 
Neuronal cultures were incubated in 0.1N HCl for 20 minutes at room temperature to 
release all remaining CGRP present in the neurons. The supernatant was collected after 
each interval and the amount of CGRP released into the supernatant was determined 
using radioimmunoassay.  
 
8. Radioimmunoassay 
 
 A radioimmunoassay was performed to quantitatively assess the levels of CGRP 
release from sensory neurons. Aliquots of supernatant from the CGRP release assay 
(mentioned in Material and Methods: Section 5) were delivered into 5 mL tubes. A 
standard curve with known concentrations of CGRP ranging from 3 – 300 fmol was 
generated to determine the concentration of CGRP present in the unknown samples. 
Equal volumes of CGRP antibody (~1:65,000 dilution) and radiolabelled CGRP peptide, 
125I-[0 Tyr]-CGRP27-37, were added to the samples and the standard curve. All tubes were 
brought up to equal volume using HEPES buffer and incubated at 4°C overnight. In 
addition, we prepared tubes to assess the maximum binding of the assay (HEPES + 
CGRP antibody + radiolabelled CGRP peptide) and non-specific binding (HEPES + 
radiolabelled CGRP peptide). The following day, charcoal solution (0.1M phosphate 
buffer, 50 mM NaCl, 1% bovine serum albumin, 1% charcoal, pH 7.4) was added to all 
tubes and they were centrifuged at 3,000 rpm for 20 minutes and decanted; charcoal 
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adsorbs CGRP not bound to antibody and this is pelleted. The radioactivity of the 
supernatant (containing radiolabelled and unlabeled CGRP bound to antibody) was 
measured with a gamma scintillation spectrometer. The standard curve was used to 
determine the concentration of CGRP in the unknown samples.  
 
9. Western blotting 
 
Cells were scraped in F-12 media and transferred to eppendorf tubes. The 
sample was centrifuged at 14,000 rpm for 4 minutes and the supernatant was discarded. 
The cell pellet was washed in ice-cold sterile phosphate-buffered saline (PBS). The 
sample was then centrifuged at 14,000 rpm for 4 minutes and the supernatant was 
discarded.  Modified RIPA lysis buffer containing 0.2 μg/mL phenylmethylsulfonyl 
fluoride (PMSF), 1 μg/mL pepstatin A, 1 mM sodium orthovanadate, 25 mM sodium 
fluoride, 0.1% sodium dodecyl sulfate and 200 μL/mL protease inhibitor cocktail (Roche 
Diagnostics) was added to the cell pellet. Following sonication, the protein concentration 
was determined using a Bio-Rad protein assay, based on the Bradford protein-dye 
binding method (Bradford, 1976). Equivalent amounts of whole cell lysate protein were 
separated on NuPAGE 4-12% Bis-Tris Gels and transferred to PVDF membranes. 
Membranes were incubated in a 5% dry milk Tris buffered saline (TBS) solution 
containing 1% Tween 20 (TBS-T) for 1 hour and incubated with primary antibodies 
diluted in 1% TBS-T overnight at 4°C. Primary antibodies included: mouse anti-PKCα 
(1:1000, Santa Cruz, sc-8393), rabbit anti-PKCβI (1:500, Santa Cruz, sc-209), rabbit 
anti-PKCβII (1:1000, Santa Cruz, sc-210), rabbit anti-PKCε (1:1000, Santa Cruz, sc-
214), rabbit anti-phospho (Ser) PKC substrate (1:1000, Cell Signaling Technology, 
#2261S), goat anti-bradykinin B1R (1:1000, Santa Cruz, sc-15045), goat anti-B2R 
(1:000, Santa Cruz, sc-15050) and mouse anti-Actin (1:1000, Thermo Fisher Scientific, 
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#MA1-37018). Membranes were washed in 1% TBS-T and incubated in HRP-conjugated 
secondary antibodies diluted in 1% TBS-T for 2 hours at room temperature. Secondary 
antibodies included: goat anti-rabbit IgG (H+L) Poly-HRP (1:3000, #32260), goat anti-
mouse IgG (H+L) Poly-HRP (1:3000, Thermo Fisher Scientific, #32230) and donkey anti-
goat IgG-HRP (1:3000, Santa Cruz, sc-2020). The membranes were washed in 1% 
TBS-T. A Pierce ECL Western Blotting Substrate kit (Thermo Fisher Scientific) was used 
to detect immunoreactive bands on blue X-Ray films and the band density was 
quantified using KODAK 1D 3.6 (Scientific Imaging Systems, New Haven, CT).  
 
10. Isolation of Cytosolic and Membrane Protein Fractions 
 
The isolation of cytosolic and membrane protein fractions was done as previously 
described (Uehara et al., 2004) with slight modifications. The cell pellet was incubated in 
homogenization buffer (20 mM Tris-HCl pH 7.5, 330 mM sucrose, 0.5 mM EGTA, 2 mM 
EDTA, 2 μg/mL aprotinin, 25 μg/mL leupeptin and 1 mM PMSF, 200 μL/mL protease 
inhibitor cocktail), homogenized with a polytron and centrifuged at 25,000 rpm for 35 
minutes at 4°C. The supernatant was collected (cytosolic fraction) and the cell pellet 
(membrane fraction) was re-suspended in homogenization buffer containing 1% Triton 
X-100 and placed on ice for 1 hour. The solution was centrifuged at 25,000 rpm for 35 
minutes at 4°C. The resulting supernatant (membrane fraction) was collected. The 
protein concentrations of the cytosolic and membrane protein fractions were determined 
using the Bio-Rad protein assay and equivalent amounts of protein were separated on 
NuPAGE 4-12% Bis-Tris Gels. We then followed the Western blot protocol described 
above in Materials and Methods: Section 9. In addition to the antibodies listed in the 
aforementioned section, primary antibodies included: mouse anti-p-PKCα (1:1000, Ser 
657, Santa Cruz, sc-377565), rabbit anti-p-PKCβI (1:500, Thr 641, Santa Cruz, sc-
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101776), mouse anti-p-PKCβII/δ (1:1000, Ser 660, Santa Cruz, sc-365463) and rabbit 
anti-Na+/K+ ATPase α (1:1000, Cell Signaling Technology, #3010). 
 
11. Immunofluorescence and Membrane Translocation 
 
Neuronal cultures were rinsed with phosphate-buffered saline (PBS) and fixed 
with 4% paraformaldehyde (PFA) for 20 minutes. The 4% PFA was aspirated and cells 
were rinsed with PBS and blocked in filtered blocking solution (normal donkey serum, 
Triton x-100 in 0.1M PBS, pH 6.0) for 1 hour. Cultures were incubated in a mixed pool of 
primary antibodies diluted in filtered blocking solution overnight at room temperature. 
Primary antibodies included: mouse anti-p-PKCα (1:500, Ser 657, Santa Cruz, sc-
377565), rabbit anti-p-PKCβI (1:500, Thr 641, Santa Cruz, sc-101776) and mouse anti-
p-PKCβII/δ (1:500, Ser 660, Santa Cruz, sc-365463). The following day, cells were 
rinsed with PBS and incubated with fluorescently labeled secondary antibodies diluted in 
filtered blocking solution for two hours at room temperature. Secondary antibodies 
included: Alexa Fluor 488 donkey anti-rabbit (1:200, Thermo Fisher Scientific, #A21206) 
and Alexa Fluor 488 donkey anti-mouse (1:200, Thermo Fisher Scientific, #A21202). 
Cultures were rinsed in PBS and 1mL PBS was added to each well of the 12-well plate. 
Fluorescent images were acquired using the Leica DMI6000 B inverted microscope. To 
measure translocation of phospho-PKC α, βI and βII, five random fields of view were 
acquired for each treatment group and neurons were scored as positive or negative for 
membrane translocation and the data expressed as % of cells with phospho-PKC 
α/βI/βII translocation, as previously described (Ron et al., 1995, Gray et al., 1997).  
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12. Immunofluorescence and Neurite Outgrowth 
 
For neurite outgrowth studies, neuronal cultures were fixed and blocked as 
described above in Material and Methods: Section 11. Neuronal cultures were then 
incubated with the neuron specific primary antibody PGP9.5 (1:1000, Thermo Fisher 
Scientific, #PA5-29012) (Wilkinson et al., 1989) diluted in filtered blocking solution 
overnight at room temperature. The next day, cultures were rinsed with phosphate-
buffered saline (PBS) and incubated with the fluorescently labeled secondary antibody 
Alexa Fluor 488 donkey anti-rabbit (1:200, Thermo Fisher Scientific, #A21206) diluted in 
blocking solution for 2 hours at room temperature. Cultures were rinsed with PBS and 1 
mL PBS was added to each well of the 12-well plate. Images were obtained with the 
ImageXpress Micro XL System (Molecular Devices, Sunnyvale, CA). A single image in 
the center of each well was obtained and spanned a total area of 1.96 mm2 (1.4 x 1.4 
mm). The Neurite Outgrowth module was used to measure neurite length and branching 
based on set parameters. Parameters were set to detect cell bodies (approximate 
maximum width = 40 μm; intensity above local background = 25,000 gray/levels; 
minimum area = 50 μm2) and neurite outgrowths (maximum width = 5 μm; intensity 
above local background = 1200 gray/levels; minimum cell growth to log as significant = 
20 μm). 
 
13. Data Analysis 
 
Data are represented as the mean ± standard error of mean (SEM). Data were 
analyzed by t-test, one-way analysis of variance (ANOVA) or two-way ANOVA and post-
hoc tests were performed using the Tukey’s or Dunnett’s multiple comparisons test using 
GraphPad Prism 7 software (La Jolla, CA) with p < 0.05 considered significant. 
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RESULTS 
 
1. Chronic treatment with paclitaxel differentially alters PDBu-stimulated release of 
CGRP  
 
Our laboratory has previously shown that long-term treatment with paclitaxel 
differentially alters capsaicin-stimulated CGRP release in sensory neurons in a 
concentration- and time-dependent manner (Pittman et al., 2014). Treatment with 300 
nM paclitaxel for 3 and 5 days attenuated capsaicin-stimulated CGRP release in sensory 
neurons, whereas treatment with 10 nM paclitaxel for the same durations enhanced 
capsaicin-stimulated CGRP release (Pittman et al., 2014). Because phorbol ester-
induced activation of conventional and novel PKC isozymes (c/nPKC) increases TRPV1 
activity (Vellani et al., 2001, Zhou et al., 2001, Numazaki et al., 2002, Bhave et al., 2003, 
Jeske et al., 2009), it is plausible that the attenuation in capsaicin-stimulated release 
upon treatment with 300 nM paclitaxel is due to a loss of c/nPKC activity and the 
subsequent loss of positive modulation of ion channels by c/nPKC.  
Since previous studies have shown that phorbol ester-induced activation of 
c/nPKC enhances the release of CGRP from cultured embryonic sensory neurons 
(Barber and Vasko, 1996), we wanted to confirm these findings in adult sensory neurons 
so that we could examine whether paclitaxel alters the ability of phorbol esters to 
enhance CGRP release. Treatment with increasing concentrations of the phorbol ester, 
12, 13-dibutyrate (PDBu) increased release of CGRP to 9.8 ± 1.2 (10 nM), 18.9 ± 1.7 (30 
nM) and 22.2 ± 2.0% of total content (100 nM PDBu) compared to vehicle-treated 
neurons (0.8 ± 1.2% of total content; Figure 3A), confirming that activation of c/nPKC via 
phorbol esters enhances CGRP release. 
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In addition to activation of c/nPKC, studies have reported that PDBu binds and 
activates other C1 domain-containing proteins (Colon-Gonzalez and Kazanietz, 2006) 
that have been implicated in the regulation of neurotransmitter release (Betz et al., 
1998). To confirm that CGRP release was due to a specific effect of PDBu to activate 
c/nPKC, neurons were pre-treated with bisindolylmaleimide I (Bis I; IC50 = 8-132 nM), an 
inhibitor that competitively inhibits ATP binding in c/nPKC (Toullec et al., 1991), for 10 
minutes prior to stimulation with 10 nM PDBu. Pre-treatment with Bis I fully abolished 
PDBu-stimulated CGRP release from 14.1 ± 1.7 to 1.4 ± 0.2% of total content (Figure 
3B). There were no changes in the basal release of CGRP (1.5 ± 0.1% of total content) 
compared to untreated neurons (1.1 ± 0.3% of total content) pre-treated with Bis I 
(Figure 3B). Treatment with 10 nM 4α-PDBu, an inactive analog of PDBu that is 
incapable of activating c/nPKC (Silinsky and Searl, 2003), did not alter the release of 
CGRP (1.2 ± 0.2% of total content) compared to basal release (1.0 ± 0.2% of total 
content; Figure 3B). These data indicate that PDBu stimulates the release of CGRP 
through the specific activation of c/nPKC.  
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Figure 3: PDBu increases CGRP release in cultured sensory neurons. 
Each column represents the mean ± SEM of basal (white columns) or 
stimulated (black columns) CGRP release expressed as % of total content. 
(A) Cultures were stimulated with phorbol 12,13-dibutyrate (PDBu; 10, 30 
or 100 nM) for 10 minutes. An * indicates a significant increase in PDBu-
stimulated release compared to vehicle-treated neurons (p < 0.05, N = 8-9). 
Significance was determined using a two-way ANOVA with Tukey’s post-
hoc test. (B) Naïve cultures were pre-treated with Bis I (1 μM) for 10 
minutes prior to stimulation with PDBu. As a control experiment, naïve 
cultures were incubated with 10 nM 4α-PDBu (dotted columns). An * 
indicates a significant decrease in PDBu-stimulated release in neurons pre-
treated with Bis I (p < 0.05, N = 10). Significance was determined using a 
two-way ANOVA with Tukey’s post-hoc test. N.S. – not significant. 
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We next examined the effects of treating sensory neuronal cultures with 300 nM 
or 1 µM paclitaxel for 1-5 days on the ability of PDBu (10 nM) to stimulate CGRP 
release. Treatment with 300 nM paclitaxel attenuated PDBu-stimulated CGRP release in 
a time-dependent manner to 19.0 ± 1.9 (1 day), 11.8 ± 1.0 (3 days) and 7.7 ± 0.9% of 
total content (5 days) compared to vehicle-treated neurons (24.0 ± 1.3% of total content; 
0.003% methylpyrrolidone (MPL); Figure 4A). Similar observations were made using a 
higher concentration of paclitaxel at shorter time intervals where treatment with 1 µM 
paclitaxel attenuated PDBu-stimulated CGRP release to 12.2 ± 1.3 (1 day), 7.7 ± 1.2 (2 
days) and 3.7 ± 0.4% of total content (3 days) compared to vehicle-treated neurons 
(23.7 ± 0.4% of total content; 0.01% MPL; Figure 4B). We previously demonstrated that 
these treatments with paclitaxel do not compromise cell viability (Pittman et al., 2014), 
thus our findings indicate that chronic treatment with 300 nM and 1 µM paclitaxel 
attenuates the release of CGRP evoked by PDBu-induced activation of c/nPKC 
isozymes and suggest that high concentrations of paclitaxel decrease the function of 
c/nPKC.  
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Figure 4: High concentrations of paclitaxel decrease PDBu-stimulated CGRP 
release in cultured sensory neurons. Each column represents the mean ± SEM 
of basal (white columns) or stimulated (black columns) CGRP release 
expressed as % of total content. Cultures were exposed to (A) 300 nM or (B) 1 
μM paclitaxel for 1, 2, 3 or 5 days prior to stimulation with PDBu (10 nM), as 
indicated. An * indicates a significant decrease in PDBu-stimulated release in 
paclitaxel-treated (300 nM and 1 μM) neurons compared to vehicle-treated 
neurons (p < 0.05, N = 7-9). Significance was determined using a two-way 
ANOVA with Tukey’s post-hoc test.  
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 We next examined the effects of treating sensory neuronal cultures with 10 nM or 
30 nM paclitaxel for 2 or 3 days on the ability of PDBu (10 nM) to augment CGRP 
release. Treatment with 10 nM (14.9  ± 1.0) and 30 nM (14.8 ± 1.3% of total content) 
paclitaxel for 2 days did not alter PDBu-stimulated release compared to vehicle-treated 
neurons (14.9 ± 1.0% of total content; Figure 5A). However, treatment with 10 nM and 
30 nM paclitaxel increased PDBu-stimulated release of CGRP to 13.4 ± 1.0 and 13.5 ± 
0.7% of total content respectively from 10.7 ± 0.6% of total content in vehicle-treated 
neurons (Figure 5B). These data indicate that chronic treatment with lower 
concentrations of paclitaxel enhances the release of CGRP evoked by PDBu-induced 
activation of c/nPKC isozymes suggesting that low concentrations of paclitaxel increase 
the function of c/nPKC.  
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Figure 5: Low concentrations of paclitaxel increase PDBu-stimulated 
CGRP release in cultured sensory neurons. Each column represents the 
mean ± SEM of basal (white columns) or stimulated (black columns) 
CGRP release expressed as % of total content. Cultures were exposed 
to 10 nM or 30 nM paclitaxel for (A) 2 days or (B) 3 days prior to 
stimulation with PDBu (10 nM). An * indicates a significant increase in 
PDBu-stimulated release in paclitaxel-treated (10 nM and 30 nM) 
neurons compared to vehicle-treated neurons (p < 0.05, N = 7-9). 
Significance was determined using a two-way ANOVA with Tukey’s 
post-hoc test.  
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2. Acute treatment with paclitaxel does not alter PDBu-stimulated release of CGRP 
 
Our laboratory has previously demonstrated that acute treatment with 300 nM 
paclitaxel for 10, 20 or 30 minutes does not alter CGRP release from cultured DRG 
sensory neurons (Pittman, 2014). While short-term treatment with paclitaxel has no 
direct effect on CGRP release, it is plausible that it could sensitize the neurons to 
enhance phorbol ester-stimulated release of CGRP. To address this, neuronal cultures 
were treated with 300 nM paclitaxel for 10, 30 or 60 minutes and stimulated with PDBu 
(10 nM). Having confirmed our previous observations that paclitaxel does not enhance 
basal CGRP release, we then showed that treatment with 300 nM paclitaxel for 10 
minutes (18.0 ± 1.8), 30 minutes (18.8 ± 1.4) and 60 minutes (20.7 ± 1.7% of total 
content) does not alter PDBu-stimulated release compared to vehicle-treated neurons 
(19.8 ± 1.7% of total content; Figure 6). These data suggest that short-term exposure to 
paclitaxel has no effects on the ability of PDBu to evoke CGRP release.  
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Figure 6: Acute paclitaxel does not alter PDBu-stimulated CGRP release 
in cultured sensory neurons. (A) Each column represents the mean ± SEM 
of basal (white columns) or stimulated (black columns) CGRP release 
expressed as % of total content. Cultures were exposed to 300 nM 
paclitaxel for 10, 30 or 60 minutes prior to stimulation with PDBu (10 nM). 
Significance was determined using a two-way ANOVA with Tukey’s post-
hoc test (N = 10-12). p < 0.05 for release in the absence versus presence 
of paclitaxel treatment. 
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3. Chronic treatment with paclitaxel inhibits the activity of conventional PKC isozymes, 
α and βI/II, to elicit a decrease in PDBu-stimulated CGRP release 
 
Since PDBu is a direct activator of both conventional and novel PKC isozymes, 
we first wanted to determine which class of PKC isozymes mediates the increase in 
CGRP release evoked by PDBu in the absence of paclitaxel. To differentiate between 
the two classes of PKC isozymes, neuronal cultures were pre-treated with Gö6976, an 
ATP competitive inhibitor that selectively inhibits the activity of conventional PKC 
isozymes at concentrations ≥ 3 µM while having no effect on novel PKC isozymes 
(Martiny-Baron et al., 1993), prior to stimulation with 10 nM PDBu. Pre-treatment with 
100 nM Gö6976 attenuated PDBu-stimulated release from 11.3 ± 0.7 (control neurons) 
to 3.4 ± 0.2% of total content (Figure 7A), suggesting that conventional PKC isozymes, 
and not novel PKC isozymes, mediate PDBu-stimulated CGRP release. Having 
identified the class of PKC isozymes that mediate release stimulated by PDBu, we next 
wanted to narrow down which specific isozymes mediate PDBu-stimulated release of 
CGRP. We investigated the specific contribution of PKCα and PKCβI/II versus PKCγ by 
pre-treating neuronal cultures with a myristolyated PKCα/β peptide inhibitor prior to 
stimulation with 10 nM PDBu. The PKCα/β peptide, which is derived from a homologous 
sequence within the pseudosubstrate region of PKCα, PKCβI and PKCβII, consists of 
alanine in place of a phosphorylatable Ser/Thr (see Figure 7B) and binds to the PKC 
substrate binding cavity to maintain the kinase in an inactive conformation (House and 
Kemp, 1987, Eichholtz et al., 1993). The activity of PKCγ, a conventional PKC isozyme, 
is unaffected by this peptide due to three amino acid mismatches in the pseudosubstrate 
region (see Figure 7C). Pre-treatment with 10 µM PKCα/β peptide inhibitor attenuated 
PDBu-stimulated CGRP release from 11.3 ± 0.7 (control neurons) to 3.5 ± 0.3% of total 
content (Figure 7A). There was no significant difference between basal (2.8 ± 0.2% of 
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total content) and PDBu-stimulated release (3.5 ± 0.2% of total content) in the presence 
of the PKCα/β peptide inhibitor (Figure 7A). These data indicate that conventional PKC 
isozymes, α, βI and/or βII, mediate PDBu-stimulated release of CGRP.  
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Figure 7: PDBu-stimulated release is mediated by the conventional PKC 
isozymes, PKCα and PKCβI/II, in cultured sensory neurons. Each column 
represents the mean ± SEM of basal (white columns) or PDBu-stimulated 
(black columns) CGRP release expressed as % of total content in the 
absence and presence of PKCα and PKCβI/II inhibitors. (A) Naïve cultures 
were pre-treated with Gö6976 (100 nM) or a myristoylated PKCα/β peptide 
inhibitor (10 μM) for 10 minutes prior to stimulation with PDBu (10 nM). An * 
indicates a significant decrease in PDBu-stimulated release in neurons pre-
treated with Gö6976 or the myristoylated PKCα/β peptide inhibitor (p < 0.05, 
N = 12). Significance was determined using a two-way ANOVA with Tukey’s 
post-hoc test. (B) Diagram showing the amino acid sequence for the PKC α/β 
peptide inhibitor. (C) Diagram showing the amino acid sequence alignment 
for PKC α, βI, βII and γ. 
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We next examined the relative contribution of PKCα and PKCβI/II in PDBu-
stimulated release in the absence and presence of paclitaxel using small molecule 
inhibitors of these kinases. We chose to use selective small molecule inhibitors of PKCα 
and PKCβI/II, as opposed to the PKCα/β peptide inhibitor, as this would allow us to later 
discern the effects of each individual kinase. Cultured sensory neurons were treated with 
300 nM paclitaxel for 3 days and pre-treated with a combination of PKCα (Bis VIII; IC50 = 
53 nM) and PKCβI/II (LY333531; IC50 = 4.7-5.9 nM) inhibitors prior to stimulation with 10 
nM PDBu; inhibitor concentrations used were based on reported values in the literature 
(Wilkinson et al., 1993, Jirousek et al., 1996, Zhou et al., 2006, Gray et al., 2013) and 
were chosen to selectively inhibit the specific isozymes. In vehicle-treated neurons, 
combined pre-treatment with 53 nM Bis VIII and 30 nM LY333531 significantly 
attenuated PDBu-stimulated release from 11.5 ± 1.1 (vehicle-only) to 2.5 ± 0.2 % of total 
content (Figure 8A), confirming our earlier findings that PKC isozymes, α, βI and/or βII,  
mediate PDBu-stimulated CGRP release (see Figure 7A). In the presence of combined 
inhibition of PKCα and PKCβI/II, there was no further decrease in PDBu-stimulated 
release in paclitaxel-treated neurons (2.3 ± 0.2% of total content) compared to vehicle-
treated neurons (2.5 ± 0.2% of total content; Figure 8A), suggesting that PKCα and 
PKCβI/II signal through common pathways. These data demonstrate that inhibition of 
PKCα and/or PKCβI/II activity is responsible for the reduction in CGRP release induced 
by paclitaxel.  
To differentiate between the individual contributions of PKCα and PKCβI/II, 
cultured sensory neurons were treated with 300 nM paclitaxel for 3 days and pre-treated 
with either Bis VIII or LY333531 prior to stimulation with 10 nM PDBu. In vehicle-treated 
neurons, we found that individual pre-treatment with either Bis VIII or LY333531 partially 
attenuated PDBu-stimulated release to similar extents (Figures 8B and 8C), but did not 
completely block the increase in release as observed following combined pre-treatment 
 74
with both inhibitors (see Figure 8A). This suggests that both PKCα and PKCβI/II are 
necessary to elicit an increase in CGRP release induced by PDBu; the single activity of 
either kinase is not sufficient to reach the given threshold. In the presence of paclitaxel, 
however, individual pre-treatment with Bis VIII (Figure 8B) and LY333531 (Figure 8C) 
resulted in a further significant reduction of PDBu-stimulated release. Based on the 
findings in Figure 8A, these results suggest that the additional reduction in release from 
paclitaxel-treated neurons following inhibition of PKCα is due to the residual activity of 
PKCβI/II (Figure 8B); likewise, the additional reduction in release following inhibition of 
PKCβI/II is due to the residual activity of PKCα (Figure 8C). Overall, these sets of data 
suggest that inhibition of both PKCα and PKCβI/II activity, as opposed to inhibition of a 
single kinase, is responsible for reduction in CGRP release induced by paclitaxel. As 
such, the two kinases share a common signaling pathway to elicit changes in sensory 
neuronal function following chronic treatment with paclitaxel. 
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Figure 8: Inhibition of PKCα and PKCβI/II activity mediates the decrease in 
PDBu-stimulated CGRP release following chronic exposure to paclitaxel in 
cultured sensory neurons. Each column represents the mean ± SEM of basal 
(white columns) or PDBu-stimulated (black columns) CGRP release expressed 
as % of total content in the absence and presence of PKCα or PKCβI/II 
inhibitors. Cultures were exposed to 300 nM paclitaxel for 3 days prior to 
stimulation with PDBu (10 nM) in the presence and absence of the (A) PKCα 
inhibitor (Bis VIII; 53 nM) + PKCβI/II inhibitor (LY333531; 30 nM), (B) Bis VIII or 
(C) LY333531. An * indicates a significant decrease in PDBu-stimulated release 
in paclitaxel-only treated neurons, vehicle- and paclitaxel-treated neurons pre-
treated with (A) Bis VIII + LY333531, (B) Bis VIII or  (C) LY333531 compared to 
vehicle-only treated neurons and a # indicates a significant decrease in PDBu-
stimulated release in paclitaxel-treated neurons compared to vehicle-treated 
neurons pre-treated with (B) Bis VIII or (C) LY333531. Significance was 
determined using a two-way ANOVA with Tukey’s post-hoc test (p < 0.05, N = 
8-12). Veh - Vehicle; Pac - Paclitaxel; LY333 - LY333531; N.S. – not significant. 
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An alternative method to assessing the effects of paclitaxel on PKCα/β activity 
involves direct activation of these specific kinases with small compound activators. Using 
this method, we questioned whether paclitaxel altered release of CGRP upon direct 
stimulation of PKCα and PKCβ isozymes. Since there are no small compound activators 
for PKCα we focused on PKCβ activation only. Studies show that the phorbol ester 12-
deoxyphorbol 13-phenylacetate 20 acetate (dPPA) is a selective activator of PKCβI 
(Evans et al., 1991). We first needed to assess whether activation of PKCβI using dPPA 
stimulated the release of CGRP release in the absence of paclitaxel. Neurons were 
treated with increasing concentrations of dPPA (1nM, 3 nM, 30 nM, 100 nM or 1000 nM) 
for 10 minutes. Treatment with 1 nM (1.2 ± 0.3), 3 nM (0.8 ± 0.1), 30 nM (1.5 ± 0.4) and 
100 nM (1.8 ± 0.7% of total content) dPPA did not alter CGRP release compared to 
basal release (1.3 ± 0.1% of total content), however 1000 nM dPPA increased release to 
11.0 ± 0.6% of total content (Figure 9A). This finding suggests that dPPA-induced 
activation of PKCβI enhances release of CGRP. We next verified whether dPPA was a 
specific activator of PKCβI. To address this question, neuronal cultures were pre-treated 
with the PKCβ selective inhibitor, LY333531, and the conventional PKC inhibitor, 
Gö6976 for 10 minutes prior to and during exposure to dPPA (1000 nM). We predicted 
that pre-treatment with LY333531 and Gö6976 would abolish dPPA-stimulated release if 
dPPA was selective for PKCβI activation. Pre-treatment with LY333531 and Gö6976 
attenuated dPPA-stimulated release from 16.8 ± 1.2 (control) to 6.8 ± 0.5 and 8.4 ± 1.1% 
of total content, respectively (Figure 9B), demonstrating only a partial reduction in dPPA-
stimulated release in the presence of these small compound inhibitors. The lack of a fully 
attenuated response suggests that dPPA does not selectively activate PKCβ to elicit 
changes in CGRP release. Based on these findings, we did not pursue the use of dPPA 
as a pharmacological modulator of PKCβ activity. 
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Figure 9: dPPA does not stimulate CGRP release in a PKCβ selective 
manner in cultured sensory neurons. Each column represents the mean ± 
SEM of basal (white columns) or stimulated (checkered columns) CGRP 
release expressed as % of total content. (A) Cultures were stimulated with 
12-deoxyphorbol 13-phenylacetate 20-acetate (dPPA; 1, 3, 10, 30 100 or 
1000 nM) for 10 minutes (N = 4). (B) As a control experiment, naïve cultures 
were incubated with Gö6976 (100 nM) or LY333531 (30 nM) for 10 minutes 
prior to stimulation with dPPA (1000 nM). An * indicates a significant 
decrease in dPPA-stimulated release in neurons pre-treated with Gö6976 or 
LY333531 compared to control neurons (p < 0.05, N = 9-12). Significance 
was determined using a two-way ANOVA with Tukey’s post-hoc test. 
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4. Chronic treatment with paclitaxel decreases the basal activity of conventional PKC 
isozymes, α and βI/II, as indicated by a reduction in the phosphorylation of 
conventional PKC substrates 
 
Researchers measure PKC activity by examining the phosphorylation of 
downstream PKC substrates (Numazaki et al., 2002, Zhang et al., 2002, Bhave et al., 
2003, Ferreira et al., 2005, Mandadi et al., 2006, Jeske et al., 2009). To determine 
whether paclitaxel altered the basal activity of PKC, neuronal cultures were treated with 
300 nM paclitaxel for 3 or 5 days and the phosphorylation of PKC substrates was 
determined using an anti-phospho (Ser) PKC substrate antibody. Studies show that PKC 
isozymes can be distinguished from one another based on their substrate sequence 
motif (Nishikawa et al., 1997). All PKC isozymes select for substrates with a hydrophobic 
residue (i.e. phenylalanine) at +1 and basic residues at -6, -4, -2, however, conventional 
PKC isozymes (α, βI, βII, and γ) and the novel PKC isozyme, PKCη, have been shown 
to have higher selectivity for substrates with basic residues (i.e. arginine and lysine) at 
positions +2 and +3 (Nishikawa et al., 1997). The antibody that was used in these 
experiments recognizes PKC substrates when phosphorylated at serine residues 
surrounded by arginine or lysine at positions -2 and +2 and a hydrophobic residue at +1.  
We found that treatment with 300 nM paclitaxel for 3 and 5 days decreased the 
phosphorylation of conventional PKC (cPKC) substrates (Figure 10A). These data 
strongly indicate that paclitaxel decreases the activity of cPKC with subsequent 
decreases in the phosphorylation of downstream cPKC substrates. As a positive control, 
neuronal cultures were treated with the c/nPKC activator, PDBu (100 nM and 1 μM), for 
5, 10 or 30 minutes and the phosphorylation of cPKC substrates was determined using 
the anti-phospho (Ser) PKC antibody. As expected, treatment with PDBu, at all tested 
concentrations and time-points, increased phosphorylation of cPKC substrates (Figure 
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10B), confirming that phorbol ester-induced activation of PKC enhances the 
phosphorylation of cPKC substrates in this assay.  
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Figure 10: Chronic treatment with paclitaxel decreases the basal 
phosphorylation of PKC α/β substrates in cultured sensory neurons. (A) 
Representative western blot image showing immunoreactivity for 
phosphorylation of PKC α, βI and βII substrates in whole cell lysates in 
neurons treated with vehicle and paclitaxel (300 nM, 3 and 5 days). (B) 
Representative western blot image showing immunoreactivity for 
phosphorylation of PKC α, βI and βII substrates in neurons treated with 
PDBu (100 nM and 1 μM; 5, 10 or 30 minutes). Veh - Vehicle; Pac – 
Paclitaxel; 3D – 3 days; 5D – 5 days. 
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5. Chronic treatment with paclitaxel does not decrease the basal protein expression of 
conventional PKC isozymes, α, βI or βII 
 
To ascertain whether the decrease in CGRP release induced by paclitaxel is due 
to a reduction in the basal protein expression of PKC α, βI and/or βII, cultured sensory 
neurons were treated with 300 nM paclitaxel for 3 days and the protein expression in 
whole cell lysates was determined using Western blots. For our studies, the term “basal” 
encapsulates the cellular environment of cells treated with paclitaxel in the absence of a 
stimulatory agent. Treatment with 300 nM paclitaxel for 3 days did not attenuate the 
expression of PKCα (1.0 ± 0.1 arbitrary units; Figures 11A and 11B), PKCβI (1.6 ± 0.4 
a.u.; Figures 11C and 11D) or PKCβII (1.1 ± 0.1 a.u.; Figures 11E and 11F) compared to 
vehicle (1.0 ± 0.0 a.u.). These findings suggest that changes in neuronal sensitivity 
induced by paclitaxel cannot be explained by a reduction in protein levels of the 
conventional PKC isozymes, α, βI and βII. 
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Figure 11: Chronic treatment with paclitaxel does not reduce basal PKC α, βI 
or βII, immunoreactivity in cultured sensory neurons. (A, C, E) Representative 
western blot images showing immunoreactivity for PKC α, βI and βII in whole 
cell lysates in neurons treated with vehicle and paclitaxel (300 nM, 3 days). (B, 
D, F) Densitometry analysis showing no significant differences in PKC 
immunoreactivity normalized to actin in paclitaxel-treated (300 nM, 3 days) 
neurons compared to vehicle-treated neurons using a t-test (N = 3-4, a.u. ± 
SEM). Veh - Vehicle; Pac -Paclitaxel. 
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6. Chronic treatment with paclitaxel does not attenuate the basal phosphorylation or 
membrane localization of conventional PKC isozymes, α, βI or βII 
 
The phosphorylation status and localization of conventional PKC isozymes 
(cPKC) are important determinants of cPKC activity. Lack of phosphorylation at three 
conserved phosphorylation sites in the catalytic domain predisposes PKC for 
degradation (Gould and Newton, 2008) and membrane translocation upon cPKC 
activation serves to position cPKC in close proximity to their downstream substrates 
(Mochly-Rosen and Gordon, 1998, Jaken and Parker, 2000).  To determine whether loss 
of phosphorylation or membrane localization under basal conditions accounted for the 
reduction of PDBu-stimulated CGRP release induced by paclitaxel, neuronal cultures 
were treated with 300 nM paclitaxel for 3 days and differential centrifugation assays 
were performed to isolate the cytosolic and membrane protein fractions. Actin and 
Na+/K+ ATPase α were used as loading controls for cytosolic and membrane protein 
fractions, respectively. Treatment with 300 nM paclitaxel for 3 days did not significantly 
alter the levels of phosphorylated PKCα in the cytosol (1.04 ± 0.1 arbitrary unit, a.u.) or 
membrane (1.48 ± 0.7 a.u.) compared to vehicle-treated neurons (1.00 ± 0.0 a.u.; 
Figures 12A and 12B). There also were no significant differences in total PKCα in the 
cytosol (1.07 ± a.u.) or membrane (0.98 ± a.u.) following treatment with paclitaxel 
compared to vehicle-treated neurons (1.00 ± 0.0 a.u.; Figures 12A and 12B). Similarly, 
treatment with 300 nM paclitaxel for 3 days did not significantly alter the levels of 
phosphorylated PKCβI in the cytosol (1.24 ± 0.0 a.u.) or membrane (1.71 ± 0.4 a.u.) or 
total PKCβI in the cytosol (1.15 ± 0.1 a.u.) or membrane (1.41 ± 0.3 a.u.) following 
treatment with paclitaxel compared to vehicle-treated neurons (1.00 ± 0.0 a.u.; Figures 
12C and 12D). There also were no significant differences in phosphorylated PKCβII in 
the cytosol (1.15 ± 0.2 a.u.) or membrane (0.96 ± 0.1 a.u.) or total PKCβII in the cytosol 
 86
(1.16 ± 0.1 a.u.) or membrane (0.89 ± 0.2 a.u.) following treatment with paclitaxel (300 
nM, 3 days) compared to vehicle-treated neurons (1.00 ± 0.0 a.u.; Figures 12E and 
12F). These data indicate that under basal conditions, chronic treatment with paclitaxel 
does not alter the phosphorylation status of PKC α, βI, or βII demonstrating that these 
isozymes are stable and catalytically competent. We also show that paclitaxel does not 
alter the membrane localization of PKC α, βI, or βII under basal conditions. 
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Figure 12: Chronic treatment with paclitaxel does not attenuate the basal 
phosphorylation level or membrane localization of PKC α, βI or βII in cultured 
sensory neurons. (A, C, E) Representative western blot images showing 
immunoreactivity for PKC α, βI and βII in cytosolic and membrane fractions of 
neurons treated with vehicle and paclitaxel (300 nM, 3 days). (B, D, F) 
Densitometry analysis showing no significant differences in PKC immunoreactivity 
in paclitaxel-treated (300 nM, 3 days) neurons compared to vehicle-treated 
neurons in cytosolic and membrane fractions when normalized to actin and Na
+
/K
+ 
ATPase α, respectively. Significance was determined using a two-way ANOVA with 
Tukey’s post-hoc test (N = 3-4, a.u. ± SEM). Veh - Vehicle; Pac -Paclitaxel. 
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7. Chronic treatment with paclitaxel inhibits PDBu-stimulated membrane localization of 
conventional PKC isozymes, α, βI and βII 
 
We demonstrated that chronic treatment with paclitaxel does not alter the 
membrane localization of phosphorylated PKC α, βI, or βII under basal conditions. 
However, activation of PKC and subsequent membrane translocation and localization at 
cellular membranes is a short-lived transient response (Cesare et al., 1999, Gould and 
Newton, 2008).  It is therefore highly plausible that the experimental design of the assay 
used in Figure 12 is not best suited to detect transient shifts in PKC localization. It was 
therefore important for us to ascertain whether chronic treatment with paclitaxel altered 
membrane translocation of phosphorylated PKC α, βI and βII following acute PDBu-
induced activation of PKC. This approach would allow us to capture transient changes in 
PKC membrane localization following paclitaxel treatment. Furthermore, it would enable 
us to determine whether PKC stimulation is necessary to observe potential differences in 
membrane localization following chronic treatment with paclitaxel. Cultured neurons 
were treated with 300 nM paclitaxel for 3 days or 5 days, and stimulated with 300 nM 
PDBu for 2 minutes. The changes in phosphorylated PKC α, βI and βII localization at the 
plasma membrane were determined using immunofluorescence in which neurons were 
labeled with a pool of PKC α, βI, and βII primary antibodies and a fluorescently labeled 
secondary antibody. Representative images are shown in Figure 13A. Studies have 
previously shown that PDBu-induced activation of c/nPKC increases membrane 
translocation of c/nPKC (Tsutsumi et al., 1993, Cesare et al., 1999, Zhu et al., 2007). 
Similarly, we demonstrate that treatment with 300 nM PDBu for 2 minutes increased the 
number of neuronal cell bodies which exhibit membrane localization of phosphorylated 
PKC α, βI, and βII from 0.0 ± 0.0 to 31.6 ± 3.0% (Figure 13B). However, treatment with 
300 nM paclitaxel for 3 days and 5 days decreased the percentage of cells with 
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membrane localized phosphorylated PKC α, βI and βII to 13.7 ± 5.0 and 16.8 ± 8.0%, 
respectively (Figure 13B). Neither 3 day nor 5 day treatment with paclitaxel altered the 
percentage of cells with membrane localized phosphorylated PKC α/βI/βII under basal 
conditions (Figure 13B), confirming our findings in Figures 12A-E. These data indicate 
that paclitaxel attenuates the membrane localization of phosphorylated PKC α, βI and βII 
under stimulatory conditions and demonstrates that the loss of functional PKC effects 
could be due to misdirected cPKC localization. 
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Figure 13: Chronic treatment with paclitaxel decreases PDBu-stimulated 
translocation of PKC α, βI and βII to the plasma membrane in cultured 
sensory neurons. (A) Representative fluorescent images showing membrane 
localization of immunoreactive phosphorylated PKC α, βI and βII in neurons 
treated with paclitaxel (300 nM, 3 days or 5 days) following stimulation with 
PDBu (300 nM, 2 minutes). (B) Graphical analysis showing the number of 
neuronal cell bodies demonstrating translocation of phosphorylated PKC α, βI 
and βII in paclitaxel-treated neurons (300 nM, 3 and 5 days) following 
stimulation with PDBu (300 nM, 2 minutes) expressed as % of phospho- PKC 
α/βI/βII translocation. An * indicates a significant decrease in the number of 
cells with PKC α, βI and βII translocation. Significance was determined using 
a two-way ANOVA with Dunnett’s post-hoc test (p < 0.05, N = 3). Scale bar = 
20 μm. Veh - Vehicle; Pac –Paclitaxel, 3D – 3 days, 5D – 5 days.  
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8. PDBu-stimulated CGRP release is dependent on TRPV1 channels 
 
It is well established that the function of TRPV1 channels is modulated by 
conventional and novel PKC isozymes (c/nPKC). Studies have shown that phorbol ester-
induced activation of c/nPKC enhanced the phosphorylation of TRPV1 channels (Jeske 
et al., 2009) and augmented capsaicin-induced currents in sensory neurons (Vellani et 
al., 2001, Zhou et al., 2001), whereas downregulation of c/nPKC by chronic phorbol 
ester treatment attenuated capsaicin-stimulated CGRP release (Barber and Vasko, 
1996). Furthermore, there is strong evidence to support that PDBu-induced CGRP 
release is mediated by TRPV1 activation in spinal cord tissue (Mogg et al., 2013). In 
Mogg et al’s studies, it was shown that PDBu- and capsaicin-stimulated CGRP release 
was attenuated following pre-treatment with multiple TRPV1 antagonists (BCTC, 
AMG517, A425619, A784168, AMG 49a, AMG9810, JNJ 17203212, SB705498, 
Neurogen) and was also blocked in spinal cord tissue from TRPV1 null mutant mice 
(Mogg et al., 2013).  
To assess whether PDBu-stimulated release was dependent on TRPV1 channels 
in cultured sensory neurons, neurons were pre-treated with increasing concentrations of 
the TRPV1 antagonist, 4-(3-Chloro-2-pyridinyl)-N-[4-(1,1 dimethylethyl)phenyl]-1-
piperazinecarboxamide (BCTC; IC50 = 35 nM for capsaicin-evoked TRPV1 activation), 
for 10 minutes prior to stimulation with 10 nM PDBu. Pre-treatment with 1 nM BCTC 
significantly attenuated PDBu-stimulated release from 9.2 ± 1.2 to 2.3 ± 0.5% of total 
content (Figure 14A); neither 0.01 nM nor 0.1 nM BCTC altered PDBu-stimulated 
release. The basal release following pre-treatment with 0.01 nM (0.8 ± 0.1), 0.1 nM (1.2 
± 0.1) and 1 nM BCTC (0.9 ± 0.1% of total content) was not significantly different when 
compared to control (0.7 ± 0.1% of total content; Figure 14A). These findings indicate 
that PDBu-stimulated release is mediated, in part, by activation of TRPV1 channels. 
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Researchers have also demonstrated that SB366791 acts as a TRPV1 
antagonist and inhibits capsaicin-, heat- and acid- evoked currents (Gunthorpe et al., 
2004). Based on these findings, we hypothesized that pre-treatment with SB366791 
would attenuate PDBu-stimulated release of CGRP from sensory neurons since TRPV1 
function is modulated by PKC. Prior to testing this hypothesis, we wanted to first 
recapitulate the findings of the aforementioned study (Gunthorpe et al., 2004) using 
CGRP release as a functional read-out of neuronal activity. Cultured neurons were pre-
treated with SB366791 for 10 minutes prior to stimulation with 30 nM capsaicin. 
Treatment with 1 μM and 10 μM SB366791 attenuated PDBu-stimulated CGRP release 
to 4.7 ± 1.1 and 4.7 ± 1.0% of total content respectively, compared to control neurons 
(18.5 ± 2.6% of total content; Figure 14B). Pre-treatment with 100 nM SB366791 (21.1 ± 
3.4) did not alter PDBu-stimulated release compared to control neurons (Figure 14B). 
These findings, which are in agreement with Gunthorpe et al.’s studies, suggest that 
capsaicin-stimulated activation of TRPV1 channels can be blocked by the SB366791.  
We next tested whether the TRPV1 antagonist, SB366791, altered PDBu-
stimulated release of CGRP from sensory neurons. Cultured neurons were pre-treated 
with SB366791 for 10 minutes prior to stimulation with 10 nM PDBu. Surprisingly, pre-
treatment with 1 μM and 10 μM SB366791 increased PDBu-stimulated release to 21.4 ± 
3.0 and 25.9 ± 2.7% of total content, respectively compared to control neurons (12.5 ± 
1.7% of total content); pre-treatment with 100 nM SB366791 (16.8 ± 2.8% of total 
content) did not alter PDBu-stimulated release compared to control neurons (Figure 
14C). These findings suggested that SB366791 acts more akin to a TRPV1 agonist 
rather than antagonist for PDBu-evoked responses. In fact, researchers have 
demonstrated that TRPV1 antagonists have differential effects on capsaicin versus 
PDBu-stimulated release from rat spinal cord tissue (Mogg et al., 2013). Interestingly, 
these studies also found that SB366791 attenuated capsaicin-stimulated release of 
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CGRP but not PDBu-stimulated release in rat spinal cord tissue. Based on these 
findings, we concluded that SB366791 differentially alters the function of TRPV1 in a 
stimulant-dependent manner in cultured sensory neurons.  
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Figure 14: The TRPV1 antagonist, BCTC, decreases PDBu-stimulated 
CGRP release in cultured sensory neurons. Each column represents the 
mean ± SEM of basal (white columns), PDBu-stimulated (black columns) 
or capsaicin-stimulated (striped columns) CGRP release expressed as % 
of total content. (A) Naïve cultures were pre-treated with the TRPV1 
antagonist, BCTC (0.01 nM, 0.1 nM or 1nM) for 10 minutes prior to 
stimulation with PDBu (10 nM). An * indicates a significant decrease in 
PDBu-stimulated release in neurons pre-treated with BCTC compared to 
control neurons (p < 0.05, N = 7-9). Significance was determined using a 
two-way ANOVA with Tukey’s post-hoc test. Naïve cultures were pre-
treated with the TRPV1 antagonist, SB366791 (100 nM, 1 μM or 10 μM), 
for 10 minutes prior to stimulation with (B) capsaicin (30 nM) or (C) PDBu 
(10 nM). An * indicates a significant (B) decrease and (C) increase in 
stimulated release in neurons pre-treated with SB366791 compared to 
control neurons (p < 0.05, N = 7-12). Significance was determined using a 
two-way ANOVA with Tukey’s post-hoc test. SB- SB366791. 
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9. Chronic treatment with paclitaxel inhibits the activity of conventional PKC isozymes, 
α and βI/II, to elicit a decrease in capsaicin-stimulated CGRP release 
 
Since our previous studies demonstrated that chronic treatment with paclitaxel 
(300 nM; 3 and 5 days) attenuates capsaicin-stimulated peptide release (Pittman et al., 
2014), we wanted to ascertain whether conventional PKCα and PKCβI/II were 
responsible for the decrease in capsaicin-stimulated CGRP release following chronic 
treatment with paclitaxel. Cultured sensory neurons were treated with 300 nM paclitaxel 
for 5 days and pre-treated with the myristolyated PKCα/β peptide inhibitor (10 μM) for 10 
minutes prior to stimulation with 30 nM capsaicin. Treatment with paclitaxel significantly 
attenuated capsaicin-stimulated release from 21.1 ± 1.5 (vehicle-only) to 17.6 ± 1.0% of 
total content (Figure 15A), confirming our previous findings (Pittman et al., 2014). Pre-
treatment with the PKCα/β peptide inhibitor in vehicle-treated neurons significantly 
attenuated capsaicin-stimulated release to 7.9 ± 1.0% of total content compared to 
vehicle-only treated neurons (Figure 15A), suggesting that a major component of 
capsaicin-stimulated release is due to PKC α, βI and βII. However, pre-treatment with 
the PKCα/β peptide inhibitor did not significantly alter capsaicin-stimulated release in 
paclitaxel-treated neurons (6.0 ± 0.7% of total content) compared to vehicle-treated 
neurons (7.9 ± 1.0% of total content; Figure 15A), suggesting that paclitaxel inhibits the 
activity of PKCα and PKCβI/II to elicit a decrease in capsaicin-stimulated peptide 
release.  
 We next verified whether inhibition of PKCα and PKCβI/II activity mediates loss 
of PDBu-stimulated release following treatment with 300 nM paclitaxel for 5 days, as 
demonstrated using the 3-day treatment paradigm. Treatment with 300 nM paclitaxel for 
5 days significantly attenuated PDBu-stimulated release from 12.2 ± 1.1 (vehicle-only) to 
9.1 ± 0.9% of total content (Figure 15B), in a manner analogous to that observed with 
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the 3-day treatment (see Figures 8A-C). As observed previously, pre-treatment with the 
10 μM myristolyated PKCα/β peptide inhibitor completely abolished PDBu-stimulated 
release; PDBu-stimulated release decreased from 12.2 ± 1.1 (vehicle-only) to 4.7 ± 0.4% 
of total content (Figure 15B). Pre-treatment with the PKCα/β peptide inhibitor did not 
further decrease PDBu-stimulated release in paclitaxel-treated neurons (5.2 ± 0.4% of 
total content) compared to vehicle-treated neurons (4.7 ± 0.4% of total content; Figure 
15B). These findings are analogous to that observed following combined pre-treatment 
with the PKCα and PKCβI/II inhibitors, Bis VIII and LY333531, following treatment with 
paclitaxel for 3 days (see Figure 8A). Similar to the 3-day paclitaxel treatment paradigm, 
a more prolonged exposure to paclitaxel decreases the activity of PKCα and PKCβI/II to 
elicit attenuation in the stimulated release of CGRP. 
 We also attempted to investigate whether phosphorylation of TRPV1 prior to 
capsaicin-evoked activation would reverse the loss of neuronal sensitivity induced by 
paclitaxel. For these experiments, a low stimulus of PDBu that does not directly alter 
CGRP release was used to elicit TRPV1 phosphorylation. Cultured sensory neurons 
were treated with 300 nM paclitaxel for 3 days and pre-treated with the PDBu (1 nM) for 
10 minutes prior to stimulation with capsaicin (30 nM). Treatment with paclitaxel 
decreased capsaicin-stimulated release to 14.5 ± 0.8 compared to vehicle-only treated 
neurons (21.8 ± 1.2 % of total content; Figure 15C), confirming earlier findings. Pre-
treatment with 1 nM PDBu in vehicle-treated neurons increased capsaicin-stimulated 
release to 48.7 ± 2.9% of total content compared to vehicle-only treated neurons, 
suggesting that activation of PKC sensitizes TRPV1. We speculate that this response is 
due to PKC-induced phosphorylation of TRPV1, but no confirmatory studies were 
performed. Interestingly, pre-treatment with 1 nM PDBu in paclitaxel-treated neurons 
had no effect on the decrease in capsaicin-stimulated release in (35.6 ± 3.4% total 
content) compared to vehicle-treated neurons (48.7 ± 2.9% of total content). This finding 
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suggested that the level of TRPV1 phosphorylation provided by a low stimulus of PDBu 
is not sufficient to reverse the effects of paclitaxel on neuronal sensitivity.  
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Figure 15: Inhibition of PKCα and PKCβI/II activity mediates the 
decrease in capsaicin-stimulated CGRP release following chronic 
exposure to paclitaxel in cultured sensory neurons. Each column 
represents the mean ± SEM of basal (white columns), capsaicin-
stimulated (striped columns) or PDBu-stimulated (black columns) CGRP 
release expressed as % of total content. Cultures were exposed to 300 
nM paclitaxel for 5 days and pre-treated with a myristolyated PKCα/β 
peptide inhibitor (10 μM) for 10 minutes prior to stimulation with (A) 30 
nM capsaicin or (B) 10 nM PDBu. An * indicates a significant decrease 
in (A) capsaicin-stimulated and (B) PDBu- stimulated release compared 
to vehicle-only treated neurons (p < 0.05, N = 8-15). N.S. – not 
significant. (C) Cultures were exposed to 300 nM paclitaxel for 3 days 
and pre-treated with PDBu (1 nM) for 10 minutes prior to stimulation with 
30 nM capsaicin. An * indicates a significant difference in capsaicin-
stimulated release compared to vehicle-only treated neurons and a # 
indicates a significant decrease in capsaicin-stimulated release in 
paclitaxel-treated neurons compared to vehicle-treated neurons pre-
treated with PDBu (p < 0.05, N = 7-9). (A, B, C) Significance was 
determined using a two-way ANOVA with Tukey‘s post-hoc test. 
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10. PDBu-stimulated CGRP release is altered following inhibition of L-type calcium 
channels but not N-type calcium channels 
 
In addition to the modulation of TRPV1 channel function, there is precedence in 
the literature to support a role for PKC-induced modulation voltage-gated calcium 
channels (Rane and Dunlap, 1986, Gross and MacDonald, 1989, Zhu and Ikeda, 1994, 
King et al., 1999). As such, we questioned whether N- or L-type calcium channels 
modulated PDBu-evoked peptide release. Cultured neurons were pre-treated with the N-
type calcium channel blocker, ω-conotoxin (100 nM), or the L-type calcium channel 
blocker, nifedipine (100 nM or 1μM) prior to stimulation with PDBu (10 nM). The tested 
concentrations of ω-conotoxin and nifedipine were previously validated in embryonic 
cultured neurons and were shown to block bradykinin- and potassium-stimulated release 
of neuropeptides, respectively (Evans et al., 1996). Pre-treatment with ω-conotoxin (6.3 
± 0.5) did not alter PDBu-stimulated release compared to control neurons (7.3 ± 0.6% 
total content; Figure 16A), suggesting that N-type calcium channels likely do not mediate 
PDBu-evoked peptide release. A concentration-response curve is needed to draw 
concrete conclusions on this data. In contrast, pre-treatment with 100 nM nifedipine 
(12.1 ± 0.6) attenuated PDBu-stimulated release compared to control neurons (14.4 ± 
0.5% total content; Figure 16B). However there were no differences observed following 
treatment with the higher concentration (1 μM) of nifedipine (14.4 ± 0.7% total content; 
Figure 16B). The significance of these findings is unclear because we have insufficient 
data points to comment on the lack of a response at the higher concentration of 
nifedipine used for these experiments.  
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Figure 16: The L-type Ca
2+ 
channel inhibitor, nifedipine, alters PDBu-
stimulated release in cultured sensory neurons. Each column represents 
the mean ± SEM of basal (white columns) or PDBu-stimulated (black 
columns) CGRP release expressed as % of total content. Naïve cultures 
were pre-treated with the (A) N-type Ca
2+ 
inhibitor, ω-conotoxin (100 nM) 
or (B) L-type Ca
2+ 
inhibitor, nifedipine (100 nM or 1 μM), for 10 minutes 
prior to stimulation with PDBu (10 nM). An * indicates a significant 
decrease in PDBu-stimulated release in neurons pre-treated with 
nifedipine compared to control neurons (p < 0.05, N = 11-12). Significance 
was determined using a two-way ANOVA with Tukey’s post-hoc test.  
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11. Chronic treatment with paclitaxel does not alter the activity of conventional PKC 
isozymes, α and βI/II, to elicit changes in AITC-stimulated CGRP release 
 
Our laboratory has previously shown that chronic treatment with paclitaxel (300 
nM, 5 days) decreased allyl isothiocyanate (AITC)-stimulated CGRP release from 
cultured sensory neurons, indicating that paclitaxel alters the function of transient 
receptor potential ankyrin 1 (TRPA1) channels (Pittman et al., 2014). Since studies have 
demonstrated that TRPA1 channels associate with TRPV1 channels in Chinese hamster 
ovary cells and trigeminal and dorsal root ganglia sensory neurons (Staruschenko et al., 
2010, Weng et al., 2015), we questioned whether paclitaxel modulated AITC-stimulated 
release in a conventional PKC (cPKC)-dependent manner. Cultured sensory neurons 
were treated with 300 nM paclitaxel for 5 days and pre-treated with the myristoylated 
PKCα/β peptide inhibitor (10 μM) for 10 minutes prior to stimulation with AITC (30 μM). 
Treatment with paclitaxel significantly attenuated AITC-stimulated release from 18.5 ± 
1.5 (vehicle-only) to 10.1 ± 0.4% of total content (Figure 17A), confirming our previous 
findings (Pittman et al., 2014). In contrast to TRPV1 channel function, pre-treatment with 
the PKCα/β peptide inhibitor did not alter AITC-stimulated release (16.1 ± 0.8% total 
content; Figure 17A) compared to vehicle-only treated neurons, suggesting that cPKC 
do not mediate AITC-stimulated release. Furthermore, pre-treatment with the PKCα/β 
peptide inhibitor had no effect on the decrease in AITC-stimulated release in paclitaxel-
treated neurons (11.5 ± 0.8% total content) compared to vehicle-treated neurons (16.1 ± 
0.8% total content; Figure 17A). These findings indicate that paclitaxel does not elicit the 
reduction of AITC-stimulated CGRP release in a cPKC-dependent manner.  
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Figure 17: Inhibition of PKCα and PKCβI/II activity does not mediate the decrease in 
AITC-stimulated CGRP release following chronic exposure to paclitaxel nor does 
inhibition of PKCα and PKCβI/II activity alter AITC-stimulated release in naïve 
cultured sensory neurons. Each column represents the mean ± SEM of basal (white 
columns) or stimulated (striped columns) CGRP release expressed as % of total 
content. (A) Cultures were exposed to 300 nM paclitaxel for 5 days and pre-treated 
with a myristolyated PKCα/β peptide inhibitor (10 μM) for 10 minutes prior to 
stimulation with AITC (30 μM). An * indicates a significant decrease in AITC-
stimulated release in paclitaxel-only treated neurons and paclitaxel treated neurons 
pre-treated with the myristolyated PKCα/β peptide inhibitor compared to vehicle-only 
treated neurons, and # indicates a significant decrease in AITC-stimulated release in 
paclitaxel-treated neurons pre-treated with the myristolyated PKCα/β peptide inhibitor 
compared to vehicle-treated neurons pre-treated with the myristolyated PKCα/β 
peptide inhibitor (p < 0.05, N = 9). Significance was determined using a two-way 
ANOVA with Tukey’s post-hoc test.  
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12. AITC-stimulated CGRP release is not dependent on c/nPKC, PLC or PKA 
 
Because we established that a paclitaxel-induced reduction in AITC-stimulated 
release of CGRP is not dependent on conventional PKC isozymes, we next sought to 
determine the importance of additional PKC isozymes in mediating AITC-stimulated 
release. By assessing the signaling protein necessary for AITC-stimulated release, we 
could then investigate whether this identified protein was responsible for the reduction in 
AITC-stimulated release of CGRP following chronic treatment with paclitaxel. To address 
this matter, cultured neurons were pre-treated with the conventional and novel PKC 
isozyme, bisindolylmaleimide I (Bis I; 1 μM) for 10 minutes prior to stimulation with AITC 
(30 μM). Pre-treatment with Bis I did not alter AITC-stimulated release (21.6 ± 1.7% total 
content) compared to vehicle-treated neurons (24.3 ± 2.0% total content, Figure 18A), 
suggesting that conventional and novel PKC isozymes do not mediate AITC-stimulated 
release. 
We then confirmed that PKC and TRPA1 do not share similar signaling pathways 
to elicit changes in CGRP release from cultured sensory neurons. For these 
experiments, neurons were pre-treated with the TRPA1 antagonist HC 030031 (5, 10 or 
30 μM) prior to stimulation with PDBu (10 nM). Pre-treatment with 5 μM (13.2 ± 0.7) and 
10 μM (13.6 ± 0.7% total content) HC 030031 did not significantly alter PDBu-stimulated 
release compared to vehicle-treated neurons (12.3 ± 0.7% total content; Figure 18B). In 
fact, pre-treatment with 30 μM (16.4 ± 0.6% total content) HC 030031 increased PDBu-
stimulated release (Figure 18B). These findings indicate that PDBu-evoked release is 
not mediated by TRPA1 channel activation. Furthermore, along with the findings in 
Figure 18A, our data demonstrates that there is no crosstalk between the PKC and 
TRPA1 to elicit enhanced release of CGRP from cultured neurons.  
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Apart from PKC, we also wanted to investigate whether the signaling proteins, 
phospholipase C (PLC) and protein kinase A (PKA) modulated AITC-stimulated release 
of CGRP since there have been multiple studies demonstrating that TRPA1 channel 
function is dependent on these two proteins. PLC is an upstream PKC signaling protein 
that catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) to 
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) with subsequent release of 
calcium from intracellular stores and PKC activation (Rhee, 2001). On the other hand, 
PKA activation occurs in an independent signaling pathway, in which receptor-mediated 
activation of adenylyl cyclase leads to the generation of cAMP and subsequent PKA 
activation. Studies have demonstrated that activation of PLC and PKA potentiated 
mustard oil- (a TRPA1 activator) induced nocifensive behaviors (Schmidt et al., 2009). It 
was also shown that bradykinin sensitized AITC-evoked currents in a PLC- and PKA-
dependent manner (Wang et al., 2008). Given the precedence in the literature 
supporting a role for PLC and PKA in the modulation of TRPA1 channels function we 
investigated whether PLC and PKA modulated TRPA1-stimulated CGRP release in 
cultured sensory neurons. Cultured neurons were pre-treated with a PLC inhibitor 
(U73122; 6 μM) or a PKA inhibitor (H-89; 10 μM) prior to stimulation with AITC (30 μM). 
Pre-treatment with U73122 (25 ± 2.3% total content) and H-89 (24.5 ± 2.0) did not alter 
AITC-stimulated release compared to vehicle-treated neurons (24.3 ± 2.0% total content; 
Figure 18A), suggesting that PLC and PKA do not alter the release of CGRP elicited by 
AITC.  
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Figure 18: Inhibition of c/nPKC, PLC and PKA does not alter AITC-
stimulated CGRP release in cultured sensory neurons. Each column 
represents the mean ± SEM of basal (white columns) or stimulated 
(striped columns) CGRP release expressed as % of total content. (A) 
Cultures were pre-treated with inhibitors of c/nPKC (Bis I; 1 μM), PLC 
(U73122; 6 μM) and PKA (H-89; 10 μM) for 10 minutes prior to 
stimulation with AITC (30 μM). Significance was determined using a two-
way ANOVA with Tukey’s post hoc test (p < 0.05, N = 9). (B) Cultures 
were pre-treated with the TRPA1 antagonist HC 030031 (5, 10 or 30 μM) 
prior to stimulation with PDBu (10 nM). An * indicates a significant 
increase in AITC-stimulated release in neurons pre-treated with HC 
030031 (p < 0.05, N = 8-9). Significance was determined using a two-
way ANOVA with Tukey’s post-hoc test.  
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13. Paclitaxel decreases neurite length and branching in a time-dependent manner 
 
In addition to modulating the sensitivity of neurons to different stimuli, paclitaxel 
also alters neurite morphology. Our laboratory has previously demonstrated that chronic 
treatment with paclitaxel (300 nM, 5 days) decreases the length and branching of 
neurites in cultured sensory neurons (Pittman et al., 2014), confirming similar findings by 
other researchers (Hayakawa et al., 1994, Konings et al., 1994, Malgrange et al., 1994, 
Melli et al., 2006, Scuteri et al., 2006, Yang et al., 2009). Importantly, there is also 
evidence to suggest that neurite retraction induced by treatment with paclitaxel is a 
causative factor in the generation of altered neuronal sensitivity (Siau et al., 2006, 
Boyette-Davis et al., 2011, Boyette-Davis et al., 2013). Based on this knowledge, it was 
important for us to investigate the mechanisms underlying the loss of neurite length and 
branching induced by paclitaxel.  
There is precedence in the literature to support a role for protein kinase C (PKC) 
in the enhancement of neurite outgrowth in different types of cells including PC12 cells 
and sensory ganglia explants (Spinelli et al., 1982, Hsu, 1985, Hsu et al., 1989, Mehta et 
al., 1993, Roivainen et al., 1993, Burry, 1998, Choe et al., 2002). Because our earlier 
studies identified PKC as a critical mediator of changes in neuronal sensitivity, we 
wanted to determine whether PKC was important in mediating the effects of paclitaxel on 
neurite morphology. As will be discussed in the upcoming section, we focused on the 
role of PKCε since the majority of detailed mechanistic studies implicated this specific 
PKC isozyme in the positive modulation of neurite outgrowth.  
 Prior to assessing the role of PKC in mediating the effects of paclitaxel on neurite 
outgrowth, we first wanted to establish the temporal profile for altered neurite 
morphology induced by chronic treatment with paclitaxel. Previous studies from our 
laboratory demonstrated that treatment with 300 nM paclitaxel for 5 days decreased 
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neurite length and branching in cultured sensory neurons (Pittman et al., 2014). Given 
this finding, we wanted to assess whether paclitaxel altered neurite length at time-points 
earlier than 5 days so as to better understand the timeline for changes in neurite length. 
Cultured sensory neurons were treated with 300 nM paclitaxel for 1-3 days, fixed, and 
stained with a primary antibody against PGP9.5 and fluorescently labeled secondary 
antibody. We then assessed changes in neurite length and branching using the neurite 
outgrowth software on the ImageXpress system, as previously published (Pittman et al., 
2016). Representative images are shown in Figures 19C. Treatment with paclitaxel 
decreased neurite length to 96,917 ± 7,915 (1 day), 72,039 ± 10,949 (2 days) and 
73,528 ± 10,585 μm (3 days) compared to vehicle-treated neurons (114,806 ± 5,906 μm; 
Figure 19A). In addition, treatment with paclitaxel decreased neurite branching to 7,532 
± 857 (1 day), 5044 ± 1132 (2 days) and 5187 ± 996 branches (3 days) compared to 
vehicle-treated neurons (9976 ± 839 branches; Figure 19B). In fact, upon visual 
examination of the neuronal cultures, we have repeatedly found that treatment with 
paclitaxel causes the density of the neurites (extensions protruding from the neuronal 
cell bodies) to be much lower compared to vehicle-treated neurons. This causes the 
network of neurites to appear quite sparse within a given field of view in paclitaxel-
treated neurons. This is in stark contrast to vehicle-treated neurons that consist of a very 
dense network of neurites. While this characteristic is apparent following treatment with 
300 nM paclitaxel for 3 days (as shown in Figure 19C), it is most evident following a 5-
day treatment paradigm (as shown in Figures 22C and 24C). Our findings indicate that 
chronic treatment with paclitaxel decreases the length and branching of neurites in a 
time-dependent manner.  
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Figure 19: Chronic treatment with paclitaxel decreases neurite length and 
neurite branching in cultured sensory neurons. Graphical analysis showing (A) 
neurite extension expressed as μM of outgrowth and (B) neurite branching 
expressed as # of branch points in cultured neurons treated with 300 nM 
paclitaxel for 1, 2 or 3 days. An * indicates a significant decrease in neurite 
extension and neurite branching in paclitaxel-treated neurons compared to 
vehicle-treated neurons (p < 0.05, N = 4). Significance was determined using a 
one-way ANOVA with post-hoc test. (C) Representative inverted 
photonegative images showing immunoreactivity for PGP9.5 in neurons 
treated with 300 nM paclitaxel for 1, 2 or 3 days. The arrow indicates a 
branching point and the asterisk the cell body of a neuron. Scale bar = 100 
μm. Veh – Vehicle; Pac – Paclitaxel; 1D- 1 day; 2D – 2 days; 3D – 3 days.   
C. 
* 
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14. Paclitaxel decreases the protein expression of the novel PKC isozyme, PKCε 
 
There is precedence in the literature that provides strong evidence to support a 
role for the novel PKC isozyme, PKCε, in the positive modulation of neurite outgrowth 
processes (Hundle et al., 1995, Hundle et al., 1997, Brodie et al., 1999, Zeidman et al., 
2002, Ling et al., 2004, Ling et al., 2005, Shirai et al., 2007). A plausible explanation for 
the loss in neurite length and branching following treatment with paclitaxel is a reduction 
in the protein expression of PKCε. Therefore, we investigated whether treatment with 
300 nM or 1 μM paclitaxel for 1-3 days altered the protein expression of PKCε in whole 
cell lysates using Western blots. Treatment with 300 nM paclitaxel decreased the protein 
expression of PKCε to 0.7 ± 0.0 (2 days) and 0.5 ± 0.1 (3 days, arbitrary units, a.u.) 
compared to vehicle-treated neurons (1.0 ± 0.0 a.u.; Figures 20A and 20B). There were 
no differences following treatment with 300 nM paclitaxel for 1 day (1.0 ± 0.0 a.u.; 
Figures 20A and 20B). Interestingly, the reduction in PKCε protein expression coincides 
with the reduction in neurite length and branching at the same time-points. We also 
made similar observations with changes in PKCε protein expression following treatment 
with the higher concentration of paclitaxel. Treatment with 1 μM paclitaxel decreased the 
protein expression of PKCε to 0.5 ± 0.1 a.u. (2 days) and 0.4 ± 0.1 (3 days) compared to 
vehicle-treated neurons (1.0 ± 0.0 a.u.; Figures 20C and 20D). Similar to treatment with 
300 nM paclitaxel, we observed no changes in PKCε expression following treatment with 
1 μM paclitaxel for 1 day 0.6 ± 0.1 a.u (Figures 20C and 20D). Our findings indicate that 
chronic treatment with paclitaxel attenuates the expression of PKCε in a time-dependent 
manner similar to the timeline for paclitaxel-induced changes in neurite length and 
branching.  
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Figure 20: Chronic treatment with paclitaxel decreases PKCε immunoreactivity 
in cultured sensory neurons. Representative western blot images showing 
immunoreactivity for PKCε in neuronal lysates treated with (A) 300 nM and (C) 
1 μM paclitaxel for 1, 2 or 3 days. Densitometry analysis showing a reduction in 
PKCε immunoreactivity in neurons treated with (B) 300 nM paclitaxel and (D) 1 
μM paclitaxel for 1, 2 or 3 days. An * indicates a significant decreases in PKCε 
immunoreactivity in paclitaxel-treated neurons compared to vehicle-treated 
neurons (p < 0.05, N = 3). Significance was determined using a one-way 
ANOVA with Tukey’s post-hoc test. Veh – Vehicle; 1D – 1 day; 2D – 2 days; 
3D- 3 days.  
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15. Phorbol-ester induced downregulation of PKCε does not alter neurite length or 
branching in the absence or presence of paclitaxel 
 
Chronic treatment with phorbol esters results in the downregulation of PKC 
expression (Gould and Newton, 2008). Since chronic treatment with paclitaxel 
decreased neurite length and branching and the protein expression of PKCε in a similar 
time-dependent fashion, we questioned whether the loss in neurite length and branching 
induced by paclitaxel was due to a reduction in the expression of PKCε. We first 
manipulated the protein expression of PKCε using a chronic phorbol ester treatment 
paradigm to assess the levels of PKCε downregulation using this treatment paradigm. 
Cultured neurons were treated with phorbol 12, 13-dibutyrate (PDBu, 0.3 nM) for 2 days 
and the protein expression in whole cell lysates was assessed using Western blots. 
Treatment with PDBu decreased the protein expression to 0.7 ± 0.1 a.u. compared to 
vehicle-treated neurons (1.0  ± 0.0 a.u.; Figures 21A and 21B), indicating that chronic 
treatment with PDBu attenuates the expression of PKCε by 30%.  
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Figure 21: Chronic treatment with PDBu attenuated PKCε 
immunoreactivity in cultured sensory neurons. (A) 
Representative western blot image showing immunoreactivity 
for PKCε in neuronal lysates treated with 0.3 nM PDBu for 2 
days. (B) Densitometry analysis showing a reduction in PKCε 
immunoreactivity in neurons treated with 0.3 nM PDBu for 2 
days. An * indicates a significant reduction in PKCε 
immunoreactivity in neurons treated with PDBu compared to 
vehicle-treated neurons (p < 0.05, N = 3). Significance was 
determined using a t-test. Veh – Vehicle. 
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Using treatment with chronic phorbol esters as a tool to manipulate the 
expression of PKCε, we next investigated the effects of PKCε downregulation on neurite 
length and branching in neurons treated with paclitaxel. Cultured neurons were treated 
with 300 nM paclitaxel for 5 days and pre-treated with PDBu (0.3 nM) for 2 days (days 4-
5 of paclitaxel treatment) prior to fixation and staining with a primary antibody against 
PGP9.5 and a fluorescently labeled secondary antibody. Representative images are 
shown in Figures 22C. Unexpectedly, pre-treatment with PDBu did not alter neurite 
length (171,023 ± 3,690 μm) compared to vehicle-treated neurons (165,324 ± 3,874 μm; 
Figure 22A) nor did it alter neurite branching (22,581 ± 1,414 branches) compared to 
vehicle-treated neurons (21,191 ± 1,246 branches; Figure 22B), suggesting that 
downregulation of PKCε does not alter neurite length or branching. As expected, 
treatment with 300 nM paclitaxel for 5 days decreased neurite length (126,523 ± 2,959 
μm) and neurite branching (12,066 ± 604 branches) compared to vehicle-treated 
neurons (Figures 22A and 22A), confirming previously published findings (Pittman et al., 
2016). However, we observed no differences in neurite length (117,231 ± 3,854 μm) or 
neurite branching (10,560 ± 631 branches) in paclitaxel-treated neurons pre-treated with 
PDBu compared to paclitaxel only-treated neurons (Figures 22A and 22B), indicating 
that downregulation of PKCε does not exacerbate the reduction neurite length and 
branching induced by chronic treatment with paclitaxel. Together, our findings suggest 
PDBu-induced downregulation of PKCε has no effect on neurite morphology in the 
absence or presence of paclitaxel. However, another plausible explanation for the lack of 
effects is that the remaining 70% protein expression of PKCε following chronic PDBu 
treatment is sufficient to maintain neurite outgrowth and therefore masks the effects of 
PDBu-induced downregulation of PKCε expression. 
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Figure 22: PDBu-induced downregulation of PKCε does not alter neurite length or 
neurite branching in the absence or presence of paclitaxel in cultured sensory 
neurons. Graphical analysis showing (A) neurite extension expressed as μM of 
outgrowth in neurons and (B) neurite branching expressed as # of branch points in 
paclitaxel- and vehicle-treated neurons pre-treated with 0.3 n PDBu for 2 days. An 
* indicates a significant decrease in neurite length and neurite branching in 
paclitaxel only-treated neurons and paclitaxel-treated neurons pre-treated with 
PDBu compared to vehicle-treated neurons (p < 0.05, N = 3). Significance was 
determined using a one-way ANOVA with Tukey’s post-hoc test. (C) 
Representative inverted photonegative images showing immunoreactivity for 
PGP9.5 in paclitaxel- and vehicle-treated neurons pre-treated with 0.3 nM PDBu 
for 2 days. Scale bar = 100 μm. Veh – Vehicle; Pac – Paclitaxel; 2D – 2 days; 3D 
– 3 days.  
C. 
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16. Knockdown of PKCε does not alter neurite length or branching in the absence or 
presence of paclitaxel 
 
In addition to using a chronic phorbol ester treatment paradigm to downregulate 
the expression of PKCε, we also used a pool of PKCε siRNA to decrease the expression 
of PKCε. Cultured neurons were treated with PKCε siRNA and scramble siRNA and the 
protein expression of PKCε in whole cell lysates was determined using Western blots. 
Treatment with PKCε siRNA attenuated the expression of PKCε to 0.5 ± 0.1 a.u. 
compared to vehicle-treated neurons (1.0 ± 0.0 a.u.; Figures 23A and 23B), indicating 
that siRNA treatment decreased the expression of PKCε by 50%. In fact, the percent 
reduction in PKCε protein expression following treatment with PKCε siRNA is analogous 
to the effects of paclitaxel on PKCε protein expression. 
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Figure 23: siRNA knockdown of PKCε attenuates PKCε 
immunoreactivity in cultured sensory neurons. (A) Representative 
western blot image showing immunoreactivity for PKCε in 
neuronal lysates treated with 100 nM PKCε siRNA or 100 nM 
scramble siRNA. (B) Densitometry analysis showing a reduction in 
PKCε immunoreactivity in neurons treated with PKCε siRNA. An * 
indicates a significant decrease in PKCε immunoreactivity in 
neurons treated with PKCε siRNA compared to scramble siRNA (p 
< 0.05, N = 3). Significance was determined using a t-test.  
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Using siRNA to manipulate the expression of PKCε, we questioned whether a 
reduction in the protein expression of PKCε is sufficient to alter neurite length and 
branching in the absence or presence of paclitaxel. Cultured neurons were treated with 
PKCε siRNA or scramble control siRNA on day 4 in culture and then treated with 300 nM 
paclitaxel for 5 days beginning on day 7. Neurons were then fixed and stained a primary 
antibody against PGP9.5 and a fluorescently labeled secondary antibody. 
Representative images are shown in Figures 24C. Treatment with PKCε siRNA did not 
alter neurite length (164,628  ± 1,258 μm) compared to treatment with scramble siRNA 
in vehicle-treated neurons (158,064 ± 3,904 μm) nor did it alter neurite branching 
(19,251 ± 445 branches) compared to scramble siRNA treatment in vehicle-treated 
neurons (17,225 ± 1,131 branches; Figure 24A and 24B). As expected, treatment with 
paclitaxel decreased neurite length to 108,705 ± 16,732 μm and decreased neurite 
branching to 8,816 ± 1,668 branches compared to vehicle-treated neurons (Figures 24A 
and 24B). However, treatment with PKCε siRNA did not alter neurite length (103,305 ± 
4,882 μm) or branching (8,249 ± 671 branches) in paclitaxel-treated neurons compared 
to scramble siRNA treatment in vehicle-treated neurons (Figures 24A and 24B), 
indicating that knockdown of PKCε does not exacerbate the reduction in neurite length 
and branching induced by chronic treatment with paclitaxel.  
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Figure 24: siRNA knockdown of PKCε does not alter neurite length or neurite 
branching in the absence or presence of paclitaxel in cultured sensory neurons. 
Graphical analysis showing (A) neurite extension expressed as μM of outgrowth in 
neurons and (B) neurite branching expressed as # of branch points in paclitaxel- 
and vehicle-treated neurons treated with 100 nM PKCε siRNA or 100 nM scramble 
siRNA. An * indicates a significant decrease in neurite length and neurite 
branching in paclitaxel only-treated neurons and paclitaxel-treated neurons 
exposed to PKCε siRNA compared to vehicle-treated neurons (p < 0.05, N = 3). 
Significance was determined using a one-way ANOVA with Tukey’s post-hoc test. 
(C) Representative inverted photonegative images showing immunoreactivity for 
PGP9.5 in paclitaxel- and vehicle-treated neurons treated with 100 nM PKCε 
siRNA or 100 nM scramble siRNA. Scale bar = 100 μm. Veh – Vehicle; Pac – 
Paclitaxel.  
C. 
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17. Activation of PKCε using ψεRACK elicits PKCε membrane translocation 
 
In addition to downregulating the protein expression of PKCε, we decided to 
directly activate PKCε in order to assess its role in neurite outgrowth. Researchers have 
demonstrated in CHO cells that activation of PKCε using ψεRACK in the presence of 
sub-optimal concentrations of phorbol esters (i.e. concentration that does not directly 
alter translocation), elicits translocation of PKCε to specific cellular structures (Brandman 
et al., 2007). This activator peptide is derived from a sequence in the C2 domain of 
PKCε and activates PKCε by binding with high affinity to the RACK binding site in PKCε, 
therefore blocking the low affinity autoinhibitory interaction between the pseudo-RACK 
site and RACK binding region within PKCε (Kheifets and Mochly-Rosen, 2007, Mochly-
Rosen et al., 2012). As such, our initial objectives were to first confirm that ψεRACK 
induced the activation of PKCε as demonstrated by PKCε membrane localization, and to 
then investigate whether treatment with ψεRACK altered neurite length and branching in 
the absence and presence of paclitaxel.  
Using the published treatment paradigm described above, we first questioned 
whether activation of PKCε using ψεRACK would alter translocation of PKCε to the 
plasma membrane. Cultured neurons were pre-treated with TAT-conjugated ψεRACK 
(10 μM) or TAT-conjugated scramble peptide (10 μM) for 10 minutes prior to 
administration of PDBu (1 nM; 2 minutes). Neurons were then fixed and stained with a 
primary antibody against PKCε and a fluorescently labeled secondary antibody. 
Representative images are shown in Figure 25A. Treatment with 1 nM PDBu did not 
elicit changes in membrane localized PKCε (0.0 ± 0.0%) compared to untreated neurons 
(1.7 ± 0.9%; Figure 25B). However, treatment with 1 nM PDBu enhanced the percentage 
of cells with membrane localized PKCε to 16.5 ± 2.5% in neurons treated with the TAT-
ψεRACK compared to untreated neurons (Figure 25B). As expected, pre-treatment with 
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1nM PDBu did not alter membrane localized PKCε in neurons treated with TAT-
scramble peptide (2.2 ± 2.2%) compared to untreated neurons (Figure 25B). As a 
positive control, neurons were treated with 1 μM PDBu to demonstrate that higher 
concentrations of PDBu directly enhance PKCε membrane translocation (20.5 ± 3.5%; 
Figure 25B). Interestingly, in contrast to previously published data showing a direct effect 
of ψεRACK on PKC activation in the absence of phorbol esters (Dorn et al., 1999), we 
found that treatment with 10 μM TAT-conjugated ψεRACK did not alter membrane 
localization of PKCε in the absence of phorbol ester treatment (2.0 ± 1.0%; Figure 25B). 
We also confirmed that ψεRACK was a specific activator of PKCε by showing that TAT-
conjugated ψεRACK had no effect on PKCβII membrane translocation. For these 
experiments, cultured neurons were treated with TAT-conjugated ψεRACK (10 μM) or 
TAT-conjugated scramble peptide (10 μM) for 10 minutes prior to stimulation with PDBu 
(1 nM; 2 minutes). Neurons were then fixed, and stained with a primary antibody against 
PKCβII and a fluorescently labeled secondary antibody. Treatment with 1nM PDBu did 
not alter the membrane localization of PKCβII in neurons treated with TAT-conjugated 
ψεRACK (0.9 ± 0.9%) or TAT-conjugated scramble peptide (0.4 ± 0.4%) compared to 
control neurons (0.3 ± 0.3%; Figure 25C). As a positive control we showed that 
treatment with 1 μM PDBu (26.2 ± 6.2%; Figure 25C) enhanced the percentage of cells 
with membrane localized PKCβII. Our findings indicate that activation of PKCε using 
ψεRACK elicits a specific increase in membrane translocation of PKCε.  
Having confirmed that ψεRACK is a specific activator of PKCε, we then 
investigated whether ψεRACK-induced activation of PKCε altered neurite length and 
branching in cultured sensory neurons. Our preliminary studies, which were performed in 
the absence on paclitaxel, demonstrated that treatment with ψεRACK in the presence of 
a sub-optimal concentration of PDBu did not alter neurite length or branching (data not 
shown; n=1). At this point, we decided to re-evaluate our scientific approach to 
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evaluating the role of PKC in neurite outgrowth due to the observed lack of effects 
following exposure to the PKCε activator, ψεRACK. Since our data suggests that PKCε 
is likely not important for mediating neurite outgrowth in cultured sensory neurons, we 
decided to broaden our scope to evaluate whether other PKC isozymes were important 
in neurite outgrowth processes, as discussed in the next section.   
 
  
 128 
 
  
B. 
A. 
PDBu + TAT- 
Scrb. peptide 
PDBu + TAT- 
ψεRACK 
 129 
 
  
C. 
Figure 25: Activation of PKCε using ψεRACK elicits PKCε membrane 
translocation in cultured sensory neurons. (A) Representative 
fluorescent images showing membrane localization of immunoreactive 
PKCε in neurons pre-treated with TAT-ψεRACK peptide (10 μM) or 
TAT-scramble peptide (10 μM) for 10 minutes prior to stimulation with 
PDBu (1 nM, 2 minutes). Graphical analysis showing the percentage of 
cells positive for membrane localized (B) PKCε or (C) PKCβII in 
neurons pre-treated with TAT-ψεRACK peptide (10 μM) or TAT-
scramble peptide (10 μM) for 10 minutes prior to stimulation with PDBu 
(1 nM; 2 minutes), and PDBu (1 nM or 1 μM) or TAT-ψεRACK peptide 
(10 μM) for 2 minutes. An * indicates a significant increase in the 
percentage of cells positive for membrane localized (B) PKCε or (C) 
PKCβII compared to control neurons (p < 0.05; N = 3). Significance was 
determined using a one-way ANOVA with Tukey’s post-hoc test. Scale 
bar = 20 μm. Scrb – Scramble. 
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18. Acute treatment with PDBu does not alter neurite length or branching 
 
Using two individual methods to downregulate PKCε protein expression, we 
demonstrated that 30-50% reduction in expression led to no changes in neurite length or 
branching in the absence of paclitaxel. Furthermore, downregulation of PKCε protein 
expression did not exacerbate the loss of neurite length or branching induced by chronic 
treatment with paclitaxel. As such, we focused on fully characterizing the sole effects of 
PKC on neurite length in the absence of paclitaxel in order to gain a better 
understanding of the role of this protein family in neurite outgrowth in sensory neurons 
cultured from adult dorsal root ganglia. Therefore, we decided to examine the effects of 
phorbol ester-induced activation of conventional and novel PKC isozymes (c/nPKC) on 
changes in neurite length and branching in cultured sensory neurons in the absence of 
paclitaxel. 
Researchers have demonstrated that treatment with 20 nM phorbol 12-myristate 
13-acetate (PMA) for 30 minutes enhanced neurite length in sensory ganglia explants 
(Mehta et al., 1993). We assessed the effects of different concentrations and treatment 
timelines for administration of PDBu on neurite length and branching. In the first 
treatment paradigm, cultured neurons were treated with 10 nM PDBu for 30 minutes, 1 
hour or 3 hours, fixed, and stained with a primary antibody against PGP9.5 and a 
fluorescently labeled secondary antibody. We chose to use the specified concentration 
of PDBu since we previously demonstrated that 10 nM PDBu modulates sensory 
neuronal function as measured by evoked peptide release. Representative images are 
shown in Figures 26C. Treatment with PDBu for 30 minutes (147,253 ± 5,280), 1 hour 
(150,702 ± 3,679) and 3 hours (150,430 ± 6,194 μm) did not alter neurite length 
compared to vehicle-treated neurons (139,059 ± 4,670 μm; Figures 26A). Also, 
treatment with PDBu for 30 minutes (15,600 ±1,174), 1 hour (15,978 ± 903) and 3 hours 
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(16,476 ± 1,089 branches) did not alter neurite branching compared to vehicle-treated 
neurons (13,879 ± 913 branches; Figures 26B). These findings indicate that short-term 
treatment with PDBu does not elicit changes in neurite length or branching. 
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Vehicle PDBu (10 nM, 30 mins) 
PDBu (10 nM, 1 hr) PDBu (10 nM, 3 hrs) 
C. 
Figure 26: Acute treatment with low concentrations of PDBu does not alter 
neurite length or neurite branching in cultured sensory neurons. Graphical 
analysis showing (A) neurite extension expressed as μM of outgrowth in neurons 
and (B) neurite branching expressed as # of branch points in neurons treated 
with 10 nM PDBu. Significance was determined using a one-way ANOVA with 
Tukey’s post-hoc test (p < 0.05, N = 3). (C) Representative inverted 
photonegative images showing immunoreactivity for PGP9.5 in neurons treated 
with 10 nM PDBu (30 minutes, 1 hour or 3 hours). Scale bar = 100 μm.  
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In the second treatment paradigm, cultured neurons were treated with 10 nM, 
100 nM or 1 μM PDBu for 10 minutes, fixed, and stained with a primary antibody against 
PGP9.5 and a fluorescently labeled secondary antibody. Representative images are 
shown in Figures 27C. Treatment with 10 nM (139,008 ± 6,407), 100 nM (137,605 ± 
12,083) and 1 μM (140,704 ± 11,536 μm) did not alter neurite length compared to 
vehicle-treated neurons (137,671 ± 9,639 μm; Figure 27A). In addition, treatment with 10 
nM (14,067 ± 1,308), 100 nM (14, 848 ± 2,176) and 1 μM (15, 351 ± 2,152 branches) did 
not alter neurite branching compared to vehicle-treated neurons (14,497 ± 1,756 
branches; Figure 27B), indicating that higher concentrations of PDBu do not elicit 
changes in neurite length or branching. Overall, these data indicate that phorbol-ester 
induced activation of c/nPKC does not elicit changes in neurite length or branching at the 
specified time-points and concentration examined in cultured sensory neurons.  
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Vehicle PDBu (10 nM, 10 mins) 
PDBu (100 nM, 10mins) PDBu (1 μM, 10mins) 
Figure 27: Acute treatment with high concentrations of PDBu does not alter 
neurite length or neurite branching in cultured sensory neurons. Graphical 
analysis showing (A) neurite extension expressed as μM of outgrowth in neurons 
and (B) neurite branching expressed as # of branch points in neurons treated with 
10 nM PDBu. Significance was determined using a one-way ANOVA with Tukey’s 
post-hoc test (p < 0.05, N = 3). (C) Representative inverted photonegative images 
showing immunoreactivity for PGP9.5 in neurons treated with PDBu (10 nM, 100 
nM or 1 μM) for 10 minutes. Scale bar = 100 μm.  
C. 
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DISCUSSION 
 
Peripheral neuropathy is an adverse and debilitating side effect of the 
chemotherapeutic drug, paclitaxel (Wiernik et al., 1987a, Sarosy et al., 1992, Dougherty 
et al., 2004). To date, no effective therapeutic agents exist to prevent or alleviate 
peripheral neuropathy and therefore patients are often forced to undergo dose 
reductions or full discontinuation of treatment with paclitaxel in order to alleviate the 
painful symptoms of peripheral neuropathy (Pachman et al., 2011), hampering the 
successful treatment of cancer. Since paclitaxel is a leading and effective agent used for 
cancer therapy, it is paramount that researchers develop a therapy to prevent or reverse 
peripheral neuropathic symptoms in order to allow for the optimal use of paclitaxel in 
cancer therapy. To accomplish this goal, detailed mechanistic studies examining the 
causative factors for altered neuronal function and morphology need to be performed so 
that targeted therapeutics can be developed to resolve the symptoms of peripheral 
neuropathy.  
The overall aim of our research studies is to better understand the effects of 
paclitaxel on sensory neuronal function and morphology. Our ability to accomplish this 
goal will advance our knowledge of how paclitaxel elicits neurotoxic effects and in 
general, contribute to scientific advances in the field of chemotherapy-induced peripheral 
neuropathy. The work presented in this dissertation investigates whether protein kinase 
C (PKC) mediates altered neuronal sensitivity and neurite morphology induced by 
paclitaxel in cultured sensory neurons. We determined that paclitaxel inhibited the 
activity and membrane localization of PKCα and PKCβI/II to elicit a loss of sensory 
neuronal function in cultured sensory neurons. In contrast, we determined that changes 
in PKC function and expression did not account for the reduction in neurite length or 
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branching induced by paclitaxel or impact neurite morphology in the absence of 
paclitaxel.  
 
1. Paclitaxel signaling in sensory neurons and the implications for PKC 
 
Researchers have proposed multiple mechanisms to explain the neurotoxic 
effects of paclitaxel. Some of the major proposed mechanisms include altered 
inflammatory signaling and calcium dysregulation. These proposed mechanisms 
highlight the effects of paclitaxel on different aspects of cellular signaling. Interestingly, 
the intracellular second messenger protein, protein kinase C (PKC), has the capacity to 
modulate various intracellular signaling pathways involved in nociceptive signaling. 
Therefore, it is possible that protein kinase C plays an important role in modulating 
paclitaxel signaling pathways previously established in the literature. 
In this sub-section we will discuss how altered inflammatory signaling and 
calcium dysregulation mediate the neurotoxic effects of paclitaxel and the potential role 
that PKC might play in these proposed pathways. Studies have found that paclitaxel 
alters inflammatory signaling. In a clinical study, it was found that a weekly treatment 
protocol with lower paclitaxel doses (80 mg/m2 weekly administration of paclitaxel over 1 
hour infusion) and a 3-week treatment protocol with higher paclitaxel doses (225 mg/m2 
over 24 hour continuous infusion or 175 mg/m2 over 3 hour infusion) increased the levels 
of interleukin- (IL) 10, and IL-8 and IL-6, respectively in the plasma of breast cancer 
patients (Pusztai et al., 2004). These differences occurred on day 3 of therapy and were 
absent on the last day of the treatment cycle (Pusztai et al., 2004), alluding to the 
possible involvement of an inflammatory response elicited by paclitaxel therapy. 
Paclitaxel also alters inflammatory signaling in peripheral neurons. It was found that 
paclitaxel increased the expression of monocyte chemoattractant protein I (MCP-1; also 
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referred to as CCL2) and CCR2 (the MCP-1 receptor) in dorsal root ganglia (Zhang et 
al., 2013). It was also found that inhibition of MCP-1/CCR2 signaling attenuated 
paclitaxel-induced mechanical hypersensitivity and loss of intraepidermal nerve fiber 
innervation (Zhang et al., 2013). MCP-1 is a chemokine that regulates the migration and 
infiltration of monocytes during normal immunological surveillance of tissues and during 
tissue inflammation (Deshmane et al., 2009). Although a causal role for PKC to mediate 
the downstream effects of MCP-1/CCR2 signaling has not been established, studies 
have implicated protein kinase C in inflammation-induced neuropathic pain. In these 
studies, inhibition of PKC activity prevented CCL2-stimulated enhancement of voltage-
gated sodium channels (Zhao et al., 2014), suggesting that PKC undergoes activation 
following stimulation with the inflammatory mediator, CCL2. It is therefore plausible that 
CCL2 enhances PKC activation to elicit enhanced sensory neuronal function via 
activation of sodium channels in paclitaxel-treated neurons. If this response occurred, 
researchers would likely attempt to block the activity of PKC using specific PKC 
inhibitors. However, such an approach would possibly exacerbate the 
immunosuppressive effect of paclitaxel in patients given the role of PKC in immune 
function. It would seem more beneficial to target the downstream target of PKC that is 
important for the direct modulation on neuronal sensitivity. You would expect that this 
approach would be more specific in reversing the effects of paclitaxel on neuronal 
sensitivity especially since PKC signaling is not limited to modulating the sensitivity of 
neurons but includes altering a plethora of cellular functions and is involved in multiple 
disease states (Mochly-Rosen et al., 2012). Since paclitaxel has concentration-
dependent differential effects on neuronal sensitivity, we speculate that loss of neuronal 
sensitivity could be due to a decrease in CCL2-induced activation of PKC therefore 
leading to a subsequent reduction in the sodium channel function. Because studies have 
implicated PKC in the positive and negative modulation of sodium channel function, it is 
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plausible that the role of PKC in a CCL2/Na+ channel signaling pathway in paclitaxel-
treated neurons would be dependent on the concentration of paclitaxel.  
Paclitaxel also results in calcium dysregulation. There are multiple studies 
showing that paclitaxel alters intracellular cytosolic calcium levels through modulation of 
plasma membrane and endoplasmic reticulum-bound channels. In animal models of 
paclitaxel-induced peripheral neuropathy (PIPN), systemic administration of gabapentin, 
which binds to the α2δ-1 subunit of voltage-gated calcium channels and blocks influx of 
extracellular calcium into the intracellular space, attenuated paclitaxel-induced 
hypersensitivity (Xiao et al., 2007). Furthermore, it was shown that paclitaxel increased 
voltage-dependent calcium currents in dorsal root ganglia (DRG) neurons isolated from 
paclitaxel-treated animals (Kawakami et al., 2012). In addition to voltage-gated calcium 
channels, paclitaxel alters the function of the calcium permeable transient receptor 
potential vanilloid 1 (TRPV1) and transient receptor potential ankyrin (TRPA1) channel. 
Altered TRPV1 and TRPA1 function is discussed later in this discussion (Section 5 and 
Section 6) with greater detail. In addition to these findings, studies in SH-SY5Y cells and 
cultured DRG sensory neurons have found time-dependent differential effects of 
paclitaxel on intracellular calcium levels mediated by the inositol 1,4,5 – trisphosphate 
receptor (IP3R) positioned on the endoplasmic (Boehmerle et al., 2006, Boehmerle et al., 
2007). These studies highlight the notion that short-term treatment with paclitaxel (on the 
order of seconds) increases calcium oscillations whereas chronic treatment with 
paclitaxel (6 hours) decreased intracellular calcium levels. It was demonstrated that 
degradation of the neuronal calcium sensor-1, a calcium binding protein, was 
responsible for the decrease in calcium signaling. These studies highlight the 
significance of calcium signaling in mediating altered neuronal function. Interestingly, our 
studies indicate that paclitaxel alters the function of calcium-dependent conventional 
PKC isozymes to elicit changes in neuronal sensitivity. It is therefore highly probable that 
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altered intracellular calcium levels following treatment with paclitaxel would affect 
activation of conventional PKC under physiological conditions. Furthermore, PKC alters 
the function of calcium permeable membrane-bound ion channels such as TRPV1 
channels. Based on the aforementioned effects of paclitaxel on calcium signaling in 
cultured DRG sensory neurons, it is plausible that there is a constant perpetuation of 
aberrant calcium signaling (i.e. decrease in calcium levels) following chronic treatment 
with paclitaxel that consequently modulates sensory neuronal function.   
Currently, there have been no studies examining the role of PKC in the 
aforementioned paclitaxel signaling mechanisms. However, there is precedence to 
suggest that PKC mediates altered neuronal sensitivity induced by paclitaxel. It was 
found that PKC isozymes mediate enhanced peptide release elicited by acute treatment 
with paclitaxel in cultured sensory neurons (Miyano et al., 2009, He and Wang, 2015). 
However, since the symptoms of peripheral neuropathy are chronic and occur weeks 
following the first administration of paclitaxel we are primarily interested in the chronic 
effects of paclitaxel on sensory neuronal function (Forsyth et al., 1997). Studies have 
found that administration of PKC isozyme-specific peptide inhibitors attenuated 
hypernocifensive behavioral responses induced by paclitaxel in animal models of PIPN 
(He and Wang, 2015). To further understand the role of PKC in mediating the neurotoxic 
effects of paclitaxel, our studies took a reductionist approach using cultured sensory 
neurons to investigate the direct role of PKC in the modulation of neuronal sensitivity 
following chronic treatment with paclitaxel. Because previous studies have demonstrated 
that paclitaxel has concentration-dependent differential effects on sensory neuronal 
function (Pittman et al., 2014), we also assessed whether a similar phenotype was 
present in relation to the role of PKC. In our studies, we showed that PKC α and 
PKCβI/II were critical mediators of the reduction in neuronal sensitivity following chronic 
treatment with high concentrations of paclitaxel  (300 nM) in cultured sensory neurons. 
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Importantly, we demonstrated that the concentration of paclitaxel is crucial to our 
understanding of how PKC mediates the effects of paclitaxel and helps to reconcile our 
findings with that of other researchers who demonstrate that PKC mediates a gain of 
function following treatment with paclitaxel (He and Wang, 2015). While PKC mediates a 
loss of function following treatment with high concentrations of paclitaxel, we showed 
that this protein was also important in the gain of function observed upon treatment with 
lower concentrations of paclitaxel (10 nM and 30 nM). In conjunction with the findings of 
other researchers, our studies help to illuminate the significance of this kinase in chronic 
paclitaxel signaling pathways. Furthermore, they provide a greater understanding of the 
possible intertwined relationship between the different proposed pathways for paclitaxel 
signaling since PKC is a secondary messenger protein that has the capacity to modulate 
multiple signaling pathways. 
 
2. Isolated dorsal root ganglia neurons as a model system to examine the effects of 
paclitaxel on neuronal function and morphology 
 
Cultured sensory neurons derived from adult rat dorsal root ganglia (DRG) were 
used as our cellular model system to study the effects of paclitaxel on sensory neuronal 
function and morphology. DRG sensory neurons are an ideal cellular system to examine 
the direct effects of paclitaxel on neuronal function and morphology for two main 
reasons: 1. Paclitaxel accumulates in DRG with little to no central nervous system 
penetrance (Glantz et al., 1995, Cavaletti et al., 2000) and 2. The clinical manifestation 
of paclitaxel-induced peripheral neuropathy indicates altered function of small, medium 
and large diameter sensory neurons (Wiernik et al., 1987a, Sarosy et al., 1992, 
Dougherty et al., 2004).  
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For our DRG neuronal culture, we measured the release of calcitonin gene-
related peptide (CGRP) from nociceptive small and medium diameter sensory neurons 
as a functional read-out of neuronal activity. CGRP is a neuropeptide that is expressed 
and released from nociceptive Aδ and C fibers (McCarthy and Lawson, 1990, Lawson et 
al., 1996), and the release of CGRP from neurons, as well as other nociceptive 
neuropeptides such as substance P, is a common method used to assess changes in 
neuronal activity (Miyano et al., 2009, He and Wang, 2015). Two major benefits to 
assessing changes in CGRP release include our ability to study the effects of paclitaxel 
on a specific subpopulation of sensory neurons and to measure changes in an 
integrated cellular response. Because DRG consists of a heterogeneous population of 
neurons, it is important to have a firm understanding of how paclitaxel alters the function 
of each individual subpopulation since the signaling pathways and neurotransmitters can 
vary between each subpopulation of sensory neurons. Assessing neuropeptide release 
is relevant because multiple studies have indicated that paclitaxel alters release of 
neuropeptides from sensory neurons. In an animal model of PIPN where stimulated 
vasodilation was used as an indirect measure of calcitonin gene-related peptide (CGRP) 
release, it was found that systemic injections of paclitaxel attenuated capsaicin-evoked 
vasodilation in the rat hindpaw (Gracias et al., 2011). It was also reported that paclitaxel 
altered the release of CGRP and substance P from cultured sensory neurons (Miyano et 
al., 2009, Pittman et al., 2014, He and Wang, 2015). In fact, our laboratory demonstrated 
that paclitaxel had concentration-, time- and stimulant-dependent differential effects on 
stimulated release of CGRP (Pittman et al., 2014). However, not all small and medium 
sensory neurons express CGRP (Averill et al., 1995) and therefore our use of CGRP as 
a read-out of neuronal activity is limited to CGRP-expressing neurons. Because of this 
limitation, it would be valuable to also measure the release of glutamate since glutamate 
is not limited to CGRP-expressing neurons, and is present in all sizes of sensory 
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neurons (Sato et al., 1993). In addition to neuropeptide and neurotransmitter release 
assays, alternative methods include calcium imaging and electrophysiology. These 
techniques would allow us to assess altered neuronal function in a wider population of 
neurons and gain an understanding for changes in calcium signaling-dependent 
processes, as well as measure the electrical properties of the cell, respectively.  
The paclitaxel treatment paradigm chosen for these studies models the chronic 
effects of paclitaxel on sensory neuronal function and morphology. Patients treated with 
paclitaxel do not develop peripheral neuropathy until 3-6 weeks following the first dose of 
paclitaxel treatment (Forsyth et al., 1997). This suggests that paclitaxel has long-term 
effects on the function of neurons. As such, we treated neurons with paclitaxel for 1-5 
days to mimic the chronic effects of paclitaxel. This treatment paradigm is in contrast to 
the vast majority of in vitro studies, which are focused on the short-term effects of 
paclitaxel (minutes-hours). While there is precedence to suggest that short-term 
treatment with paclitaxel could predispose an individual to the development of more 
severe chronic peripheral neuropathy (Reeves et al., 2012), there is a strong need to 
mechanistically investigate the chronic neurotoxic effects of paclitaxel given our 
knowledge of the temporal profile for the development of neuropathic symptoms. 
For our neurite morphology studies, we incorporated the use of an established 
paradigm showing that treatment with paclitaxel for 5 days decreased neurite length and 
branching in established adult sensory neurons (Pittman et al., 2014); a phenomenon 
observed in the clinic following paclitaxel administration (Boyette-Davis et al., 2013). For 
our experiments, cultured sensory neurons were maintained in culture until day 7 and 
treated with paclitaxel for 1-5 days, fixed and stained with a neuron specific antibody 
(PGP9.5). An important consideration for our neurite studies is that sensory neurons are 
grown on a poly-D-lysine/laminin-coated surface. These substances are important for 
cell adhesion to the plate. However, laminin, an adhesive glycoprotein that is 
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physiologically present within the extracellular matrix, is known to positively enhance the 
growth of neurites (Kiryushko et al., 2004). Therefore, it is important to keep this in mind 
when interpreting the role of PKC in mediating the effects of paclitaxel on neurite 
morphology. Staining of the neurons with PGP9.5 was performed to distinguish between 
the processes of neurons and supporting cells in our heterogeneous cell culture system. 
The changes in neurite length and branching were measured using the Neurite 
Outgrowth module on the ImageXpress Micro XL instrument. This instrument allowed for 
quick high throughput analysis of changes in neurite morphology in a large number of 
neurons at a given time. Another advantage of the Image Xpress system is that it 
allowed us to visualize neurons in a pre-defined region in the center of each well. This 
ensured that we avoided any slight differences in neurite growth that may have occurred 
in one region of the culture well versus another since we have noticed that the growth of 
neurons is sparser towards the peripheral edges of the culture plate. Another key 
advantage of this system is that it allowed us to measure overall changes in neurite 
outgrowth. Some systems, such as the compartmentalized microfluidics culture systems, 
can be limiting since they are designed to track the growth of a few individual neurites 
through a “channel”. We believe that our system encapsulates a more relevant 
physiological state of the neurons since we can track the growth of numerous neurite 
extensions that are physically and dynamically interacting with one another constantly. 
Furthermore, we believe that our work is critical to gaining a mechanistic understanding 
of how paclitaxel modulates neurite morphology in established neurons. Much of the 
published data is focused on the effects of paclitaxel on embryonic DRG sensory 
neurons (Hayakawa et al., 1994, Scuteri et al., 2006, Yang et al., 2009). However, it has 
been shown that different signaling pathways mediate neurite growth processes in 
embryonic DRG sensory neurons compared to adult neurons (Liu and Snider, 2001). 
Therefore, it is important to assess the chronic effects of paclitaxel on neurite 
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morphology in a system that closely matches the developmental stage of neurons 
affected in patients.  
While there are numerous advantages to using sensory neuronal cultures, there 
are limitations to the use of this model when evaluating the effects of paclitaxel on 
neuronal sensitivity and neurite morphology. Some of the limitations are addressed in 
earlier paragraphs. These neurons, which are isolated from DRG, no longer have an 
intact structure consisting of peripheral and central axonal branches as present in an in 
vivo setting (Julius and Basbaum, 2001), and instead have neurites that project 
outwards from the cell body of the neuron. We are not able to determine whether a 
neurite has a peripheral or central origin because of the isolation and cell preparation 
techniques. Our use of cell cultures allows us to establish a basic mechanism of how 
paclitaxel affects neuronal morphology and the importance of specific proteins and 
cellular pathways. However, in order for us to conclusively state that a candidate 
protein/pathway is important for peripheral nerve fiber morphology (a phenotype that is 
altered by paclitaxel treatment), we would need to stain for these proteins in skin slices 
obtained from animals treated with paclitaxel as done by other researchers within the 
field (Siau et al., 2006, Boyette-Davis et al., 2011). Another limitation of our model is that 
the cellular microenvironment differs from an in vivo setting. The sensory neurons are 
not exposed to the same composition of cell types (e.g. glial support cells and immune 
cells). Because of the complex nature of signaling between different types of cells, the 
‘artificial’ nature of a cell culture system is bound to impact the cell-cell signaling that 
occurs amongst neurons and other types of cells. In our neuronal cultures, the sensory 
neurons are primarily surrounded by supporting fibroblast cells. It is more likely than not 
that these fibroblasts secrete factors that can impact the sensitivity of the neurons. 
Interestingly, we have observed that that the effects of paclitaxel on neuronal sensitivity 
are dependent on the ‘health’ of the neuronal culture (i.e. high density of both neurons 
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and support cells). While we have not examined the nature of this interaction between 
the two types of cells and its relevance in paclitaxel signaling, it is important to be 
cognizant of the possible effects that fibroblasts are likely to have on neuronal sensitivity.  
 
3. Paclitaxel differentially alters stimulated release in a PKC-dependent manner 
 
Published data from our laboratory previously demonstrated that chronic 
treatment with paclitaxel (300 nM, 3 and 5 days) differentially altered capsaicin-evoked 
neuropeptide release in a concentration- and time-dependent manner from cultured 
sensory neurons, (Pittman et al., 2014), therefore indicating that paclitaxel altered the 
function of transient receptor potential vanilloid 1 (TRPV1) channels. Because it is well-
established that protein kinase C (PKC) is a modulator of TRPV1 channel function, our 
studies questioned whether changes in the function of PKC were responsible for 
mediating the effects of paclitaxel on sensory neuronal function as measured by 
neuropeptide release.   
To determine the role of PKC in the modulation of sensory neuronal function 
induced by paclitaxel, our model relied upon measuring changes in neuropeptide release 
following stimulation with the phorbol ester, phorbol 12,13-dibutyrate (PDBu), in cultured 
sensory neurons. PDBu is a potent stimulator of CGRP release from sensory neurons 
(Supowit et al., 1995, Barber and Vasko, 1996), and has a binding affinity for the C1 
domain of conventional and novel PKC isozymes (c/nPKC) that is two orders of 
magnitude higher than the physiological activator of c/nPKC, diacylglycerol (Gould and 
Newton, 2008). Due to the high potency of PDBu to elicit activation of c/nPKC, it was 
important for us to first assess the optimal concentration of PDBu needed to elicit CGRP 
release via activation of c/nPKC. We found that treatment with increasing concentrations 
of PDBu (10 nM, 30 nM and 100 nM) enhanced the release of CGRP in a concentration-
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dependent manner. We opted to use the lowest concentration of PDBu tested (i.e. 10 
nM) to activate c/nPKC for all further experiments to enhance the sensitivity of our 
release assay by ensuring that we did not reach a maximal “ceiling” effect on the ability 
of PDBu to elicit CGRP release from sensory neurons. Using a maximal concentration 
would potentially hinder us from observing any further enhancement of PDBu-evoked 
release following treatment with paclitaxel. In addition, it is important to note that the 
levels of release elicited by PDBu stimulation were variable among different release 
assay experiments and this variation is likely due to slight differences in cell density. 
There is an approximate density of 30,000 cells per well, however, variations in the cell 
density will affect the total content of CGRP per well. To control for these differences, 
each individual experiment consisted of vehicle-treated (control) neurons and the data 
was normalized to the total content of CGRP per well.  
It was also important to demonstrate that the enhanced release of CGRP elicited 
by PDBu was due to specific activation of c/nPKC since phorbol esters have been 
shown to alter the function of other C1 domain-containing proteins involved in 
neurotransmitter release (Betz et al., 1998, Colon-Gonzalez and Kazanietz, 2006). We 
found that pre-treatment with bisindolylmaleimide I (Bis), a selective c/nPKC inhibitor, 
abolished PDBu-stimulated release, indicating that PDBu was a specific activator of 
PKC. In the event that PDBu had non-specific effects, an alternative pharmacological 
approach would be to use the non-phorbol ester PKC stimulant, 1-oleoyl-2-acetyl-sn-
gylcerol, (OAG). Similar to PDBu, OAG-induced activation of PKC enhances capsaicin-
stimulated release from sensory neurons (Barber and Vasko, 1996), providing 
justification for OAG as an alternative PKC stimulant for peptide release studies in 
cultured sensory neurons.  
Having established a method for manipulating the activity of PKC, we then 
assessed the effects of paclitaxel on the ability of PDBu to elicit release of CGRP from 
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sensory neurons. Our findings demonstrate that chronic treatment with paclitaxel 
differentially alters PDBu-stimulated release of CGRP from cultured sensory neurons in 
a concentration- and time-dependent manner. We found that chronic treatment with 
higher concentrations of paclitaxel (300 nM and 1 μM) for 1-5 days attenuated PDBu-
stimulated release of CGRP whereas treatment with lower concentrations of paclitaxel 
(10 nM and 30 nM) for 3 days augmented the PDBu-stimulated release of CGRP. These 
findings indicate that high concentrations of paclitaxel induce a loss of PKC function 
whereas low concentrations of paclitaxel induce a gain of PKC function, highlighting a 
delicate balance in PKC signaling that is heavily dependent on the concentration of 
paclitaxel. We hypothesized that the altered function of PKC could be due to changes in 
the protein kinase expression, phosphorylation, or membrane localization. In-depth 
analysis of these properties is discussed in later sections.  
The differential effects of paclitaxel on PDBu- stimulated release of CGRP are 
unsurprising given the precedence in the literature to support that paclitaxel has 
concentration- and time-dependent differential effects on sensory neuronal function. Our 
laboratory has previously shown that exposure to higher concentrations of paclitaxel 
(300 nM) for 3 or 5 days attenuated capsaicin-evoked CGRP release, whereas, 
exposure to low concentrations of paclitaxel (10 nM) for 3 or 5 days enhanced capsaicin-
evoked CGRP release, indicating both a loss and gain of function in the heat-responsive 
TRPV1 channels, respectively (Pittman et al., 2014). Similar differential effects are also 
found in animal models of paclitaxel-induced peripheral neuropathy (PIPN). In high dose 
models of PIPN (18 - 80 mg/kg cumulative dose of paclitaxel), paclitaxel elicits a 
decrease in thermal sensitivity (Campana et al., 1998, Authier et al., 2000), whereas low 
dose models of PIPN (2 – 8 mg/kg cumulative dose of paclitaxel) show opposite effects 
of paclitaxel on thermal sensitivity. Our studies are most interesting because we have 
demonstrated that paclitaxel has differential concentration-dependent effects on release 
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stimulated by the activation of the TRPV1 modulator, PKC, therefore suggesting a 
possible role of PKC in both the gain and loss of TRPV1 function.  
For our studies, we focused on investigating the mechanisms underlying the 
decrease in PDBu-stimulated CGRP release induced by chronic treatment with 
paclitaxel in cultured sensory neurons isolated from dorsal root ganglia (DRG). 
Therefore, our studies are geared towards elucidating the mechanisms underlying the 
loss of sensory neuronal function upon exposure to paclitaxel treatment. We opted to 
concentrate on how paclitaxel elicits a loss, rather than gain, of sensory neuronal 
function, for several reasons. Firstly, there is strong precedence in the literature 
indicating that paclitaxel induces thermal hypoalgesia, decreases capsaicin-stimulated 
CGRP and decreases capsaicin-evoked vasodilation, therefore indicating that paclitaxel 
reduces the function of TRPV1, a well-established substrate of PKC (Campana et al., 
1998, Authier et al., 2000, Gracias et al., 2011, Pittman et al., 2014). These studies bring 
into question the possibility that PKC might be a critical signaling protein necessary for 
mediating the loss of sensory neuronal function induced by paclitaxel in TRPV1 positive 
sensory neurons. In addition, there was an interesting study that highlighted the 
importance of crosstalk between dorsal root ganglia peripheral neurons and spinal 
central neurons, and how loss of function within a specific subpopulation of peripheral 
neurons could ultimately lead to the enhanced neuronal sensitivity in the spinal cord. In 
this study, it was found that ablation of the CGRP-expressing sensory neurons, which 
were demonstrated to be important for enhancing the sensitivity to noxious heat and 
capsaicin (i.e. stimulants of TRPV1 function) led to disinhibition of cold-responsive spinal 
neurons and unmasked hypersensitivity to cold stimuli (McCoy et al., 2013). This finding 
demonstrates the functional importance and implications for crosstalk between 
peripheral and central neurons. 
 151 
 While the focus for this dissertation pertains to the chronic neurotoxic effects of 
paclitaxel on sensory neuronal function, it was also important to investigate whether 
acute treatment with paclitaxel altered PDBu-stimulated release of CGRP. Paclitaxel 
causes both acute pain (paclitaxel-associated pain syndrome, P-APS) and chronic 
neuropathy (paclitaxel-induced peripheral neuropathy, PIPN) that can be differentiated 
based on their temporal nature and symptomology (Forsyth et al., 1997, Dougherty et 
al., 2004, Loprinzi et al., 2011, Reeves et al., 2012). Since there is evidence to suggest 
that there is a correlation between the development of P-APS and the severity of PIPN 
(Reeves et al., 2012), it was important to have an understanding of the temporal nature 
for the development of changes in sensory neuronal function induced by paclitaxel. 
Using cultured sensory neurons, we demonstrated that treatment with 300 nM paclitaxel 
for 10, 30 or 60 minutes did not alter PDBu-stimulated release, suggesting that acute 
treatment with paclitaxel does not alter the ability of PDBu to elicit neuropeptide release. 
Therefore, these findings demonstrated that acute treatment with high concentrations of 
paclitaxel (300 nM) does not alter the function of PKC, and therefore do not account for 
the altered neuronal sensitivity observed following prolonged exposure to paclitaxel. 
Interestingly, He and Wang demonstrated that acute exposure to 10 nM paclitaxel for 10 
minutes increased the release of neuropeptide from cultured DRG sensory neurons (in 
the absence of any stimulus), and that PKC mediated this neuronal response (He and 
Wang, 2015). While our laboratory has not examined the acute effects of low 
concentrations of paclitaxel on neuropeptide release, we showed that acute treatment 
with 300 nM paclitaxel (10, 20 or 30 minutes) does not alter neuropeptide release in the 
absence of any stimulus (Pittman, 2014). Although it is possible that the differences in 
the concentration of paclitaxel are responsible for the observed lack of effect, the cell 
conditions including cell density, the proportion of neurons to support cells and 
concentrations of nerve growth factor, could also account for our observed effect.   
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 Together, our studies show that chronic treatment with paclitaxel differentially 
alters PDBu-stimulated peptide release from cultured sensory neurons in a 
concentration- and time-dependent manner. Our studies recapitulate the gain and loss of 
sensory neuronal function that is observed in animal models of PIPN and in patients 
treated with paclitaxel.  
 
4. Loss of PKCα and PKCβI/II activity and membrane localization mediates the 
reduction of stimulated CGRP release induced by paclitaxel 
 
PKC isozymes are differentially expressed in various cell types, exhibit 
differential sensitivity to calcium, and interact with different substrates (Way et al., 2000). 
It was imperative for us to first ascertain which class of PKC isozymes was responsible 
for the actions of PDBu on neuropeptide release. Pharmacological manipulation of the 
activity of PKC is limited by narrow ranges of concentrations at which many of the small 
molecule inhibitors demonstrate selectivity for a given PKC isozyme. Therefore, in 
addition to using multiple small molecule inhibitors, we also used a myristoylated 
PKCα/β peptide inhibitor to discern the contribution of specific PKC isozymes. We did 
not employ a genetic approach to modulate PKC expression due to the propensity for 
compensation between PKC isozymes and the ability of PKC isozymes to alter the 
cellular localization of each another (Collazos et al., 2006). Pre-treatment with 100 nM 
Gö6976, a selective inhibitor of conventional PKC isozymes (cPKC), significantly 
reduced PDBu-stimulated release. Studies have shown that concentrations up to 3 µM 
Gö6976 selectively inhibit cPKC while having no effect on the activity of novel PKC 
isozymes (Martiny-Baron et al., 1993), therefore our findings suggest that novel PKC 
isozymes are not involved in mediating PDBu-stimulated neuropeptide release from 
isolated sensory neurons. Using the PKCα/β peptide inhibitor, which consists of a 
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sequence derived from homologous regions within the pseudosubstrate of PKC 
isozymes α, βI and βII (House and Kemp, 1987, Eichholtz et al., 1993), we were able to 
further isolate and examine the contributions of specific conventional PKC isozymes. 
The PKCα/β peptide inhibitor does not alter the activity of PKCγ due to differences in 
amino acid sequences, therefore allowing us to specifically examine the contributions of 
PKCα and PKCβI/II. Pre-treatment with the PKCα/β peptide inhibitor fully abolished 
PDBu-stimulated release indicating that PKCα and/or PKCβI/II were responsible for 
mediating the actions of PDBu. We were able to show that both PKCα and PKCβI/II 
mediated PDBu-stimulated release using combined pre-treatment with selective small 
molecule inhibitors of PKCα (Bis VIII) and PKCβI/II (LY333531). Importantly, in 
paclitaxel-treated neurons, combined pre-treatment with PKCα (Bis VIII) and PKCβI/II 
(LY333531) inhibitors and pre-treatment with the PKCα/β peptide inhibitor, did not 
further alter PDBu-stimulated release, suggesting that loss of PKCα and PKCβI/II activity 
was responsible for the loss of neuronal sensitivity induced by paclitaxel. 
In addition to the use of selective PKCα and PKCβI/II inhibitors, we demonstrated 
that paclitaxel has a direct effect on the activity of cPKC using an antibody that 
recognizes the phosphorylation of cPKC substrates. There is strong precedence in the 
literature showing that activation of PKC results in the phosphorylation of downstream 
target substrates (Numazaki et al., 2002, Zhang et al., 2002, Bhave et al., 2003, Ferreira 
et al., 2005, Jeske et al., 2009). Although all PKC isozymes select for substrates with a 
hydrophobic residue at +1 and basic residues at -6, -4, -2 (Nishikawa et al., 1997), they 
can be distinguished from one another base on their selectivity for substrates with 
specific phosphorylation consensus sequences. In the case of cPKC (α, βI, βII, and γ), 
these kinases have higher selectivity for basic residues at positions +2 and +3 
(Nishikawa et al., 1997). The antibody used in our experiments allowed us to probe the 
phosphorylation of cPKC substrates since it recognizes the phosphorylation of serine 
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residues surrounded by the basic residues arginine or lysine at position +2; an amino 
acid site recognized by PKC. We showed that paclitaxel decreased the phosphorylation 
of cPKC substrates, therefore indicating loss of cPKC activity. In addition, these data 
indicated that paclitaxel attenuated the phosphorylation of multiple cPKC substrates. 
This was crucial to our general understanding of cPKC signaling in paclitaxel-treated 
neurons as it implies that cPKC could alter the function of multiple targets involved in 
neuronal sensitivity.  
In addition to the use of a cPKC substrate antibody, alternative approaches to 
measure PKC activity include a genetically encoded fluorescence resonance energy 
transfer (FRET)-based PKC activity reporter assay, commercially available PKC activity 
assays and 32P ATP labeling assays. These methods provide unique and different 
advantages and/or disadvantages. While the FRET-based PKC activity reporter assay 
provides real-time analysis about spatio-temporal changes in PKC activity under basal 
and stimulated conditions (Violin et al., 2003, Gallegos et al., 2006, Kajimoto et al., 2010, 
Wu-Zhang and Newton, 2013), there is no guarantee that this method will be selective 
and furthermore it is very time-consuming since cPKC specific substrates must be 
determined in order to generate the cPKC specific substrate sequence constructs. 
Conversely, commercially available PKC activity assays allow for relatively quick 
assessment of PKC activity but these assays are not specific for given isozymes and 
instead depend on the application of pharmacological inhibitors to assess the individual 
contributions of a given isozyme. As the name suggests, the 32P ATP labeling assays is 
based on the incorporation of radioactively labeled phosphate from ATP into the PKC 
substrate (Hastie et al., 2006). Although this method used to be a staple in assessing 
PKC activity, it still has the same limitations as other PKC activity assays and requires 
that the PKC target substrate is known, expressed, and detectable via Western blots in 
order to assess changes in the function of PKC through downstream phosphorylation of 
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the specific target substrate. For our studies, we used the phospho-PKC substrate 
antibody to examine changes in cPKC substrate phosphorylation because this method 
provided a fast, non-radioactive means of determining the specific changes in cPKC 
substrate phosphorylation. Because this method is not dependent on the sequence of an 
individual cPKC substrate, we were able to assess changes in phosphorylation of a 
wider variety of cPKC substrate proteins. Together, our data show that PKCα and 
PKCβI/II are the major mediators of PDBu-evoked neuropeptide release, and that 
paclitaxel inhibits the activity of these kinases to elicit a reduction in neuronal sensitivity.  
In addition to modulating the activity of cPKC, it is plausible that paclitaxel alters 
the basal expression, phosphorylation status and/or localization of cPKC. The term 
“basal” is used to describe the cellular environment of cells that were treated with 
paclitaxel for days, but were not exposed to a stimulatory agent. We first investigated 
whether paclitaxel modulated total cPKC protein levels under basal conditions. A 
reduction in cPKC protein levels could provide an explanation for the loss in substrate 
phosphorylation and neuropeptide release induced by chronic treatment with paclitaxel, 
however, we observed no changes in the total protein levels of either PKC α, βI or βII.  
While total cPKC levels remained unchanged, it was plausible that paclitaxel 
attenuated the phosphorylated levels of cPKC and/or inhibited the localization of 
phosphorylated cPKC at cellular membranes under basal conditions. Studies have 
shown that phosphorylation of residues in the kinase domain, turn motif and hydrophobic 
motif, are required for catalytic competence and stability of PKC (Shirai and Saito, 2002, 
Gould and Newton, 2008) whereas a lack of phosphorylation predisposes the protein to 
undergo degradation via the ubiquitin-proteasome pathway (Lu et al., 1998, Gould and 
Newton, 2008). Following activation, phosphorylated cPKC translocate from the cytosol 
to cellular membranes positioning them in close proximity to membrane-bound 
substrates involved in altering neuronal sensitivity. We found that paclitaxel did not 
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decrease the degree of phosphorylation of either PKC α, βI or βII in the cytosolic or 
membrane fractions under basal conditions. Studies examining the acute (10 minutes -1 
hour) effects of paclitaxel have demonstrated enhanced membrane localization of 
conventional PKC isozymes in cultured DRG sensory neurons (He and Wang, 2015). 
Another investigator found that treatment with paclitaxel for 2-10 minutes also enhanced 
translocation of PKCβ, using a pan PKCβ antibody, to the membrane fraction while 
having no effect on PKCα localization (Miyano et al., 2009). It is apparent that acute 
exposure to paclitaxel enhances the translocation of PKCβII to cellular membranes, 
however, membrane localization of PKCβII is not maintained following chronic exposure 
to paclitaxel under basal conditions. Given the physiological nature of PKC membrane 
localization, it is somewhat unsurprising that we did not observe any effects on cPKC 
translocation following chronic treatment with paclitaxel under basal conditions. PKC 
localization at cellular membranes upon activation is a short-lived response (Cesare et 
al., 1999, Gould and Newton, 2008). In fact, prolonged localization of activated PKC at 
cellular membranes results in downregulation of PKC (Gould and Newton, 2008). Having 
determined that cPKC was not downregulated, it became apparent that our experimental 
design examining changes in phosphorylated cPKC localization under basal conditions 
was not suited to detect small changes in PKC localization, given the transient nature of 
PKC activation and the potential short time intervals of membrane localization. 
Therefore, to better understand the effects of chronic paclitaxel treatment on membrane 
localization of phosphorylated cPKC, neurons treated with paclitaxel were stimulated 
acutely (2 minutes) with PDBu and the percentage of cells that exhibited cPKC 
membrane localization was determined. We demonstrated that chronic treatment with 
paclitaxel decreased phorbol ester-stimulated plasma membrane localization of 
phosphorylated PKC α, βI and βII. The observation that chronic treatment with paclitaxel 
(under basal conditions) decreased cPKC substrate phosphorylation while having no 
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effects on phosphorylated cPKC membrane localization highlights the temporal nature of 
PKC signaling. We believe that the effects of paclitaxel on cPKC substrate 
phosphorylation are a composite of phosphorylation events over time. On the other 
hand, because of the short-lived nature of cPKC membrane localization, changes in 
membrane translocation of phosphorylated PKC after chronic treatment with paclitaxel 
would be undetectable in the absence of an acute stimulus to activate PKC.  
 Together, our studies show that the conventional PKC isozymes, α, βI and βII, 
are critical mediators of changes in neuronal sensitivity following chronic treatment with 
paclitaxel. Chronic treatment with paclitaxel attenuated the activity and membrane 
localization of PKC α, βI and βII to elicit a reduction in stimulated peptide release from 
cultured sensory neurons. Currently, we do not know the mechanism of how chronic 
treatment with paclitaxel elicits a decrease in the activity and membrane localization of 
PKC, however, there are a few possible explanations. Studies show that receptor for 
activated C kinase proteins (RACKs) act as scaffolds for PKC and position the enzyme 
within close proximity to its target downstream substrate (Jaken and Parker, 2000). 
Because paclitaxel stabilizes the microtubule structure, which is essential for the proper 
intracellular trafficking of proteins, it is plausible that chronic treatment with paclitaxel 
interferes with the trafficking of RACKs to specific locations within the cell, specifically at 
the plasma membrane of sensory neurons. Another possibility is that paclitaxel 
decreases the expression of RACKs. If the amount of RACKs is decreased and/or 
RACKs are incapable of residing at designated cellular locations, this would undoubtedly 
prevent membrane localization of PKC and consequently impede PKC phosphorylation 
of downstream substrates residing at cellular membranes (plasma membrane).  
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5. Paclitaxel decreases the function of TRPV1 channels in a cPKC-dependent manner  
 
The activity of the nociceptive ligand-gated transient receptor potential vanilloid 1 
(TRPV1) channel (Caterina et al., 1997) is positively modulated by PKC phosphorylation. 
Under physiological conditions, PKC dependent phosphorylation of TRPV1 occurs 
downstream of Gq coupled receptor activation by inflammatory substances such as 
bradykinin (Cesare et al., 1999, Sugiura et al., 2002). Enhancing PKC activity, either via 
phorbol ester activation or via overexpression of a constitutively active PKCε construct, 
potentiates capsaicin- and heat-activated TRPV1 currents (Cesare et al., 1999, 
Numazaki et al., 2002, Bhave et al., 2003). In addition, studies have also demonstrated 
that PKCβII directly binds to TRPV1 to elicit phosphorylation and enhanced sensitivity of 
the channel (Li et al., 2014). It has been determined that the following sites on TRPV1 
are phosphorylated by PKC: S502 and S800 (PKCε) and T705 (PKCβII) (Numazaki et 
al., 2002, Li et al., 2014). In contrast, downregulation of PKC function reduces TRPV1-
mediated responses. In NIH 3T3 cells expressing TRPV1, it was shown that PDBu-
induced downregulation of PKCα attenuates PDBu-stimulated calcium uptake (Olah et 
al., 2002). These studies highlight the significance of PKC in the modulation of TRPV1 
channel function via phosphorylation-dependent mechanisms. 
Our previous studies have shown that paclitaxel has concentration- and time-
dependent effects on TRPV1 function in cultured sensory neurons. Treatment with 300 
nM paclitaxel for 5 days decreased capsaicin-stimulated release, whereas treatment with 
lower concentrations (10 nM) increased capsaicin-stimulated release (Pittman et al., 
2014). These in vitro findings recapitulated the gain and loss of TRPV1 function that is 
observed in animal models of paclitaxel-induced peripheral neuropathy (Campana et al., 
1998, Authier et al., 2000, Chen et al., 2011, Gracias et al., 2011, Hara et al., 2013, Li et 
al., 2015). It was therefore imperative to perform mechanistic studies to evaluate the 
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signaling mediators important for the changes in TRPV1 function following chronic 
treatment with paclitaxel.  
Our study focuses on the importance of PKC in mediating the loss of TRPV1 
function following chronic treatment with paclitaxel (300 nM, 3 or 5 days). We found that 
pre-treatment with the myristolyated PKCα/β peptide inhibitor attenuated capsaicin-
evoked release in the absence of paclitaxel, suggesting that full activation of TRPV1 is 
dependent on phosphorylation of the channel by PKCα/β. These findings were 
unsurprising given the numerous studies implicating PKC in modulating TRPV1 function. 
However we also showed that the reduction in capsaicin-stimulated release upon 
chronic exposure to paclitaxel is due to a loss of PKCα and PKCβI/II activity. This data 
was critical to our mechanistic understanding of how TRPV1 function was altered by 
paclitaxel because it suggested that paclitaxel altered the phosphorylation status of 
TRPV1 in a conventional (cPKC)-dependent manner to elicit a reduction in neuronal 
sensitivity. We speculated that paclitaxel-induced inhibition of PKCα and PKCβI/II 
activity causes a decrease in TRPV1 phosphorylation resulting in a subsequent 
reduction of neuropeptide release (see Figure 28 for diagram of proposed mechanism). 
We attempted to co-immunoprecipitate PKC and TRPV1 and analyze TRPV1 
phosphorylation using phospho-threonine/serine antibodies, however, these experiments 
were not successful due to poor antibody staining. An alternative approach to assessing 
the effects of paclitaxel on TRPV1 phosphorylation is to use mass spectrometry 
(discussed in further detail in Future Directions). Another possible explanation for the 
reduction in capsaicin-stimulated release is the desensitization of TRPV1 channels. 
Various signaling proteins have been implicated in regulating the desensitization of 
TRPV1 channels. Activation of protein kinase A (PKA) and inhibition of the phosphatase, 
calcineurin, have both been shown to reduce capsaicin-induced TRPV1 desensitization 
(Mohapatra and Nau, 2003, 2005, Por et al., 2010, Sanz-Salvador et al., 2012). Unlike 
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with PKA and calcineurin, there has been conflicting data regarding the role of PKC in 
TRPV1 desensitization. It was found that phorbol ester-induced activation of PKC 
reversed TRPV1 desensitization in a calcium-dependent manner, whereas inhibition of 
PKC, using an inhibitory peptide, prevented the recovery of TRPV1 sensitization 
(Mandadi et al., 2004, Mandadi et al., 2006). While these findings oppose the 
observations of others who found no involvement of PKC in the reversal of TRPV1 
desensitization (Mohapatra and Nau, 2003, 2005), these studies suggest the decrease 
in capsaicin-stimulated release following chronic exposure to paclitaxel could be 
attributable to a loss in the recovery of desensitized TRPV1 channels via decreased 
activity of PKC.  
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Figure 28: Proposed mechanism for the reduction in neuronal sensitivity 
induced by chronic treatment with paclitaxel. (A) Under normal conditions in 
culture, capsaicin-evoked activation of TRPV1 is a cPKC-dependent process. 
cPKC phosphorylation of TRPV1 causes the influx of calcium ions into the 
neuron which leads to enhanced release of CGRP from the neuron. (B) 
Following chronic treatment with paclitaxel, there is a reduction in the activity 
and plasma membrane localization of cPKC resulting in a decrease in 
phosphorylation of TRPV1. This causes a decrease in calcium influx into the 
neuron, and results in a reduction in the release of CGRP from the neuron.  
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 The observed loss of TRPV1 function in isolated sensory neurons is analogous 
to findings in in vivo models of paclitaxel-induced peripheral neuropathy. It was shown 
that systemic injections of paclitaxel (cumulative doses ranging between 18 and 80 
mg/kg) induced thermal hypoalgesia (Campana et al., 1998, Authier et al., 2000) and (4 
mg/kg cumulative dose) attenuated capsaicin-evoked blood flow in the rat hindpaw 
(Gracias et al., 2011). These in vivo studies demonstrate that paclitaxel decreased the 
function of small diameter TRPV1-expressing neurons. Interestingly, a recent study 
found that the loss of peptidergic TRPV1-expressing sensory neurons unmasked cold 
hypersensitivity (McCoy et al., 2013), a major symptom of paclitaxel-induced peripheral 
neuropathy (Dougherty et al., 2004). Therefore, it is plausible that the observed loss of 
TRPV1 function following chronic treatment with paclitaxel enhances neuronal sensitivity 
to cold temperatures. In conjunction with our studies, the aforementioned findings 
highlight a possible physiological role for PKC α, βI and βII as critical regulators of hot 
and cold sensitivity following chronic exposure to paclitaxel in patients. 
 
6. Paclitaxel decreases the function of TRPA1 channels in a PKC-independent manner 
 
Similar to the transient receptor potential vanilloid I (TRPV1) channel, paclitaxel 
attenuates the function of the transient receptor potential ankyrin (TRPA1) channels. Our 
laboratory demonstrated that paclitaxel attenuated allyl isothiocyanate (AITC)-stimulated 
peptide release (Pittman et al., 2014), suggesting that paclitaxel altered either the 
function and/or protein expression of TRPA1 channels. In this dissertation we wanted to 
further examine the mechanism of altered TRPA1 function. Similar to TRPV1, studies 
have demonstrated that activation of TRPA1 channels elicits nocifensive behavioral 
responses via protein kinase A (PKA) and phospholipase C (PLC)-dependent signaling 
pathways in inflammatory animal models (Obata et al., 2005, Dai et al., 2007, Wang et 
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al., 2008, Schmidt et al., 2009, Bautista et al., 2013). Furthermore, TRPA1 and TRPV1 
are co-expressed in small diameter DRG neurons (Story et al., 2003) and physically 
interact with one another (Weng et al., 2015). Due to the functional association of 
TRPA1 and TRPV1 and the importance of PKC signaling in TRPV1 function, we 
hypothesized that PKC was a critical mediator of changes in AITC-stimulated release 
induced by paclitaxel. In contrast to our TRPV1 studies, we found that PKC was not 
responsible for changes in AITC-stimulated release in the absence or presence of 
paclitaxel, demonstrating that PKC-dependent phosphorylation of TRPA1 is not involved 
in altered TRPA1 function. In addition, neither modulation of protein kinase A (PKA) nor 
phospholipase C (PLC) activity altered AITC-stimulated release. An interesting 
consideration is the signaling differences responsible for neuronal responses elicited by 
sensitization of TRPA1 versus direct activation of TRPA1. The majority of the 
aforementioned citations regarding modulation of TRPA1 channel function studied 
TRPA1 sensitization-based mechanisms. However, for our release studies we analyzed 
whether PKC is necessary for eliciting TRPA1 evoked responses. A sensitizing 
paradigm differs from the direct activation paradigm in that the question revolves around 
whether pre-treatment with a molecule lowers the threshold for activation of the channel, 
i.e. potentiates agonist-evoked channel responses. The differences between our 
experimental design therefore provide a plausible explanation for the lack of findings. 
However, another study examined the role of PKC, PKA, PLC and p38 MAPK in AITC-
evoked release of substance P. These studies found that pre-treatment with inhibitors of 
PKC, PKA and PLC did not alter AITC-evoked release whereas inhibition of p38 
attenuated AITC-evoked release of substance P (Nakamura et al., 2012). We found 
similar effects on CGRP release following pre-treatment with PKC, PKA and PLC 
inhibitors; however, our preliminary studies also suggest that p38 is not involved in 
AITC-stimulated release of CGRP. To make a more conclusive statement comparing our 
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findings to that of the Nakamura group, we would need to repeat the experiment exactly 
as it was done using similar AITC concentrations. In addition, for these series of 
experiments, positive controls are needed to ensure that the optimal concentrations of 
inhibitors are used.  
In addition to examining intracellular signaling molecules, we investigated 
whether a decrease in TRPA1 protein expression would explain the loss of neuronal 
sensitivity induced by paclitaxel. While there is no consensus within the field on a highly 
specific antibody, we attempted to try a commercially available TRPA1 antibody that had 
been used by other researchers (Weng et al., 2015). Using this TRPA1 antibody we 
found that treatment with paclitaxel decreased protein expression of TRPA1 (data not 
shown) suggesting that the reduction in AITC-induced release induced by paclitaxel was 
due to loss of protein expression. However, when we tested the specificity of this 
antibody in detecting the appropriate size TRPA1 band in commercially available cell 
lysate obtained from HEK cells expressing TRPA1, we found that the TRPA1 band 
identified in HEK cells expressing TRPA1 was also present in our negative control (i.e. 
HEK cells not expressing TRPA1). Due to these findings, we cannot make any 
conclusive statements as to whether TRPA1 protein expression is responsible for the 
loss of neuronal sensitivity induced by paclitaxel. Future studies could probe the 
specificity of a wider panel of commercially available TRPA1 antibodies. An alternate 
approach to protein expression analysis would be to examine changes in mRNA 
expression. We decided not to pursue this option since changes in the mRNA profile do 
not always correlate with changes in protein expression (Chen et al., 2002). 
 In addition to altered TRPA1 expression, it is possible that TRPA1 channels are 
desensitized following treatment with paclitaxel. Studies have demonstrated that TRPA1 
undergoes calcium-dependent heterologous desensitization by TRPV1 agonists due to 
depletion of phosphatidylinositol 4,5-bisphophate (PIP2) levels (Akopian et al., 2007, 
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Ruparel et al., 2008); PIP2 is a well-established regulator of TRP channel function that 
has been demonstrated to alter the activity of specific TRP channels in a differential 
manner (Clapham, 2003). However, heterologous desensitization of TRPA1 by TRPV1 
activation seems unlikely due to the lack of effects of PKC inhibition on AITC-stimulated 
release of CGRP. Additional studies are needed to investigate the signaling mechanism 
responsible for altered TRPA1 function following treatment with paclitaxel.  
 
7. The function of L-type calcium channels, not N-type, is altered in a PKC-dependent 
manner 
 
In addition to TRP channels, studies have demonstrated that paclitaxel alters the 
function of voltage-gated calcium channels. Studies show that paclitaxel increases 
voltage-dependent calcium currents and protein expression of the calcium channel 
subunit, α2δ-1 in dorsal root ganglia neurons isolated from animals treated with paclitaxel 
(Kawakami et al., 2012); α2δ-1 is a subunit found in multiple voltage-gated calcium 
channels. It was also demonstrated that treatment with gabapentin, which blocks 
calcium influx via voltage-gated calcium channels by binding to the α2δ-1 subunit, 
reversed mechanical hypersensitivity induced by paclitaxel (Xiao et al., 2007). Additional 
studies have solidified the importance of altered intracellular calcium levels in mediating 
the neurotoxic effects as it was shown that treatment with membrane impermeable 
calcium chelators in paclitaxel-treated animals reduced nocifensive behavioral 
responses (Siau and Bennett, 2006). Furthermore, there is precedence in the literature 
indicating that N- and L-type voltage-gated calcium currents are enhanced following 
activation of PKC (Yang and Tsien, 1993, Hall et al., 1995) and that bradykinin-
stimulated peptide release, which is a PKC-dependent phenomenon, is attenuated 
following pre-treatment with the N-type calcium channel blocker, ω-conotoxin (Evans et 
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al., 1996). Based on the precedence in the literature supporting a role for PKC in the 
modulation of voltage-gated calcium channel function, and the involvement of the 
aforementioned channels in mediating the effects of paclitaxel on sensory neuronal 
function, we speculated that loss of PKC activity induced by chronic treatment with 
paclitaxel could result in the negative modulation of voltage-gated calcium channel 
function. Therefore, our intention was to first identify whether voltage-gated calcium 
channels elicited peptide release in a PKC-dependent manner. If so, we would then 
evaluate the role of these channels in paclitaxel signaling. However, we found that pre-
treatment with ω-conotoxin, had no effect on PDBu-stimulated release. Pre-treatment 
with the L-type calcium channel blocker, nifedipine, attenuated stimulated release, but 
lacked a concentration-response effect. Since our findings do not represent a typical 
concentration-dependent profile it is important for future work to test the effects of 
nifedipine at lower and higher concentrations. This would enable us to better understand 
the role of L-type calcium channels in PDBu-stimulated release from sensory neurons.  
 
8. Paclitaxel decreases neurite length and branching but PKC does not mediate altered 
neurite morphology 
 
Previous studies from our laboratory demonstrated that treatment with paclitaxel 
for 5 days reduces neurite length and branching in cultured sensory neurons (Pittman et 
al., 2014). Our experiments further expand our understanding of the temporal nature of 
altered neurite morphology. We show that paclitaxel attenuates neurite length and 
branching at earlier time-points i.e. days 2 and 3 following paclitaxel exposure. The 
disruption of microtubule dynamics following paclitaxel treatment is a likely reason for 
the reduction in neurite length and branching. There is a balance of interacting forces 
between microtubules and actin filaments in the growing regions of neurites (i.e. growth 
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cone) that regulates the growth of neurons. Microtubules and actin filaments are highly 
dynamic and are continually growing and shortening, and rearranging their organization 
within the growth cone in order to respond to and elicit changes in neurite growth based 
on neuronal guidance cues, extracellular matrix proteins, and cell adhesion molecule-
dependent signaling pathways (Tanaka and Sabry, 1995, Luo, 2002, Dent et al., 2003, 
Kiryushko et al., 2004). As such, disruption of the microtubule dynamics would adversely 
affect the coordinated and dynamic interplay of cytoskeletal rearrangement necessary 
for neurite outgrowth.  
Our neurite findings are physiologically relevant since they closely mimic the 
effects of paclitaxel on intraepidermal nerve fiber innervation in patient and rodent skin 
biopsy samples where it was found that paclitaxel reduced the length of established 
peripheral nerve endings (Lauria et al., 2005, Siau et al., 2006, Jin et al., 2008, Lauria et 
al., 2010, Boyette-Davis et al., 2011, Ko et al., 2014). Furthermore, our neurite outgrowth 
model is pertinent to the field of neuropathy because it allows us to study the chronic 
effects of paclitaxel on established peripheral neurites from adult dissociated DRG 
sensory neurons. Most of the published literature has been done using other cell types 
(for example, superior cervical ganglia neurons) or embryonic DRG neuronal cultures 
(Hayakawa et al., 1994, Scuteri et al., 2006, Yang et al., 2009). A current unknown factor 
within the peripheral neuropathy field is whether alterations in neuronal sensitivity are 
caused by neurite retraction or whether these two phenomena occur independently of 
one another. Our temporal studies suggest that altered neuronal sensitivity occurs 
independent of neurite retraction since we observed loss of sensory neuronal function 
evoked by PKC activation following 1-day exposure to paclitaxel, whereas neurite 
retraction did not occur until 2 days following exposure to paclitaxel. This highlights the 
possibility that aberrant release of transmitters from the nerve ending could 
consequently have an effect on the motility and growth of neurons resulting in retraction 
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which could subsequently result in further diminished release of transmitters resulting in 
a vicious aberrant cycle.  
PKC has been implicated in modulating cell adhesion molecule (CAM)-
dependent changes in neuronal outgrowth (Kolkova et al., 2000, Leshchyns'ka et al., 
2003, Kiryushko et al., 2004, Kolkova et al., 2005); a signaling pathway that impacts 
cytoskeletal structures including microtubules.  Given that paclitaxel disrupts microtubule 
dynamics, it is plausible that these effects are mediated through loss of PKC function.  
Amongst all other PKC isozymes, PKCε has been the most strongly implicated in neurite 
outgrowth processes in different cell types. Since we observed a parallel reduction in 
neurite length/branching and protein expression of PKCε following treatment with 
paclitaxel and no changes in conventional PKC isozyme (α, βI or βII) expression, we 
hypothesized that loss of PKCε was responsible for the reduction in neurite length and 
branching induced by paclitaxel. We used two methodologies to manipulate the 
expression of PKCε: siRNA knockdown and phorbol ester downregulation of PKCε. 
siRNA knockdown provided a more specific and targeted approach to altering the 
expression of PKCε since chronic phorbol ester treatment is more than likely to affect the 
expression of other phorbol sensitive PKC isozymes (Roivainen et al., 1993). 
Unexpectedly, we found that decreasing the expression of PKCε did not alter neurite 
morphology in the absence or presence of paclitaxel, suggesting that PKCε does not 
play a role in neurite outgrowth in cultured sensory neurons. It would not necessarily be 
surprising if PKC was not important for mediating changes in both the sensitivity and 
morphology of neurons following chronic treatment with paclitaxel because other 
researchers have determined that there is not always a correlation between the 
development of neuropathic symptoms and altered nerve morphology (Kalliomaki et al., 
2011). However, while our data suggests that PKCε does not play a role in neurite 
outgrowth in cultured sensory neurons, this finding does not negate its potential role in 
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altering the length of nerve fibers in an in vivo setting due to the physical and signaling 
differences between sensory neurons in their native environment compared to a culture 
environment. Furthermore, because both siRNA and chronic phorbol ester treatment 
only elicited 30 - 50% reduction in PKCε protein expression, it is still possible that the 
residual levels of PKCε were sufficient to maintain neurite morphology, and therefore 
masked effects caused by our manipulation of PKCε protein expression.  
 Because the levels of residual PKCε might be sufficient to maintain neurite 
morphology, we decided to take a more direct approach to manipulate PKCε function. 
Using the PKCε activator, ψεRACK, we questioned whether activation of PKCε would 
elicit changes in neurite morphology. As a positive control, we confirmed that ψεRACK 
enhanced translocation of PKCε to the plasma membrane since this is used as an 
indication of PKC activation (Tsutsumi et al., 1993, Cesare et al., 1999, Dorn et al., 
1999, Zhu et al., 2007). However, we observed no differences in neurite morphology 
using ψεRACK (data not shown; studies done in absence of paclitaxel). Due to the 
negative findings, we did not pursue studies to examine the effects of ψεRACK on 
neurite morphology in the presence of paclitaxel. 
Due to the negative findings for siRNA, chronic phorbol ester and ψεRACK 
studies, we broadened our scope to include additional PKC isozymes and questioned 
whether phorbol ester-induced activation of conventional and novel PKC isozymes 
enhanced neurite length and/or branching. However, we found no differences in neurite 
morphology following exposure to different concentrations or exposure periods to 
phorbol ester. One possibility that we considered for the lack of effects of PKC in neurite 
outgrowth was the developmental stage of our neurons. Studies demonstrating a 
positive modulatory role of PKC on neurite outgrowth in neuronal cells have been done 
in embryonic cultures or explants (Hsu, 1985, Hsu et al., 1989, Mehta et al., 1993). In 
addition, these neurite studies were performed shortly after plating the neurons and 
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therefore address the question of PKC involvement in neurite initiation and not neurite 
outgrowth from established neurons. There is precedence in the literature to suggest 
that different signaling pathways mediate neurite outgrowth in embryonic versus adult 
neurons (Liu and Snider, 2001). These studies highlight the differences in neuronal 
growth between a growing and immature neuron versus regenerative growth from an 
established and mature adult neuron. It was found that inhibition of mitogen activated 
protein kinase kinase (MEK) and phosphoinositide 3-kinase (PI3K) blocked axonal 
growth from embryonic sensory neurons, whereas Janus Kinase (JAK) inhibition had no 
effect. In contrast, inhibition of JAK blocked axonal growth from axotomized adult 
sensory neurons, whereas inhibition of MEK and PI3K had no effect (Liu and Snider, 
2001). Based on this knowledge, future studies will do a side-by-side comparison 
between embryonic and adult sensory neurons to investigate whether there are 
differences in neuronal growth between these two types of neurons.  
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CONCLUSION AND FUTURE DIRECTIONS 
 
In summary, our work indicates that the conventional PKC isozymes, PKCα and 
PKCβI/II, are critical mediators of changes in neuronal sensitivity in TRPV1 positive 
sensory neurons following chronic exposure to paclitaxel. We show that chronic 
treatment with paclitaxel inhibits the activity of PKCα and PKCβI/II and the membrane 
localization of phosphorylated PKCα and PKCβI/II to elicit a reduction in the stimulated 
release of neuropeptide from capsaicin-sensitive neurons. These findings enhance our 
mechanistic understanding of the effects of chronic exposure to paclitaxel on sensory 
neuronal function. Conversely, our studies indicate that the novel PKC isozyme, PKCε, 
does not mediate the change in neurite morphology induced by paclitaxel. We 
demonstrate that treatment with paclitaxel results in a correlative reduction in neurite 
length and branching and protein expression of PKCε; a PKC isozyme strongly 
implicated to modulate neurite outgrowth. However, manipulation of PKCε protein 
expression via siRNA-mediated knockdown did not alter basal outgrowth or further 
exacerbate the changes in neurite morphology induced by paclitaxel. In addition, when 
we broadened our scope to investigate whether other PKC isozymes were important for 
modulating neurite morphology we found no differences in neurite morphology following 
phorbol ester-induced activation of conventional and novel PKC isozymes in the 
absence or presence of paclitaxel. Overall, our studies highlight the importance of PKCα 
and PKCβI/II in mediating the effects of paclitaxel on sensory neuronal function and the 
lack thereof of PKC signaling in altered neurite morphology in our tested experimental 
paradigms.   
The work presented in this dissertation provides mechanistic insight into how 
paclitaxel elicits a reduction in neuronal sensitivity. Unfortunately, a majority of studies 
examining the effects of paclitaxel on neuronal sensitivity have focused on how 
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paclitaxel elicits a gain of neuronal function and have neglected to investigate the 
mechanisms underlying the loss of neuronal function induced by paclitaxel. In order to 
develop therapies to alleviate or prevent paclitaxel-induced peripheral neuropathy 
(PIPN), we must have a holistic and detailed understanding of the different ways that 
paclitaxel modulates sensory neuronal function since it is highly plausible that signaling 
pathways mediating the gain and loss of neuronal function do not occur in isolation of 
one another.  
Our work is important to the field of PIPN because it shows that loss of function 
induced by paclitaxel is mediated by a reduction in the activity and membrane 
localization of cPKC. These findings take us one step closer to having a holistic 
understanding of the involvement of PKC in paclitaxel signaling. In addition, we 
demonstrated that PKC mediates enhanced neuropeptide release following treatment 
with lower concentrations of paclitaxel. Together, these findings suggest that there is a 
delicate balance in how paclitaxel affects the function of PKC. We speculate that the 
concentration and time of exposure to paclitaxel are key factors in determining whether 
PKC contributes to the gain or loss of neuronal function.  
Our findings bring into question the potential for targeting PKC to reverse the loss 
of neuronal function induced by paclitaxel. Because our mechanistic studies 
demonstrate that the reduction in neuronal sensitivity following chronic treatment with 
paclitaxel is due to a loss in the activity and membrane localization of PKC, it seems 
apparent that efforts could be made to re-activate PKC so that it is functionally capable 
of interacting with and phosphorylating its downstream target substrates (for instance, 
TRPV1) that play a role in modulating neuronal sensitivity. Theoretically, we would 
expect “re-activated PKC” to reverse the loss of neuronal function induced by paclitaxel. 
However, directly targeting PKC could be quite problematic for a number of reasons. 
Firstly, long-term activation of PKC leads to subsequent downregulation of the protein 
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(Olivier and Parker, 1994, Gould and Newton, 2008). Therefore, it might be difficult to 
develop a clinically relevant means of short-term activation of PKC. Our studies also 
strongly suggest that PKC is involved in both the loss and gain of neuronal sensitivity 
following treatment with paclitaxel (Figures 4 and 5), suggesting that there is a fine 
balance in how much PKC activation is needed to reverse the loss of function without 
tipping the balance to favor a gain of function phenotype. We speculate that targeting the 
downstream substrate of PKC that is necessary for mediating the neurotoxic effects of 
paclitaxel is a more realistic approach because PKC is involved in such a plethora of 
cellular functions and signaling pathways that achieving the activation or blockage of 
specific functions would be very difficult. Finally, targeting PKC substrates could provide 
selectivity to ameliorate only the neuronal effects of PKC. Such selectivity would reduce 
the possibility of compromising the efficacy of the anti-cancer properties of PIPN 
therapeutics. Our proposed future direction experiments are aimed at gaining a better 
holistic understanding of how PKC signals in sensory neurons to mediate the changes in 
neuronal sensitivity induced by paclitaxel. 
Our work highlights a few critical and unanswered questions concerning the role 
of cPKC in paclitaxel signaling. First, how does chronic treatment with paclitaxel reduce 
cPKC activity? The role of PKC as a kinase is to phosphorylate downstream substrates 
by transferring a phosphate group from ATP to a respective substrate sequence. A 
plausible explanation for the reduction in PKC activity is that paclitaxel decreases 
adenosine triphosphate (ATP) levels. As such, there would be less ATP available for 
PKC to use in its capacity as a kinase. Previous studies have demonstrated that 
paclitaxel (100 nM, 24 hours) attenuates the levels of ATP in a DRG neuronal cell line, 
50B11 (Zhu et al., 2013). If there were less ATP available, this would have a direct 
impact on the activity levels of cPKC causing the kinase to function at a much lower 
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level. To test this hypothesis, future work will measure the levels of ATP following 
treatment with paclitaxel using commercially available bioluminescent ATP assays.  
Our studies also raised the question of how paclitaxel causes the mislocalization 
of PKC. Inhibiting the proper localization of PKC would subsequently alter the ability of 
PKC to interact with and phosphorylate downstream target substrates, thereby reducing 
the function of PKC. Our findings demonstrated that paclitaxel disrupted the ability of 
cPKC to be localized at the plasma membrane of sensory neuronal cell bodies. A 
plausible explanation for this finding is that paclitaxel disrupts the ability of cPKC to 
associate with receptors for activated C kinase (RACKs). As discussed earlier, RACKs 
are necessary for the proper localization of PKC within the cell and allow for PKC to be 
poised at distinct sites so that it can respond to upstream signaling partners and 
phosphorylate downstream substrates (Jaken and Parker, 2000). Co-
immunoprecipitation studies and western blots will be done to assess whether paclitaxel 
alters the association of cPKC with RACKs and the protein expression of RACKs, 
respectively. In addition to causing PKC mislocalization, there is also the possibility that 
paclitaxel impedes trafficking of RACKs to the plasma membrane. To evaluate the 
effects of paclitaxel on RACK membrane localization we could use 
immunocytochemistry analysis as was done in the cPKC isozyme experiments.  
The third question addresses the effects of paclitaxel on cPKC substrates. Our 
release studies implicate loss of TRPV1 function; however, our experiments 
demonstrate that paclitaxel decreased the phosphorylation of multiple cPKC substrates. 
Because the activity of many membrane-bound channels involved in nociceptive 
signaling are modulated by phosphorylation, it is important to identify the cPKC 
substrates that are adversely affected by paclitaxel signaling. To do this, future 
experiments will incorporate mass spectrometry to identify the bands shown via western 
blot to have decreased cPKC phosphorylation following treatment with paclitaxel. Once 
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identified, we can then perform release assay experiments to determine whether this 
protein is necessary for mediating altered neuronal sensitivity induced by paclitaxel.  
For the neurite outgrowth studies, our data suggests that PKCε does not mediate 
the reduction of neurite length and branching induced by paclitaxel. However, we did not 
perform any experiments to determine whether other PKC isozymes were responsible 
for the effects of paclitaxel on neurite outgrowth. While our data shows that chronic 
phorbol ester-induced downregulation of PKCε did not alter neurite morphology, chronic 
treatment with phorbol esters has been shown to differentially affect the expression of 
other conventional and novel PKC isozymes in a time-dependent manner (Roivainen et 
al., 1993). As such, it is possible that the expression of additional phorbol-sensitive PKC 
isozymes (i.e. conventional and novel PKC isozymes) was altered following exposure to 
the phorbol ester, PDBu. Western blot analysis could be done to assess the protein 
expression of the other PKC isozymes. Altered protein expression of the other isozymes 
would complicate our data interpretation of the PKCε studies because we do not have a 
full grasp of how different PKC isozymes affect neurite outgrowth in sensory neurons. It 
is possible that the different isozymes have similar or opposing effects. Suppose for 
example that PKCε enhanced neurite outgrowth whereas PKCδ decreased neurite 
outgrowth. If the protein expression of PKCε were to decrease following chronic phorbol 
ester to a greater extent than PKCδ, it is possible that the function of PKCε also 
decreases to a greater extent compared to PKCδ. Such changes in protein function 
would block the growth-promoting effects that PKCε would have on the neurites. 
Because the function of PKCδ is affected to a lesser degree than PKCε, we would 
expect the growth-inhibiting effects of PKCδ to prevail. Due to the non-specificity of a 
chronic phorbol ester treatment paradigm, it becomes essential to individually 
manipulate the function of the other PKC isozymes. Future studies could incorporate the 
use of both knockdown and overexpression of other PKC isozymes to determine their 
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significance in changes in neurite outgrowth induced by paclitaxel. By taking this step-
wise approach we would be able to determine the individual contributions of each 
isozyme on neurite outgrowth and determine which isozymes were responsible for either 
enhancing or decreasing neurite outgrowth, or those isozymes that had no effect on 
outgrowth. For isozymes that enhanced outgrowth, we hypothesize that paclitaxel 
decreases the function of these proteins to elicit a reduction in neurite length. We would 
expect that overexpression of these neurite outgrowth-enhancing isozymes would 
reverse the loss of neurite length induced by paclitaxel. Conversely for isozymes that 
decreased outgrowth, we hypothesize that these outgrowth-inhibiting isozymes mediated 
the reduction in neurite length induced by paclitaxel. As such, we would expect that 
knockdown of these PKC isozymes would prevent the loss of neurite length induced by 
paclitaxel.  
Alternatively, another approach could be to assess the effects of paclitaxel on 
signaling proteins involved in the rearrangement of the cytoskeletal structure since the 
dynamic rearrangement of the cytoskeleton is necessary for neurite outgrowth 
processes. As such, future work will examine whether proteins and pathways involved in 
regulating the cytoskeletal structure are modulated by paclitaxel since paclitaxel affects 
the cytoskeletal structure through its stabilization of microtubules. Further studies also 
are needed to determine whether changes in neurite morphology are involved in altered 
neuronal sensitivity induced by paclitaxel. The stabilizing actions of microtubules are 
likely to affect the trafficking of proteins that could impact neuronal function and 
subsequently neurite morphology.   
There is still much work needed in order for us to have a full understanding of the 
role of PKC in paclitaxel signaling. It seems reasonable to speculate that targeting PKC 
for the development of therapeutic agents to prevent PIPN would be desirable yet 
difficult due to its role in both the loss and gain of sensory neuronal function. It is 
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imperative that additional studies are performed to determine the mechanism of how 
paclitaxel elicits changes in PKC activity and localization. In doing so, we will have a 
better understanding of the holistic role that PKC plays in paclitaxel signaling and 
therefore be better poised to develop appropriate drug targets. Overall, our work 
contributes to the field of PIPN as it provides mechanistic insight into how paclitaxel 
elicits neurotoxic effects on sensory neuronal function.  
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APPENDIX 
 
Prior to elucidating the mechanism of how protein kinase C (PKC) mediated 
altered neuronal sensitivity following treatment with paclitaxel, our research was focused 
on the role of bradykinin in paclitaxel signaling. Although significant, the small changes 
in bradykinin-stimulated release were difficult to manipulate experimentally and the 
research direction was suspended; however, we wanted to document some of the 
findings from this work since there are still meaningful lessons to be learnt.  
Furthermore, this project helped to shape the trajectory of my dissertation project.  
 
The Role of Bradykinin Signaling in Altered Neuronal Sensitivity Induced by 
Paclitaxel 
 
Introduction 
Our initial interest in bradykinin as a potential mediator of the neurotoxic effects 
of paclitaxel on sensory neuronal function stemmed from the knowledge that bradykinin 
is a physiological substance that mediates inflammatory responses and causes pain in 
humans. Bradykinin mediated inflammation occurs as a result of the release of cytokines 
and prostanoids from different types of cells, degranulation of mast cells accompanied 
by the subsequent release of inflammatory mediators such as histamine, and the 
induction of plasma extravasation caused by the contraction of vascular endothelial cells 
(Dray and Bevan, 1993). In addition to inflammation, bradykinin also causes overt pain in 
humans and hypernociceptive responses in animal models of pain (Whalley et al., 1987, 
Steranka et al., 1988). The physiological actions of bradykinin, a nonapeptide kinin, are 
due to its binding and activation of the B2 receptor (Dray et al., 1992, Kaplan et al., 
2002, Tang et al., 2006). The B2 receptor is a G protein coupled receptor that commonly 
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signals via a Gαq-coupled PLC/IP3/DAG/PKC signaling pathway (Petho and Reeh, 2012). 
Similar to the B2 receptor, the B1 receptor (which has lower affinity for bradykinin) 
signals in a similar Gαq-coupled coupled signaling pathway (Kaplan et al., 2002, Prado et 
al., 2002). The B2 receptor is constitutively expressed, whereas the B1 receptor is 
inducible under inflammatory conditions; there are reports suggesting that the B1 
receptor is also expressed at low levels under basal conditions (Ma et al., 2000, 
Wotherspoon and Winter, 2000, Kaplan et al., 2002). 
The actions of bradykinin in pain production are due to its direct and sensitizing 
effects on sensory neurons. Using a peripheral nerve tail-spinal cord preparation, studies 
demonstrated that exposure to bradykinin depolarizes neuronal cells and sensitizes 
them to thermal and chemical (i.e. capsaicin) stimuli (Dray et al., 1992, Rueff and Dray, 
1993). In addition, treatment with bradykinin induced depolarization and the generation 
of action potentials in cultured dorsal root ganglion (DRG) sensory neurons (Naruse et 
al., 1992, Jeftinija, 1994, Nicol and Cui, 1994). Furthermore, bradykinin also modulated 
the release of the neuropeptides, substance P and calcitonin gene-related peptide 
(CGRP) from sensory neurons. In cultured DRG sensory neurons, it was found that pre-
treatment with bradykinin enhanced capsaicin-stimulated substance P release (Tang et 
al., 2006), indicating that bradykinin sensitized the transient receptor potential vanilloid 1 
(TRPV1) channels. Similarly, bradykinin induced thermal hypersensitivity and 
potentiated capsaicin-evoked currents in TRPV1-expressing HEK cells (Chuang et al., 
2001). Further studies found that exposure to bradykinin directly enhanced the release 
of substance P and CGRP from sensory neurons (Vasko et al., 1994, Tang et al., 2005, 
Tang et al., 2006, Supowit et al., 2011). It has been suggested that the enhanced 
release of neuropeptides induced by bradykinin is mediated by both the activation of 
mitogen activated protein kinase kinase (MEK) and the synthesis of prostaglandins. Pre-
treatment with the MEK inhibitor, U0126, and the COX inhibitor, indomethacin, reduced 
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bradykinin-stimulated release (Vasko et al., 1994, Tang et al., 2006). Furthermore, it was 
found that bradykinin increased the phosphorylated levels of ERK1/2 (the downstream 
MEK substrates) and enhanced the protein expression of COX-2 (Tang et al., 2006). In 
addition to these findings, it has been suggested that altered intracellular calcium levels 
play an important role in mediating the effects of bradykinin, however there is some 
disagreement in the field regarding the source of calcium. Studies have found that influx 
of extracellular calcium into the intracellular space is necessary for the enhancement of 
CGRP release induced by bradykinin (Vasko et al., 1994), however other researchers 
have found that this requirement is not needed for bradykinin-evoked responses (Dray et 
al., 1992, Linhart et al., 2003).  
Researchers have implicated the B1 and B2 receptors in mediating paclitaxel-
induced peripheral neuropathy (PIPN). Using animal models of PIPN, it was 
demonstrated that treatment with antagonists for the B1 (DABLK; des-Arg9-Leu8-BK) and 
B2 (HOE140) receptor attenuated thermal and mechanical hypernocifensive behavioral 
responses elicited by paclitaxel; similar findings were found in B1 and B2 receptor 
knockout mice (Costa et al., 2011). Recent studies have further elucidated the 
mechanism behind the anti-nociceptive effect of B1 and B2 receptor antagonists in 
PIPN. It was demonstrated that bradykinin sensitized the TRP channel, TRPV4, in a 
PLC/PKC- dependent manner leading to the development of hypernociceptive 
responses to mechanical stimuli following treatment with paclitaxel (Costa et al., 2017). 
These studies strongly suggest that bradykinin signaling plays a key role in mediating 
the neurotoxic effects of paclitaxel.  
Based on the precedence in the literature, we were interested in determining 
whether paclitaxel elicited altered neuronal sensitivity following stimulation with 
bradykinin in cultured DRG sensory neurons. Given that prior studies were done in 
animal models of PIPN, it was important for us to ascertain the direct effects of paclitaxel 
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on sensory neuronal function using an in vitro reductionist approach. This would help to 
eliminate confounding factors inherent using animal models. The aim for this project was 
to investigate the signaling pathway through which bradykinin elicited changes in 
neuronal sensitivity in the absence and presence of paclitaxel in cultured adult DRG 
sensory neurons. For our studies, the release of CGRP was measured as a functional 
read-out of neuronal sensitivity (as described earlier in the Material and Methods 
section).   
 
Results and Discussion 
In the absence of paclitaxel, we found that bradykinin enhanced peptide release 
via the B2 receptor. For these studies, cultured neurons were pre-treated with 
antagonists for the B1 and B2 receptor, Lys-(Des-Arg9-Leu8)BK and HOE140, 
respectively for 10 minutes prior to stimulation with bradykinin (1 μM; 10 minutes). Pre-
treatment with 10 nM, 100 nM and 1000 nM HOE 140 attenuated bradykinin-stimulated 
release to 1.8 ± 0.3, 1.2 ± 0.2 and 1.7 ± 0.6% of total content compared to vehicle-
treated neurons (3.1 ± 0.3% of total content; Figure 1A), suggesting that bradykinin-
stimulated release is mediated by the B2 receptor. We found no significant differences in 
bradykinin-stimulated release following pre-treatment with 0.1 nM (3.1 ± 0.3) and 1 nM 
HOE140 (2.8 ± 0.3% of total content; Figure 1A). In contrast to the effects observed with 
HOE140, pre-treatment with 4 nM (2.4 ± 0.3), 10 nM (2.7 ± 0.2), 100 nM (2.4 ± 0.2), 400 
nM (2.2 ± 0.2) and 1000 nM (2.4 ± 0.3% of total content) Lys-(Des-Arg9-Leu8)BK did not 
alter bradykinin-stimulated release compared to vehicle-treated neurons (2.9 ± 0.3% of 
total content; Figure 1B), suggesting that bradykinin-stimulated release is not mediated 
by the B1 receptors. Furthermore, we observed no changes in stimulated release 
following exposure to the B1 receptor agonist; treatment with 10 nM (1.2 ± 0.5), 100 nM 
(1.1 ± 0.5), 1 μM (1.0 ± 0.5) and 10 μM (0.9 ± 0.2% of total content; Figure 1C) des-Arg9-
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bradykinin. Together these data indicate that bradykinin-stimulated CGRP release is 
mediated by the bradykinin B2 receptor.  
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Figure A-1: Bradykinin-stimulated CGRP release is mediated by the B2 receptor in 
cultured sensory neurons. Each column represents the mean ± SEM of basal (white 
columns), bradykinin-stimulated (dotted columns) or des-Arg
9
-bradykinin-stimulated 
(striped columns) CGRP release expressed as % of total content. Naïve cultures 
were pre-treated with the (A) B2 receptor antagonist (HOE 140; 0.1, 1, 10, 100 and 
1000 nM), (B) B1 receptor antagonist (Lys-(Des-Arg
9
-Leu
8
BK), 4, 10, 100, 400 and 
1000 nM), or (D) PKC inhibitor (Bis I; 1, 10, 100, 1000 nM) for 10 minutes prior to 
stimulation with bradykinin (1 μM). (A) An * indicates a significant decrease in 
bradykinin-stimulated release in neurons pre-treated with the B2 receptor antagonist 
compared to vehicle-treated neurons (p < 0.05, N = 11-12). Significance was 
determined using a two-way ANOVA with Tukey’s post-hoc test. (C) Naïve cultures 
were stimulated with the B1 receptor agonist (desArg
9
-bradykinin; 10 nM, 100 nM, 1 
μM, 10 μM) for 10 minutes. Significance was determined using a two-way ANOVA 
with Tukey’s post-hoc test (p < 0.05, N = 8-9).  Bis I – bisindolylmaleimide I; BK – 
bradykinin; N.S. not significant. 
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Since the Gαq-coupled PLC/IP3/DAG/PKC pathway is one of the most established 
signaling pathways for bradykinin (Petho and Reeh, 2012), we next questioned whether 
bradykinin-stimulated release was dependent on PKC. Cultured neurons were pre-
treated with the PKC inhibitor, bisindolylmaleimide I (Bis I) for 10 minutes prior to 
stimulation with bradykinin (1 μM). Pre-treatment with 100 nM (2.4 ± 0.4) and 1000 nM 
(1.6 ± 0.4% of total content) Bis I slightly attenuated bradykinin-stimulated release 
compared to vehicle-treated neurons (3.1 ± 0.5% of total content; Figure 1D) however, 
the observed differences were not significant. In addition, we no longer observed 
significant enhancement in CGRP release following exposure to bradykinin (Figure 1D). 
We strongly believe that the loss of bradykinin effects on CGRP release and subsequent 
findings regarding the lack of significant attenuation in stimulated release following PKC 
inhibition can be explained by the small changes in basal release. We noticed that basal 
levels of CGRP were 2.1 ± 0.4% total content in vehicle-treated neurons for these 
experiments (Figure 1D), whereas in earlier experiments we found lower basal levels in 
vehicle-treated neurons (1.6 ± 0.2% total content; Figure 1A). Basal CGRP release 
levels are dependent on the resting level of neuronal activity. A plausible reason for the 
enhanced basal release of CGP is that paclitaxel penetrates the cells more easily. Since 
different vials of paclitaxel were used for these experiments, it is possible that slight 
differences in the formulation of paclitaxel could account for great cell penetrance and 
therefore result in higher basal activity of the neurons. A more plausible explanation is 
that because the scale of differences from one experiment to another is so small, very 
slight shifts in basal release appear magnified. As will be discussed later, our inability to 
consistently stimulate a significant level of CGRP following exposure to bradykinin 
hampered the development of this project.  
The next two questions that we attempted to address were: 1. Does paclitaxel 
alter the protein expression of the B1 and B2 receptors and 2. Does paclitaxel alter 
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bradykinin-stimulated CGRP release? To address the first question, whole cell lysates 
were collected from paclitaxel- (1 μM, 2 days) and vehicle-treated neurons and western 
blots were performed to determine the effects of paclitaxel on B1 and B2 protein 
expression. Treatment with paclitaxel did not alter the protein expression of the B1 (1.2 ± 
0.2) or B2 (1.1 ± 0.1 arbitrary unit) receptors compared to vehicle-treated neurons (1.0 ± 
0.0 arbitrary unit; Figure 2A-D). To address the second question, cultured neurons were 
treated with paclitaxel for 2 days and then stimulated with bradykinin (1 μM) for 10 
minutes. Treatment with 1 μM paclitaxel increased bradykinin-stimulated release to 2.7 ± 
0.3% of total content compared to vehicle-treated neurons (1.7 ± 0.2% of total content; 
Figure 2E), suggesting that paclitaxel alters the signaling pathway stimulated by 
bradykinin. Treatment with 10 nM (2.0 ± 0.3), 30 nM (2.2 ± 0.3), 100 nM (2.0 ± 0.3) and 
300 nM (2.2 ± 0.4% of total content) paclitaxel did not alter bradykinin-stimulated release 
(Figure 2E). One huge problem that we encountered with this experiment was the lack of 
a significant enhancement in CGRP release following stimulation with bradykinin in 
vehicle-treated neurons. This was the same experimental limitation encountered in 
earlier release studies described above (Figure 1D). In comparison to stimulants such as 
phorbol 12,13-dibutyrate (PDBu) and capsaicin which stimulate the release of ~10 – 
20% of the total CGRP content, bradykinin only elicited ~3%. Therefore, the levels of 
released CGRP following exposure to bradykinin were always very low and in fact 
hovered quite close to the basal levels of released CGRP. Our attempts at performing a 
bradykinin concentration response curve in order to determine the optimal concentration 
of bradykinin needed to elicit changes in release proved fruitless (data not shown). Due 
to the reproducibility issues that we encountered for these sets of experiments we were 
not able to consistently show that bradykinin enhanced the release of CGRP from 
cultured sensory neurons and therefore were incapable of proceeding with the use of 
bradykinin as a direct stimulant for CGRP release.  
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Figure A-2: Paclitaxel does not alter the B1 or B2 receptor protein 
expression but does enhance bradykinin-stimulated CGRP release from 
cultured sensory neurons. (A, C) Representative western blot images 
showing immunoreactivity for B1 and B2 receptor in whole cell lysates in 
neurons treated with vehicle and paclitaxel (1 μM, 2 days). (B, D) 
Densitometry analysis showing no significant differences in B1 and B2 
receptor immunoreactivity normalized to actin in paclitaxel-treated (1 μM, 2 
days) neurons compared to vehicle-treated neurons using a t-test (N = 2-3 
a.u. ± SEM). (E) Each column represents the mean ± SEM of basal (white 
columns) or stimulated (dotted columns) CGRP release expressed as % of 
total content. Cultures were exposed to 1 μM paclitaxel for 2 days prior to 
stimulation with bradykinin (1 μM). An * indicates a significant increase in 
bradykinin-stimulated release in paclitaxel-treated neurons compared to 
vehicle-treated neurons (p < 0.05, N = 11). Significance was determined 
using a two-way ANOVA with Tukey’s post-hoc test. Veh - Vehicle; Pac –
Paclitaxel; B1R – B1 receptor; B2R – B2 receptor. 
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Due to the problems that arose with our model, we decided to investigate 
whether signaling proteins downstream of the bradykinin receptor could account for 
altered neuronal sensitivity following treatment with paclitaxel.  Since we had previously 
observed a decrease in bradykinin-stimulated release following inhibition of PKC (Figure 
1D), we decided to assess whether PKC was important for mediating the neurotoxic 
effects of paclitaxel. This question spawned the development and trajectory for my 
dissertation project. From this point forward we were able to directly modulate the 
activity of PKC using a phorbol ester in order to assess its respective role in paclitaxel 
signaling. Data from these experiments are discussed in the main body of the 
dissertation.  
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